

## Long term impact of pre-incision antibiotics on children born by caesarean section

Sumilo, Dana; Nirantharakumar, Krishnarajah; Willis, Brian H; Rudge, Gavin; Martin, James; Gokhale, Krishna; Thayakaran, Rasiah; Adderley, Nicola; Chandan, Joht; Okoth, Kelvin; Harris, Isobel ; Hewston, Ruth; Skrybant, Magdalena; Deeks, Jon; Brocklehurst, Peter

DOI:  
[10.3310/ZYZC8514](https://doi.org/10.3310/ZYZC8514)

License:  
Creative Commons: Attribution (CC BY)

*Document Version*  
Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*  
Sumilo, D, Nirantharakumar, K, Willis, BH, Rudge, G, Martin, J, Gokhale, K, Thayakaran, R, Adderley, N, Chandan, J, Okoth, K, Harris, I, Hewston, R, Skrybant, M, Deeks, J & Brocklehurst, P 2022, 'Long term impact of pre-incision antibiotics on children born by caesarean section: a longitudinal study based on UK electronic health records', *Health Technology Assessment*, vol. 26, no. 30, pp. 1-192. <https://doi.org/10.3310/ZYZC8514>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## Health Technology Assessment

Volume 26 • Issue 30 • June 2022

ISSN 1366-5278

# Long-term impact of pre-incision antibiotics on children born by caesarean section: a longitudinal study based on UK electronic health records

*Dana Šumilo, Krishnarajah Nirantharakumar, Brian H Willis, Gavin M Rudge, James Martin, Krishna Gokhale, Rasiyah Thayakaran, Nicola J Adderley, Joht Singh Chandan, Kelvin Okoth, Isobel M Harris, Ruth Hewston, Magdalena Skrybant, Jonathan J Deeks and Peter Brocklehurst*





# Long-term impact of pre-incision antibiotics on children born by caesarean section: a longitudinal study based on UK electronic health records

Dana Šumilo<sup>1,2\*</sup> Krishnarajah Nirantharakumar<sup>1,3</sup>  
Brian H Willis<sup>1</sup> Gavin M Rudge<sup>1</sup> James Martin<sup>1</sup>  
Krishna Gokhale<sup>1</sup> Rasiah Thayakaran<sup>1</sup>  
Nicola J Adderley<sup>1</sup> Joht Singh Chandan<sup>1</sup>  
Kelvin Okoth<sup>1</sup> Isobel M Harris<sup>1</sup> Ruth Hewston<sup>4</sup>  
Magdalena Skrybant<sup>4</sup> Jonathan J Deeks<sup>1,5</sup>  
and Peter Brocklehurst<sup>1</sup>

<sup>1</sup>Institute of Applied Health Research, University of Birmingham, Birmingham, UK

<sup>2</sup>Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK

<sup>3</sup>Midlands Health Data Research UK, University of Birmingham, Birmingham, UK

<sup>4</sup>Patient and public contributor, UK

<sup>5</sup>NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK

\*Corresponding author

**Declared competing interests of authors:** Krishnarajah Nirantharakumar reports grants from the Medical Research Council (MRC) (London, UK), National Institute for Health and Care Research (NIHR), Health Data Research UK (London, UK), AstraZeneca (Cambridge, UK), Vifor Pharma (Glattbrugg, Switzerland) and Action Against AMD (London, UK); grants and personal fees from Boehringer Ingelheim (Bracknell, UK); and personal fees from Sanofi SA (Paris, France) and Merck Sharp & Dohme (London, UK). He is also the director of OpenClinical.net and a trustee of the Network for Improving Critical care Systems and Training (Colombo, Sri Lanka) outside the submitted work. Magdalena Skrybant received grants from the NIHR Applied Research Collaboration West Midlands (Coventry, UK) during the conduct of the study. Jonathan J Deeks reports grants from the NIHR Health Technology Assessment (HTA) programme, during the conduct of the study. He is a former member of the HTA Medical Tests Methods Group, Pre-Exposure Prophylaxis Impact Review Panel, HTA Post-Funding Committee teleconference (POC members to attend), HTA Funding Committee Policy Group (formerly CSG), HTA Commissioning Committee, HTA Efficient Study Designs – 2, HTA Commissioning Committee and HTA End of Life Care and Add-on Studies. Peter Brocklehurst is a member of a Clinical Trials Unit funded by NIHR, a former member of HTA Efficient Study Designs – 2, the former chairperson of the HTA Maternal, Neonatal and Child Health Panel, an emeritus senior NIHR investigator and the former chairperson of MRC/NIHR Methodology Research Programme panel. He has received research grants as chief investigator from the NIHR HTA programme, the NIHR Efficacy and Mechanism Evaluation programme and the Wellcome Trust (London, UK), and consultancy fees from Biotest AG (Dreieich, Germany).



Published June 2022  
DOI: 10.3310/ZYZC8514

This report should be referenced as follows:

Šumilo D, Nirantharakumar K, Willis BH, Rudge GM, Martin J, Gokhale K, *et al.* Long-term impact of pre-incision antibiotics on children born by caesarean section: a longitudinal study based on UK electronic health records. *Health Technol Assess* 2022;**26**(30).  
<https://doi.org/10.3310/ZYZC8514>



# Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.014

Launched in 1997, *Health Technology Assessment* (HTA) has an impact factor of 4.014 and is ranked 27th (out of 108 titles) in the 'Health Care Sciences & Services' category of the Clarivate 2021 Journal Citation Reports (Science Edition). It is also indexed by MEDLINE, CINAHL (EBSCO), EMBASE, NCBI Bookshelf, DOAJ, Europe PMC, the Cochrane Library, INAHTA, the British Nursing Index, Ulrichsweb, and the Clarivate Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/hta](http://www.journalslibrary.nihr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 16/150/01. The contractual start date was in April 2018. The draft report began editorial review in December 2020 and was accepted for publication in June 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care.

Copyright © 2022 Šumilo *et al.* This work was produced by Šumilo *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: <https://creativecommons.org/licenses/by/4.0/>. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).



## NIHR Journals Library Editor-in-Chief

---

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

## NIHR Journals Library Editors

---

**Professor John Powell** Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Consultant in Public Health, Delta Public Health Consulting Ltd, UK

**Dr Peter Davidson** Interim Chair of HTA and EME Editorial Board. Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

**Ms Tara Lamont** Senior Adviser, School of Healthcare Enterprise and Innovation, University of Southampton, UK

**Dr Catriona McDaid** Reader in Trials, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, School of Healthcare Enterprise and Innovation, University of Southampton, UK

**Dr Rob Riemsma** Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

**Professor Helen Roberts** Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## Long-term impact of pre-incision antibiotics on children born by caesarean section: a longitudinal study based on UK electronic health records

Dana Šumilo<sup>1,2\*</sup> Krishnarajah Nirantharakumar<sup>1,3</sup> Brian H Willis<sup>1</sup>  
Gavin M Rudge<sup>1</sup> James Martin<sup>1</sup> Krishna Gokhale<sup>1</sup>  
Rasiah Thayakaran<sup>1</sup> Nicola J Adderley<sup>1</sup> Joht Singh Chandan<sup>1</sup>  
Kelvin Okoth<sup>1</sup> Isobel M Harris<sup>1</sup> Ruth Hewston<sup>4</sup>  
Magdalena Skrybant<sup>4</sup> Jonathan J Deeks<sup>1,5</sup> and Peter Brocklehurst<sup>1</sup>

<sup>1</sup>Institute of Applied Health Research, University of Birmingham, Birmingham, UK

<sup>2</sup>Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK

<sup>3</sup>Midlands Health Data Research UK, University of Birmingham, Birmingham, UK

<sup>4</sup>Patient and public contributor, UK

<sup>5</sup>NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK

\*Corresponding author [D.Sumilo@bham.ac.uk](mailto:D.Sumilo@bham.ac.uk)

**Background:** Since changes in the national guidance in 2011, prophylactic antibiotics for women undergoing caesarean section are recommended prior to skin incision, rather than after the baby's umbilical cord has been clamped. Evidence from randomised controlled trials conducted outside the UK has shown that this reduces maternal infectious morbidity; however, the prophylactic antibiotics also cross the placenta, meaning that babies are exposed to them around the time of birth. Antibiotics are known to affect the gut microbiota of the babies, but the long-term effects of exposure to high-dose broad-spectrum antibiotics around the time of birth on allergy and immune-related diseases are unknown.

**Objectives:** We aimed to examine whether or not in-utero exposure to antibiotics immediately prior to birth compared with no pre-incisional antibiotic exposure increases the risk of (1) asthma and (2) eczema in children born by caesarean section.

**Design:** This was a controlled interrupted time series study.

**Setting:** The study took place in primary and secondary care.

**Participants:** Children born in the UK during 2006–18 delivered by caesarean section were compared with a control cohort delivered vaginally.

**Interventions:** In-utero exposure to antibiotics immediately prior to birth.

**Main outcome measures:** Asthma and eczema in children in the first 5 years of life. Additional secondary outcomes, including other allergy-related conditions, autoimmune diseases, infections, other immune system-related diseases and neurodevelopmental conditions, were also assessed.

**Data sources:** The Health Improvement Network (THIN) and the Clinical Practice Research Datalink (CPRD) primary care databases and the Hospital Episode Statistics (HES) database. Previously published linkage strategies were adapted to link anonymised data on mothers and babies in these databases. Duplicate practices contributing to both THIN and the CPRD databases were removed to create a THIN-CPRD data set.

**Results:** In the THIN-CPRD and HES data sets, records of 515,945 and 3,945,351 mother-baby pairs were analysed, respectively. The risk of asthma was not significantly higher in children born by caesarean section exposed to pre-incision antibiotics than in children whose mothers received post-cord clamping antibiotics, with an incidence rate ratio of 0.91 (95% confidence interval 0.78 to 1.05) for diagnosis of asthma in primary care and an incidence rate ratio of 1.05 (95% confidence interval 0.99 to 1.11) for asthma resulting in a hospital admission. We also did not find an increased risk of eczema, with an incidence rate ratio of 0.98 (95% confidence interval 0.94 to 1.03) and an incidence rate ratio of 0.96 (95% confidence interval 0.71 to 1.29) for diagnosis in primary care and hospital admissions, respectively.

**Limitations:** It was not possible to ascertain the exposure to pre-incision antibiotics at an individual level. The maximum follow-up of children was 5 years.

**Conclusions:** There was no evidence that the policy change from post-cord clamping to pre-incision prophylactic antibiotics for caesarean sections during 2006-18 had an impact on the incidence of asthma and eczema in early childhood in the UK.

**Future work:** There is a need for further research to investigate if pre-incision antibiotics have any impact on developing asthma and other allergy and immune-related conditions in older children.

**Study registration:** This study is registered as [researchregistry3736](https://www.researchregistry.com/record/researchregistry3736).

**Funding:** This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 26, No. 30. See the NIHR Journals Library website for further project information.

# Contents

List of tables	xi
List of figures	xiii
List of supplementary material	xix
List of abbreviations	xxi
Plain English summary	xxiii
Scientific summary	xxv
<b>Chapter 1</b> Background, aims and objectives	<b>1</b>
Background and rationale	1
Aims and objectives	2
<i>Overall aim</i>	2
<i>Primary objectives</i>	3
<i>Secondary objectives</i>	3
<b>Chapter 2</b> Methods	<b>5</b>
Study design and setting	5
Population and eligibility criteria	6
Study outcomes	7
Covariates	8
Data sources and mother–baby linkage	8
<i>Electronic primary and secondary health-care records</i>	8
<i>National survey data</i>	16
Estimated sample size and statistical power	16
<i>THIN–CPRD database sample size estimates</i>	16
<i>HES database sample size estimates</i>	17
<i>Estimates of statistical power</i>	19
Statistical methods and analyses	20
<i>Primary care data (THIN–CPRD)</i>	20
<i>Secondary care data (HES)</i>	23
Research Ethics Committee approval	25
Changes to protocol	25
Patient and public involvement	25
<i>Aims</i>	25
<i>Methods</i>	26
<i>Results</i>	26
<i>Discussion and conclusions</i>	27
<i>Reflections</i>	27
<b>Chapter 3</b> Results	<b>29</b>
THIN–HES-linked and THIN primary care data sets descriptions	29
CPRD–HES-linked and CPRD primary care data sets descriptions	29
Final THIN–CPRD data set description	31
HES data set description	32

## CONTENTS

Results of the national survey of hospital prophylactic antibiotic administration policies	32
Results of covariate analysis	35
Primary outcome results	35
<i>Main analysis</i>	35
<i>Sensitivity analyses</i>	36
Secondary outcome results	37
<i>Outcomes in children</i>	37
<i>Maternal outcomes</i>	42
<i>Additional sensitivity analyses</i>	43
Results of subgroup analyses	45
<i>Type of caesarean section</i>	45
<i>Antibiotic regimen</i>	45
<b>Chapter 4 Discussion and implications</b>	<b>49</b>
Implications for practice and research recommendations	50
<b>Acknowledgements</b>	<b>53</b>
<b>References</b>	<b>57</b>
<b>Appendix 1</b> Uptake of pre-incision antibiotics policy for caesarean section across England and the UK	<b>65</b>
<b>Appendix 2</b> Covariate graphs	<b>67</b>
<b>Appendix 3</b> Rates of outcomes of interest in the study population over time and by delivery mode	<b>93</b>
<b>Appendix 4</b> Risk of different study outcomes by delivery mode	<b>155</b>

# List of tables

<b>TABLE 1</b> The list of secondary outcomes	9
<b>TABLE 2</b> The list of potential covariates and data sets used to analyse each variable	11
<b>TABLE 3</b> Estimated person-years of follow-up and the number of new asthma cases by the year of life in children born by CS and VD during 2006–18, using the THIN–CPRD database (if the incidence of asthma was the same in all children irrespective of the mode of delivery)	17
<b>TABLE 4</b> Estimated person-years of follow-up and the number of first-time hospital admissions for asthma by the year of life in children born by CS and VD during 2006–18, using the THIN–CPRD database (if the incidence of asthma was the same in all children irrespective of the mode of delivery)	18
<b>TABLE 5</b> The number of births, years of follow-up and expected events in each simulation	19
<b>TABLE 6</b> Impact of pre-incision vs. post-cord clamping antibiotics on primary outcomes in the primary care (THIN–CPRD) database	35
<b>TABLE 7</b> Impact of pre-incision vs. post-cord clamping antibiotics on primary outcomes in the secondary care (HES) database	36
<b>TABLE 8</b> Impact of pre-incision vs. post-cord clamping antibiotics on asthma in the primary care (THIN–CPRD) database (sensitivity analyses)	37
<b>TABLE 9</b> Impact of pre-incision vs. post-cord clamping antibiotics on asthma in the secondary care (HES) database (sensitivity analyses)	37
<b>TABLE 10</b> Impact of pre-incision vs. post-cord clamping antibiotics on eczema in the primary care (THIN–CPRD) database (sensitivity analyses)	38
<b>TABLE 11</b> Impact of pre-incision vs. post-cord clamping antibiotics on eczema in the secondary care (HES) database (sensitivity analyses)	38
<b>TABLE 12</b> Impact of pre-incision vs. post-clamping antibiotics on secondary outcomes in children in the primary care (THIN–CPRD) database	39
<b>TABLE 13</b> Impact of pre-incision vs. post-clamping antibiotics on secondary outcomes in children in the secondary care (HES) database	41
<b>TABLE 14</b> Impact of pre-incision vs. post-clamping antibiotics on maternal outcomes in the primary care (THIN–CPRD) database	42
<b>TABLE 15</b> Impact of pre-incision vs. post-clamping antibiotics on maternal outcomes in secondary care (HES) database	43
<b>TABLE 16</b> Sensitivity analyses for secondary outcomes recorded in primary care, with unexpected findings in the main analysis	44

<b>TABLE 17</b> Sensitivity analyses for secondary outcomes recorded in secondary care, with unexpected findings in the main analysis	44
<b>TABLE 18</b> Impact of pre-incision vs. post-cord clamping antibiotics on child outcomes by emergency and elective CS in the primary care (THIN-CPRD) database	46
<b>TABLE 19</b> Impact of pre-incision vs. post-cord clamping antibiotics on child outcomes by emergency and elective CS in the secondary care (HES) database	46
<b>TABLE 20</b> Impact of pre-incision vs. post-cord clamping antibiotics on child outcomes in units administering different antibiotic regimens in the secondary care (HES) database	47
<b>TABLE 21</b> Example CIs for the outcome rates found in primary care (THIN-CPRD) data	93
<b>TABLE 22</b> Example CIs for the outcome rates found in secondary care (HES) data	93
<b>TABLE 23</b> Risk of developing primary outcomes in children born by CS compared with children born by VD in the primary care (THIN-CPRD) database	155
<b>TABLE 24</b> Risk of developing primary outcomes in children born by CS compared with children born by VD in the secondary care (HES) database	155
<b>TABLE 25</b> Risk of developing secondary outcomes in children born by CS compared with children born by VD in the primary care (THIN-CPRD) database	156
<b>TABLE 26</b> Risk of developing secondary outcomes in children born by CS compared with children born by VD in the secondary care (HES) database	157
<b>TABLE 27</b> Risk of developing maternal outcomes in the primary care (THIN-CPRD) database by delivery mode	158
<b>TABLE 28</b> Risk of developing maternal outcomes in the secondary care (HES) database by delivery mode	158
<b>TABLE 29</b> Risk of developing child outcomes in the secondary care (HES) database in CS vs. VD in hospitals with different antibiotic regimens for CS	159
<b>TABLE 30</b> Risk of developing child outcomes by emergency and elective CS vs. VD in the primary care (THIN-CPRD) database	160
<b>TABLE 31</b> Risk of developing child outcomes by emergency and elective CS vs. VD in the secondary care (HES) database	160

# List of figures

<b>FIGURE 1</b> Illustration of the need to use VDs as the comparator group because of changing temporal patterns in outcome events unrelated to routine exposure to pre-incision antibiotics, using asthma as an example	6
<b>FIGURE 2</b> Study population selection, including mother–baby data linkage in THIN data sets	30
<b>FIGURE 3</b> Study population selection in CPRD data sets	30
<b>FIGURE 4</b> Flow diagram of the final THIN–CPRD data set	31
<b>FIGURE 5</b> The number of births by delivery mode and year in the final THIN–CPRD data set	31
<b>FIGURE 6</b> The number of births by delivery mode and year from the THIN–CPRD data set, with linked HES data used for sensitivity analysis	32
<b>FIGURE 7</b> Flow diagram for derivation of the mother–baby-linked HES data set covering the whole of England and linkage to the national survey of the hospital prophylactic antibiotic administration policies	33
<b>FIGURE 8</b> The number of births by delivery mode and year in (a) the HES data set covering the whole of England; and (b) the HES data set linked to the data from the national survey of hospital prophylactic antibiotic administration policies used in the main analysis	34
<b>FIGURE 9</b> Cumulative percentage of hospitals over time with policies to administer antibiotic prophylaxis before skin incision for women undergoing CS in the whole of the UK and England separately	34
<b>FIGURE 10</b> Cumulative percentage of hospitals with policies to administer antibiotic prophylaxis before skin incision for women undergoing CS over time and in different countries in the UK	65
<b>FIGURE 11</b> Cumulative percentage of hospitals with policies to administer antibiotic prophylaxis before skin incision for women undergoing CS over time and in different regions in England	65
<b>FIGURE 12</b> Proportion of delivery mode in the THIN–CPRD data set over time and across different maternal age groups at childbirth: (a) < 20 years; (b) 20–29 years; (c) 30–39 years; and (d) ≥ 40 years	67
<b>FIGURE 13</b> Proportion of delivery mode in the HES data set over time and by maternal age groups at childbirth: (a) < 20 years; (b) 20–29 years; (c) 30–39 years; and (d) ≥ 40 years	68
<b>FIGURE 14</b> Proportion of delivery mode in the THIN–CPRD data set over time and by maternal ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white	69



<b>FIGURE 15</b> Proportion of delivery mode in the HES data set over time and by maternal ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white	71
<b>FIGURE 16</b> Proportion of delivery mode in the THIN-CPRD data set over time and by maternal smoking status before delivery: (a) discontinued; (b) missing; (c) no; and (d) yes	72
<b>FIGURE 17</b> Proportion of delivery mode in the THIN-CPRD data set over time and by different maternal body mass index groups (latest measurement was 9 months before delivery): (a) 0–18.5 kg/m <sup>2</sup> ; (b) 18.5–25 kg/m <sup>2</sup> ; (c) 25–30 kg/m <sup>2</sup> ; (d) 30–34 kg/m <sup>2</sup> ; (e) ≥ 35 kg/m <sup>2</sup> ; and (f) missing	74
<b>FIGURE 18</b> Proportion of delivery mode in the HES data set over time and by parity: (a) 0; (b) 1; (c) ≥ 2; and (d) missing	75
<b>FIGURE 19</b> Proportion of delivery mode in the HES data set with premature rupture of membranes over time	77
<b>FIGURE 20</b> Proportion of delivery mode in the HES data set with post-partum haemorrhage over time	78
<b>FIGURE 21</b> Proportion of delivery mode in the HES data set with manual placental removal/retained products of conception over time	78
<b>FIGURE 22</b> Proportion of women by delivery mode in the THIN-CPRD data set who were prescribed antibiotics during pregnancy over time	79
<b>FIGURE 23</b> Proportion of women by delivery mode in the THIN-CPRD data set over time and with a record of (a) asthma; (b) eczema; and (c) allergic rhinitis and conjunctivitis	79
<b>FIGURE 24</b> Proportion of delivery mode in the THIN-CPRD data set over time and living in different areas of deprivation (as measured by Townsend score, with 1 being most affluent and 5 being most deprived): (a) Townsend score of 1; (b) Townsend score of 2; (c) Townsend score of 3; (d) Townsend score of 4; (e) Townsend score of 5; and (f) missing	81
<b>FIGURE 25</b> Proportion of delivery mode in the HES data set over time and living in different areas of deprivation (as measured by Index of Multiple Deprivation 2015 score, with the lowest score being most affluent and the highest score being most deprived): (a) 0–0.2; (b) 0.2–0.4; (c) 0.4–0.6; (d) 0.6–0.8; (e) 0.8–1; and (f) missing	82
<b>FIGURE 26</b> Proportion of boys in CS and VD births over time in (a) the THIN-CPRD data set and (b) the HES data set	84
<b>FIGURE 27</b> Proportion of delivery mode in the THIN-CPRD data set over time and by child's ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white	85
<b>FIGURE 28</b> Proportion of delivery mode in the HES data set over time and by child's ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white	87

<b>FIGURE 29</b> Proportion of delivery mode in the HES data set over time and by gestational age: (a) < 32 weeks; (b) 32–36 weeks; (c) $\geq$ 37 weeks; and (d) missing	<b>89</b>
<b>FIGURE 30</b> Proportion of delivery mode in the HES data set over time and by the child's birthweight: (a) < 2500 g; (b) 2500–3999 g; (c) $\geq$ 4000 g; and (d) missing	<b>90</b>
<b>FIGURE 31</b> Proportion of women feeding their babies with breast milk only in the few days after birth by delivery mode (data source: Care Quality Commission's Maternity Surveys in 2007, 2010, 2013 and 2017)	<b>91</b>
<b>FIGURE 32</b> Proportion of women feeding their babies with breast milk only at 3 months of age by delivery mode (data source: National Perinatal Epidemiology Unit maternity surveys in 2006, 2010 and 2014)	<b>92</b>
<b>FIGURE 33</b> Incidence rate of asthma per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>94</b>
<b>FIGURE 34</b> Incidence rate of eczema per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>96</b>
<b>FIGURE 35</b> Incidence rate of allergic rhinitis and conjunctivitis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>98</b>
<b>FIGURE 36</b> Incidence rate of food allergy and intolerance per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>100</b>
<b>FIGURE 37</b> Incidence rate of having two or more allergy-related conditions (e.g. asthma, eczema, food allergy/intolerance, allergic rhinitis and conjunctivitis) per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>102</b>
<b>FIGURE 38</b> Incidence rate of penicillin allergy per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>104</b>
<b>FIGURE 39</b> Incidence rate of anaphylaxis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>106</b>
<b>FIGURE 40</b> Incidence rate of high risk of anaphylactic reaction (prescribing of automatic injection devices containing adrenaline) per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>108</b>
<b>FIGURE 41</b> Incidence rate of type 1 diabetes per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>110</b>
<b>FIGURE 42</b> Incidence rate of coeliac disease per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>112</b>
<b>FIGURE 43</b> Incidence rate of childhood vitiligo per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>114</b>
<b>FIGURE 44</b> Incidence rate of wheeze per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>116</b>

<b>FIGURE 45</b> Incidence rate of upper respiratory tract infections per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>118</b>
<b>FIGURE 46</b> Incidence rate of lower respiratory tract infections per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>120</b>
<b>FIGURE 47</b> Incidence rate of bronchiolitis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>122</b>
<b>FIGURE 48</b> Incidence rate of gastroenteritis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>124</b>
<b>FIGURE 49</b> Incidence rate of urinary tract infection per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>126</b>
<b>FIGURE 50</b> Incidence rate of first-time antibiotic prescription per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>128</b>
<b>FIGURE 51</b> Incidence rate of cerebral palsy per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>130</b>
<b>FIGURE 52</b> Incidence rate of autism spectrum disorder per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>132</b>
<b>FIGURE 53</b> Incidence rate of ADHD per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>134</b>
<b>FIGURE 54</b> Incidence rate of colic per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>136</b>
<b>FIGURE 55</b> Incidence rate of failure to thrive per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>138</b>
<b>FIGURE 56</b> Incidence rate of primary care consultations in the first 12 months of life per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set	<b>140</b>
<b>FIGURE 57</b> Incidence of maternal composite infectious morbidity (e.g. wound infection, endometritis/endomyometritis, pelvic abscess and maternal sepsis) per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set	<b>140</b>
<b>FIGURE 58</b> Incidence of wound infection per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set	<b>141</b>
<b>FIGURE 59</b> Incidence of endometritis/endomyometritis per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set	<b>141</b>
<b>FIGURE 60</b> Incidence rate of maternal sepsis per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set	<b>142</b>

<b>FIGURE 61</b> Incidence rate of maternal urinary tract infection per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set	142
<b>FIGURE 62</b> Incidence of antibiotic prescribing in the post partum period per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set	143
<b>FIGURE 63</b> Incidence rate of asthma per 1000 person-years in children born by CS and VD by year of birth in the HES data set	143
<b>FIGURE 64</b> Incidence rate of eczema per 1000 person-years in children born by CS and VD by year of birth in the HES data set	144
<b>FIGURE 65</b> Incidence rate of anaphylaxis per 1000 person-years in children born by CS and VD by year of birth in the HES data set	144
<b>FIGURE 66</b> Incidence rate of type 1 diabetes per 1000 person-years in children born by CS and VD by year of birth in the HES data set	145
<b>FIGURE 67</b> Incidence rate of juvenile idiopathic arthritis per 1000 person-years in children born by CS and VD by year of birth in the HES data set	145
<b>FIGURE 68</b> Incidence rate of autoimmune (idiopathic) thrombocytopenic purpura per 1000 person-years in children born by CS and VD by year of birth in the HES data set	146
<b>FIGURE 69</b> Incidence of late-onset neonatal sepsis per 1000 births in children born by CS and VD by year of birth in the HES data set	146
<b>FIGURE 70</b> Incidence of early-onset neonatal sepsis per 1000 births in children born by CS and VD by year of birth in the HES data set	147
<b>FIGURE 71</b> Incidence rate of other sepsis in children (developed after the neonatal period of 28 days after birth) per 1000 person-years in children born by CS and VD by year of birth in the HES data set	147
<b>FIGURE 72</b> Incidence rate of lower respiratory tract infections per 1000 person-years in children born by CS and VD by year of birth in the HES data set	148
<b>FIGURE 73</b> Incidence rate of bronchiolitis per 1000 person-years in children born by CS and VD by year of birth in the HES data set	148
<b>FIGURE 74</b> Incidence rate of gastroenteritis per 1000 person-years in children born by CS and VD by year of birth in the HES data set	149
<b>FIGURE 75</b> Incidence rate of urinary tract infections per 1000 person-years in children born by CS and VD by year of birth in the HES data set	149
<b>FIGURE 76</b> Incidence of necrotising enterocolitis per 1000 births in children born by CS and VD by year of birth in the HES data set	150
<b>FIGURE 77</b> Incidence rate of leukaemia per 1000 person-years in children born by CS and VD by year of birth in the HES data set	150

## LIST OF FIGURES

<b>FIGURE 78</b> Incidence rate of first-time hospital admission per 1000 person-years in children born by CS and VD by year of birth in HES data set	<b>151</b>
<b>FIGURE 79</b> Incidence of maternal composite infectious morbidity (e.g. wound infection, endometritis/endomyometritis and maternal sepsis) per 1000 births by CS and VD by year of delivery in HES data set	<b>151</b>
<b>FIGURE 80</b> Incidence of wound infection per 1000 births by CS and VD by year of delivery in HES data set	<b>152</b>
<b>FIGURE 81</b> Incidence of maternal sepsis per 1000 births by CS and VD by year of delivery in HES data set	<b>152</b>
<b>FIGURE 82</b> Incidence of maternal urinary tract infection per 1000 births by CS and VD by year of delivery in HES data set	<b>153</b>

# List of supplementary material

**Report Supplementary Material 1** Questionnaire for the national survey of hospitals

**Report Supplementary Material 2** Wider clinician and public consultation survey questionnaire

Supplementary material can be found on the NIHR Journals Library report page (<https://doi.org/10.3310/ZYZC8514>).

Supplementary material has been provided by the authors to support the report and any files provided at submission will have been seen by peer reviewers, but not extensively reviewed. Any supplementary material provided at a later stage in the process may not have been peer reviewed.



## List of abbreviations

ADHD	attention deficit hyperactivity disorder	NICE	National Institute for Health and Care Excellence
CI	confidence interval	OPCS-4	Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures, 4th revision
CPRD	Clinical Practice Research Datalink		
CS	caesarean section	PPI	patient and public involvement
GP	general practitioner	QOF	Quality and Outcomes Framework
HES	Hospital Episode Statistics	RCOG	Royal College of Obstetricians and Gynaecologists
ICD-10	<i>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision</i>	THIN	The Health Improvement Network
IRR	incidence rate ratio	VD	vaginal delivery
MHRA	Medicines and Healthcare products Regulatory Agency		





# Plain English summary

## What was the question?

Women giving birth by caesarean section are at risk of developing infections (such as wound infections) and are offered antibiotics at the time of their operation to reduce this risk. In 2011, the national guidelines changed from recommending antibiotics after cord clamping to giving them before the operation to further reduce the risk of maternal infection. During birth, the newborn gut is colonised by microbes. Antibiotics given to the mother before caesarean section can reach the baby through the placenta and disrupt the normal microbes that colonise the gut. These microbes are believed to play a role in the development of the immune system and altering the normal development of these microbes has been linked to children developing allergic conditions, such as asthma and eczema. This study investigated whether or not giving antibiotics before the caesarean section had a longer-term impact on children's health.

## What did we do?

We used routine NHS information already collected by hospitals and general practitioners about women who gave birth in the UK between 2006 and 2018, and their children. We compared the risk of asthma, eczema and other health conditions in the first 5 years after birth in children born by caesarean section before and after the change in hospital policies. We also compared their health with children born vaginally.

## What did we find?

We found that there was no increased risk of asthma or eczema for children born by caesarean section after the policy decision in 2011 to give the mother antibiotics before the operation.

## What does this mean?

The study findings provide further evidence for the current recommendation to give preventative antibiotics to women shortly before the caesarean section to reduce the overall risk of infections after birth.



# Scientific summary

## Background

In the UK, a caesarean section (CS) is a common surgical procedure, with around one-third of babies being delivered this way. The risk of developing an infection in the post-partum period is considerably higher following CS than vaginal delivery (VD). National Institute for Health and Care Excellence (NICE) Clinical Guideline 132 on CS recommends offering prophylactic antibiotics to women undergoing a CS to reduce the risk of post-partum infections (NICE. *Caesarean Birth*. NICE Guideline NG192. London: NICE; 2021).

Before 2011, this clinical guideline recommended providing intravenous prophylactic antibiotics after cord clamping to prevent the baby from being exposed to the maternal antibiotics. In 2011, the recommendation was changed to offering antibiotics to women before skin incision. This change in recommendation was based on evidence that earlier administration reduces the risk of maternal infections, although most of the infections are mild and respond well to treatment.

Pre-operative antibiotics can cross the placenta, resulting in babies being exposed to them at the time of birth. During birth, the intestines are colonised by microbes and there is a growing body of evidence that intestinal microbe composition in infants plays a key role in the development of their immune system. This intestinal microbiota can be altered by exposure to antibiotics, and disruptions to intestinal microbiota are associated with susceptibility to asthma, eczema, allergies and other immune-related diseases later in childhood.

This study aimed to examine the effect, if any, that changing national guidelines from recommending prophylactic antibiotics after cord clamping to pre-incision antibiotics has had on the incidence of allergic and other related health conditions in children born by CS.

## Objectives

- To investigate if in-utero exposure to pre-incision antibiotics immediately prior to birth compared with no pre-incisional antibiotic exposure increases the risk of (1) asthma and (2) eczema in children born by CS.
- To investigate the effect of pre-incision antibiotics in children born by CS on (1) other allergic and allergy-related diseases, (2) autoimmune diseases, (3) infections and inflammation, (4) other immune system-related conditions, (5) neurodevelopmental conditions and (6) less specific measures of child health (i.e. colic and failure to thrive).
- To investigate the effect of pre-incision antibiotics in children born by CS on health service use (defined as overall consultation frequency in primary care and hospital admissions).
- To investigate if the effects of reducing post-partum maternal infectious morbidity, as shown in randomised controlled trials outside the UK, can be replicated in the UK using routine health-care data.

## Methods

A controlled interrupted time series study was undertaken using data from two routine primary care databases, The Health Improvement Network (THIN) and the Clinical Practice Research Datalink (CPRD), and one secondary care database, Hospital Episode Statistics (HES).

Both THIN and the CPRD contain anonymised patient records from general practices across the UK. Previously published algorithms were adapted to identify those general practices that were contributing to both databases to ensure that the study database did not include duplicate records and to link mother and baby records in THIN.

In the UK health-care system, hospital records relating to delivery and those relating to the baby are separate clinical records and do not have linkage identifiers. This means that, in observational studies, it is difficult to obtain the unique identifiers of children, attribute clinical variables of their delivery to their identifiers and then map future health events back to these variables. Previously validated deterministic and probabilistic linkage strategies were used to link mother and baby records in HES.

All live-born children between 2006 and 2018 were included in the study if their mode of delivery could be determined and if their record could be linked with that of their mother in the databases. The follow-up of children was until the age of 5 years.

The outcomes of the study were defined based on previous literature and refined following two research engagement sessions with parents and parents-to-be from diverse backgrounds and a wider public and clinician consultation. For outcomes recorded in primary care, the study data set containing records of diagnoses in THIN and CPRD was used. For outcomes resulting in hospital admission, the anonymised HES data set was analysed.

The timing of prophylactic antibiotic administration is not recorded in the above databases, and we used information from our national survey of maternity care providers to determine the year when the national guidance was adopted in each unit undertaking CSs.

We compared rates of diagnosis of asthma, eczema and other outcomes over the study period in children delivered by CS. Outcomes were compared according to whether or not the mother of each child received antibiotics before skin incision. In the primary analysis, for primary care data, national policy uptake rates in the year of delivery were used as a basis for estimating the probability that each mother had received pre-incisional antibiotics. For secondary care data, each hospital's response indicating the year of local policy implementation was used.

Children born vaginally were used as a comparator, as these children would have been subject to all the same temporal changes as children delivered by CS, but would not have routinely received prophylactic antibiotics at the time of birth. To investigate the validity of the study model, we also examined changes over time in the case mix covariates to assess any differential changes over the study period in relation to delivery mode.

Data were analysed using a Poisson regression model, with an offset for follow-up duration and adjustment for calendar year of delivery, child's year of life, their interaction, delivery type (vaginal or caesarean) and the probability of exposure to pre-incision prophylactic antibiotics.

## Results

The primary care data set included records of 515,945 mother–baby pairs [144,861 (28.1%) of which were CS deliveries] and the main secondary care data set included records of 3,945,351 mother–baby pairs [1,001,598 (25.4%) of which were CS deliveries] linked to the survey data on pre-incision antibiotics.

Pre-incision antibiotics were not associated with a significantly higher risk of asthma diagnosis in children born by CS [incidence rate ratio (IRR) 0.91, 95% confidence interval (CI) 0.78 to 1.05] and asthma resulting in hospital admission (IRR 1.05, 95% CI 0.99 to 1.11). There was also no evidence of

increased risk of eczema (IRR 0.98, 95% CI 0.94 to 1.03), including for hospital admissions (IRR 0.96, 95% CI 0.71 to 1.29). The results of subgroup analyses by the type of CS (i.e. emergency or elective) and by the type of antibiotic regimen administered (i.e. cefuroxime alone, cefuroxime and metronidazole, co-amoxiclav alone) did not alter these findings.

There were no significantly increased risks associated with exposure to pre-incision antibiotics for any of the other allergic and allergy-related conditions in this study, that is allergic rhinitis and conjunctivitis (IRR 0.98, 95% CI 0.83 to 1.16), food allergy and intolerance (IRR 1.02, 95% CI 0.89 to 1.17), having two or more of the above allergic and allergy-related conditions (IRR 0.99, 95% CI 0.88 to 1.12), penicillin allergy (IRR 0.68, 95% CI 0.42 to 1.08), being at high risk of anaphylactic reaction (IRR 0.81, 95% CI 0.60 to 1.09) and anaphylaxis (IRR 1.07, 95% CI 0.43 to 2.67 and IRR 1.01, 95% CI 0.82 to 1.25 based on diagnosis recorded in primary care and hospital admission, respectively).

We did not find evidence for significantly increased risk in relation to the change to pre-incision antibiotic administration for any of the autoimmune diseases in this study, that is type 1 diabetes diagnosis recorded in primary care (IRR 0.57, 95% CI 0.20 to 1.67) and hospital admissions (IRR 0.99, 95% CI 0.82 to 1.20), coeliac disease diagnosis recorded in primary care (IRR 0.54, 95% CI 0.21 to 1.39), hospital admissions for juvenile idiopathic arthritis (IRR 0.97, 95% CI 0.54 to 1.74), hospital admissions for autoimmune (idiopathic) thrombocytopenic purpura (IRR 1.11, 95% CI 0.88 to 1.39) and childhood vitiligo diagnosis recorded in primary care (IRR 1.13, 95% CI 0.36 to 3.52). The rates of autoimmune conditions in children aged < 5 years, however, were low and there is a high level of uncertainty around the estimates. The number of children with diagnoses of systemic sclerosis and scleroderma, inflammatory myopathies, systemic lupus erythematosus and juvenile pernicious (megaloblastic) anaemia were very small in this age group and meaningful risk estimates could not be calculated.

There was a relative decrease in the risk of neonatal sepsis in children whose mothers gave birth after the introduction of the pre-incision antibiotic policy, with an IRR of 0.75 (95% CI 0.65 to 0.87) for early-onset sepsis and an IRR of 0.88 (95% CI 0.80 to 0.97) for late-onset neonatal sepsis. There was no evidence of differential risk for hospital admissions for sepsis in older children (IRR 0.98, 95% CI 0.91 to 1.04), recording of wheeze in primary care (IRR 1.00, 95% CI 0.93 to 1.06), upper respiratory tract infections (IRR 0.99, 95% CI 0.97 to 1.02), lower respiratory tract infections (IRR 1.04, 95% CI 0.99 to 1.10, for diagnoses in primary care and IRR 0.99, 95% CI 0.9 to 1.01, for hospital admissions), bronchiolitis (IRR 1.05, 95% CI 0.98 to 1.12, for diagnoses in primary care and IRR 1.01, 95% CI 0.98 to 1.03, for hospital admissions), urinary tract infections (IRR 1.00, 95% CI 0.90 to 1.11, for diagnoses in primary care and IRR 1.00, 95% CI 0.95 to 1.04) and gastroenteritis for diagnoses recorded in primary care (IRR 1.03, 95% CI 0.97 to 1.10). The point estimate for gastroenteritis resulting in a hospital admission (IRR 1.02, 95% CI 1.00 to 1.05) was lower than that for all gastroenteritis recorded in primary care; however, because of the much larger size of the secondary data set, the CI was narrower. There was also a very small relative increase in the likelihood of being prescribed antibiotics in early childhood (IRR 1.03, 95% CI 1.00 to 1.06).

Changes in necrotising enterocolitis (IRR 1.16, 95% CI 0.95 to 1.42) and leukaemia (IRR 0.97, 95% CI 0.74 to 1.29) had considerable uncertainty. The number of children with a diagnosis of neurodevelopmental conditions was also small in this study, resulting in estimates with a very wide range of compatible values and, consequently, preventing us from drawing conclusions regarding association with pre-incision antibiotics. The IRR for cerebral palsy was 1.65 (95% CI 0.79 to 3.45) and the IRR for autism spectrum disorder was 1.14 (95% CI 0.77 to 1.67). For attention deficit hyperactivity disorder, the IRR decreased from 2.53 (95% CI 1.05 to 6.12) in the main analysis to 1.24 (95% CI 0.66 to 2.34) in the sensitivity analysis comparing years with > 50% uptake of pre-incision antibiotics (2013–18) with years with very low uptake of pre-incision antibiotics.

We also did not find a convincing increase in risk for colic (IRR 1.06, 95% CI 0.96 to 1.16) and failure to thrive (IRR 1.08, 85% CI 0.87 to 1.34). There was a very small relative increase in the total number of consultations recorded in primary care (IRR 1.02, 95% CI 1.01 to 1.02) and the risk of having a hospital admission for any reason (IRR 1.01, 95% CI 1.01 to 1.02).

Pre-incision antibiotics were associated with a decreased risk of composite maternal infectious morbidity in the unadjusted analysis in primary care (IRR 0.67, 95% CI 0.56 to 0.79), but not in secondary care (IRR 0.98, 95% CI 0.94 to 1.02). In the analysis that controlled for rates in the VD group (as overall rates of recorded maternal sepsis diagnoses in routine health-care records have increased markedly over the study period), the composite risk estimate was significantly decreased for maternal infectious morbidity recorded in both primary care (IRR 0.70, 95% CI 0.63 to 0.77) and secondary care (IRR 0.84, 95% CI 0.81 to 0.87). These estimates are in line with the evidence from randomised controlled trials and the evidence forming the NICE recommendation to give prophylactic antibiotics for CS before skin incision. When controlling for rates in the VD group, we did not find evidence of significantly reduced risk of urinary tract infections (IRR 1.01, 95% CI 0.87 to 1.17 in primary care and IRR 1.04, 95% CI 0.96 to 1.13 in secondary care), but women who gave birth after the pre-incision antibiotic policy was introduced were less likely to be prescribed antibiotics in primary care in the post-partum period (IRR 0.89, 95% CI 0.85 to 0.92) and the length of hospital stay was also slightly reduced (mean difference of -0.23 days, 95% CI -0.24 to -0.21 days).

## Conclusions

Change in the recommendation to pre-incision antibiotics for CS, aiming to further reduce maternal post-partum infectious mortality, was not associated with an increased risk of asthma, eczema and other allergic and allergy-related conditions in young children. It may have reduced the relative risk of neonatal sepsis, although these results should be interpreted with caution, as the study relied on recording of diagnoses in routine health-care records, which have increased for neonatal sepsis over time because of changing thresholds for prevention and treatment of suspected sepsis. There was no convincing evidence for reduced or increased risk in autoimmune and other child health outcomes in this study because of considerable uncertainty around the estimates, and further research in other populations and older children may be warranted.

## Study registration

This study is registered as [researchregistry3736](https://www.researchregistry.com/record/3736).

## Funding

This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 26, No. 30. See the NIHR Journals Library website for further project information.

# Chapter 1 Background, aims and objectives

## Background and rationale

In the UK, a caesarean section (CS) is a common surgical procedure, with around one-third of babies being delivered this way.<sup>1-4</sup> The risk of maternal post-partum infections is considerably higher following CS than following vaginal delivery (VD).<sup>5</sup> National Institute for Health and Care Excellence (NICE) Guideline 192 on caesarean birth<sup>6</sup> recommends offering women undergoing CS prophylactic antibiotics that work against the organisms causing wound infections, endometritis and urinary tract infections to reduce the risk of post-partum infections.

Before 2011, this NICE clinical guideline recommended giving intravenous prophylactic antibiotics after cord clamping to prevent the baby from being exposed to the maternal antibiotics. In 2011, the recommendation was changed to offering antibiotics to women before skin incision for CS.<sup>7</sup> This change in recommendation was based on evidence that earlier administration reduces the risk of maternal infections, although most of these infections are mild and tend to respond well to treatment.<sup>8</sup> A Cochrane review<sup>9</sup> on the timing of intravenous prophylactic antibiotics for preventing post-partum infectious morbidity in women undergoing cs delivery included evidence from 10 randomised controlled trials (including a total of 5041 women). The review showed a significant reduction in the risk of combined post-partum infections [43%, 95% confidence interval (CI) 28% to 55%], wound infection (41%, 95% CI 19% to 56%) and endometritis (46%, 95% CI 21% to 64%) in women receiving antibiotics prior to cord clamping, compared with administering antibiotics after cord clamping.<sup>9</sup>

It is known, however, that these high-dose broad-spectrum pre-operative antibiotics cross the placenta, with concentrations detectable within 20–30 minutes, resulting in babies being exposed to the antibiotics at the time of birth.<sup>9,10</sup> Although the Cochrane review found no evidence of neonatal adverse effects,<sup>9</sup> intrapartum antibiotics have been shown to significantly disrupt the intestinal microbiota of babies.<sup>11</sup> During birth, the gut is colonised by microbes<sup>12</sup> and the mode of delivery is known to significantly affect the composition of intestinal microbiota both in the neonatal period and later in infancy.<sup>13</sup> These microbiota appear to be key for intestinal immune tissue to differentiate resident commensal bacteria from potential pathogens.<sup>14</sup> In addition, there is a growing body of evidence that intestinal microbe composition in infants plays a key role in the development of their immune system, including regulation of response to different antigens and inflammation, and disruptions to intestinal microbiota are associated with susceptibility to asthma, allergies and other immune-related diseases later in childhood.<sup>15-22</sup>

A recent systematic review<sup>14</sup> explored the association between intestinal microbiota and the development of asthma, eczema and allergic sensitisation to food allergens in newborns and children. The review found evidence that reduced bacterial diversity and a greater or reduced abundance of particular bacteria was associated with the development of these health conditions. There is also an association between reduced intestinal bacterial diversity in the first months of life and development of allergic rhinitis.<sup>23</sup>

Some evidence also suggests that gut microbiota may have an influence on the development of autoimmune diseases. For example, gut microbiota have been linked to the development of type 1 diabetes,<sup>24</sup> coeliac disease<sup>25</sup> and systemic connective tissue disorders.<sup>26,27</sup> The evidence in this area is acknowledged to be limited. It is, however, hypothesised that the mechanisms driving autoimmune disease development are similar to those involved in the development of allergic diseases.<sup>28</sup>



There is limited evidence that explores the link between the gut microbiome and infectious and inflammatory disease and other immune system-related conditions. Intestinal microbiota are likely to be involved in the development of necrotising enterocolitis and inflammatory bowel disease.<sup>29</sup> It has also been hypothesised that childhood acute lymphoblastic leukaemia development could have an immune component driven by microbial exposures in early life.<sup>30</sup>

One study has shown an increased risk of cerebral palsy in children born to mothers who were given antibiotics in spontaneous pre-term labour.<sup>31</sup> There is also a small body of research evidence that suggests associations between differences in gut microbiota and other neurodevelopmental conditions, but there is a consensus that further longitudinal assessment of the role of the gut microbiome in neurodevelopmental disorders is required.<sup>32,33</sup>

In the broader area of child health, there is a small amount of evidence looking at gut microbiota and symptoms, such as colic, and general health measures, such as expected weight gain. Infants affected by colic have been reported to have different levels of intestinal bacterial diversity from unaffected infants.<sup>34</sup> Some types of gut bacteria appear to be associated with different growth patterns in babies.<sup>35</sup>

As antibiotic exposure around the time of birth leads to different gut microbiota patterns in newborns and different microbiota patterns are associated with longer-term health conditions, the change in the timing of when mothers receive prophylactic antibiotics presents a natural experiment. Babies born to mothers who were provided antibiotics after cord clamping are exposed to no antibiotics. Those born to mothers given pre-operative antibiotics are exposed to high-dose broad-spectrum antibiotics that are likely to affect their gut microbiota.

In this study, we aimed to compare the outcomes for babies born by CS who were and who were not exposed to antibiotics given to the mother at the time of birth. The primary outcomes of interest in this study were asthma and eczema. These are the two most frequent allergy-related, doctor-diagnosed conditions in childhood and are associated with changes in gut microbiota composition in infants.<sup>18,20</sup> They are commonly seen in primary care and are well recorded.<sup>36,37</sup> With a prevalence of 3% in children aged 0–5 years, asthma is a relatively common health condition in childhood, with the largest numbers of emergency hospital admissions for any long-term condition in young children in the UK.<sup>38,39</sup> Although deaths due to asthma in children are rare, they do occur, accounting for 1–2% of all asthma deaths.<sup>38,40</sup>

Eczema is a very common condition in childhood, with a prevalence of 18% of ‘ever diagnosed eczema’ in children aged 0–5 years reported in the UK.<sup>41</sup> Eczema usually develops in very early childhood and can affect a child’s sleep, their social and emotional development, and quality of life. It incurs significant societal costs because of lost school days, lost working days for parents and costs to the NHS, including prescription of topical corticosteroids.<sup>42</sup>

As the evidence regarding the role of microbiota in the development of diseases is evolving, we also assessed whether or not in-utero exposure to broad-spectrum antibiotics immediately prior to birth increases the risk of a range of other immune system-related health conditions in the first 5 years of life in children born by CS.

## Aims and objectives

### Overall aim

The overall aim of the study was to examine the impact, if any, that the change in the national recommendation from advising administering prophylactic antibiotics post-cord clamping to administering antibiotics before skin incision has had on the risk of allergic and other related health outcomes in children delivered by CS.

### **Primary objectives**

The main objective was to investigate if prophylactic antibiotic exposure of the fetus immediately before birth (intervention) compared with no antibiotic exposure (comparator) increases the risk of (1) asthma and (2) eczema (outcomes) in children delivered by CS (population).

### **Secondary objectives**

- To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS on (1) other allergic and allergy-related health conditions, (2) autoimmune conditions, (3) infections and inflammation, (4) other immune system-related health conditions, (5) neurodevelopmental health conditions and (6) less specific child health measures (i.e. colic and failure to thrive).
- To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS on health service use (defined as overall primary care consultation frequency and hospital admissions).
- To investigate if the effects of reducing post-partum infections in mothers, as reported in randomised controlled trials conducted outside the UK,<sup>9</sup> can be replicated in the UK using routine health-care records.



# Chapter 2 Methods

## Study design and setting

The primary objective and first two secondary objectives were addressed by undertaking a controlled interrupted time series study.<sup>43</sup> It comprised a cohort of children born in the UK between 2006 and 2018 and their mothers, whose health-care records were included on a primary care database [i.e. The Health Improvement Network (THIN) or the Clinical Practice Research Datalink (CPRD)] or a secondary care database [Hospital Episode Statistics (HES)].

The interrupted time series component of the study compared rates of diagnosis of asthma, eczema and other immune system-related diseases over the study period in children delivered by CS between time periods when the mother of each child was likely to receive antibiotics before skin incision and periods when it was likely that antibiotics would be administered after cord clamping.

Validity in this comparison of incidence rates is mostly threatened by temporal changes in the diagnosis and recording of health conditions and different exposures that can have an impact on the number of cases identified in routine data, rather than from case mix confounders, as indications for CS and CS incidence have changed little over the study period. As an example, patterns of asthma diagnosis have changed over time, which can, in part, be attributed to the revisions in the national asthma management guidance<sup>44</sup> and the potentially conflicting compliance and prevalence issues faced in meeting asthma-specific Quality and Outcomes Framework (QOF) indicators introduced in 2004.<sup>45</sup>

Conducting an analysis dependent on adjustment for confounding factors was unlikely to succeed in controlling for these changes, because (1) it is uncertain what all the drivers of all these changes have been, (2) it is uncertain whether or not any covariates exist that accurately describe these changes without substantial missing data and (3) there are challenges in specification of a functional form for the relationship between these covariates and outcome. Instead, to account for such temporal changes, we included children born by VD as a control group, as these children would have been subject to all the same temporal changes as children delivered by CS, but would not have routinely received prophylactic antibiotics. *Figure 1* shows that, although the national uptake of pre-incision antibiotic policy has increased over the study period, incidence rates of asthma decreased equally in children born by CS and those born by VD.

Our model first computed the ratio of the incidence of outcomes in those receiving CS compared with VD in each year and age group. The incidence of some outcomes, including asthma, is known to differ by delivery mode.<sup>46-48</sup> It then compared these ratios between periods when mothers of children delivered by CS would have received antibiotics before skin incision and periods when mothers of children delivered by CS would have received antibiotics after cord clamping. This 'ratio-of-ratios' is an indicator of how the incidence of disease has increased (if  $> 1$ ) with pre-incision antibiotics, stayed the same (if = 1) or decreased (if  $< 1$ ), while adjusting for temporal changes through the matching of outcomes in children born vaginally. Subject to the assumption that the model of the difference between CS and VD rates is transferable across the time periods, differences between the observed and counterfactual CS event rates were interpreted as likely to be caused by the change in practice.

In the primary analysis, for primary care data, national policy uptake rates in the year of delivery were used as a basis for estimating a probability that each mother had received pre-incisional antibiotics and, therefore, the analysis actually used this probability as the explanatory variable, rather than a 0–1 variable. For secondary care data, we used each hospital's response indicating the year of local policy implementation. This was obtained from our national survey of maternity care providers, which provided a 0–1 variable.




FIGURE 1 Illustration of the need to use VDs as the comparator group because of changing temporal patterns in outcome events unrelated to routine exposure to pre-incision antibiotics, using asthma as an example. (Rates after 2014 are further reduced because of < 5 years of follow-up and much lower incidence of asthma in very young children.)

To address the final secondary objective, we compared the incidence of post-partum maternal infectious morbidity post intervention with pre-intervention rates to investigate if the effects of reduced morbidity that are shown in randomised controlled trials outside the UK<sup>9</sup> that form the basis for the NICE guideline change<sup>7</sup> can be replicated in the UK using routine health-care data. This analysis has been carried out for two reasons: (1) to measure the assumed impact using 'real-world data' to enable us to compare the benefits of pre-incisional antibiotics on maternal outcomes against any potential harms for the child and (2) to assure us that any lack of effect of the different prophylactic antibiotic policies was not due to the quality of the routine data. We calculated the crude estimates and, because of the observed overall changes in the incidence of different maternal post-partum infections recorded in routine data over time, we also undertook controlled analysis adjusting for delivery mode.

## Population and eligibility criteria

To be eligible for inclusion in the study, records of all live-born children needed to meet the following criteria:

- The year of birth was between 2006 and 2018.
- It was possible to link the baby and their mother's health-care record in primary care (THIN or CPRD) databases or a secondary care (HES) database.
- The delivery mode (CS or VD) could be determined based on recording in primary (THIN or CPRD) and/or secondary care (HES).

If children had missing delivery information, they were excluded. In the case of multiple births (such as twins), one of the children was included randomly to ensure independence of observations.<sup>49</sup>

The duration of follow-up of children born between 2006 and 2014 was until the age of 5 years. The follow-up of children born in 2015, 2016, 2017 and 2018 was limited to 4, 3, 2 and 1 years, respectively.

For primary care data, the exposure, outcomes and covariates were defined using the Read clinical code classification system. In HES, *International Statistical Classification of Diseases and Related Health Problems*, Tenth Revision (ICD-10) was used for clinical diagnoses and the Office of Population Censuses and Surveys *Classification of Surgical Operations and Procedures*, 4th revision (OPCS-4)

for procedures. The code lists are available online at URL: <https://github.com/NIHR-Pre-incision-Antibiotics/ClinicalCodes> (accessed 8 July 2021).

The process for Read code selection was as follows:

- Stage 1 – a list of key words and synonyms for each variable of interest was compiled.
- Stage 2 – the terms identified in stage 1 were used to search the description column of the Read code dictionary/database to identify the main chapter and appropriate level 3 stem code in the Read code dictionary.
- Stage 3 – stem codes were then used to identify other related Read codes, up to level 7, associated with the main stem codes. These Read codes were then selected and stored.
- Stage 4 – where available, for each outcome of interest, online Read code repositories and supplementary information from published articles that had used a similar set of Read codes were identified. These were then compared with our selected set of Read codes and further useful codes were added at this point.
- Stage 5 – with reference to the inclusion and exclusion criteria, the team identifying and selecting Read codes allocated weights to each Read code as follows: (1) definite (the team were sure that the Read code met the study inclusion criteria), (2) probable (the team felt that these codes could meet the inclusion criteria but needed further discussion), and (3) excluded (the study team felt that these codes definitely did not meet the inclusion criteria).
- Stage 6 – consensus was sought through consultation with study team researchers and public contributors, general practitioners (GPs) or specialty field experts on the final list of codes to be used, which were utilised for electronic data extraction.

Selection of ICD-10 and OPCS-4 codes to obtain admitted patient care data was generally straightforward. The validity of each coding algorithm was checked through triangulation of a number of sources. First, recently published studies based on routinely collected data were screened to check for consensus in the research community as to how to code specific reasons for admission. Second, checks of resources for clinical coders (the NHS coding clinic and the Terminology and Classifications Service in NHS Digital) were carried out. Third, technical appendices of outputs produced by the NHS and the Office for National Statistics were checked to see what coding definitions were used in reporting by public bodies. Last, to check for the specificity of coding (i.e. the extent to which fourth digits were commonly used or, if coding tended to default to 'other' or 'not elsewhere classified') individual analyses of English admitted patient care data were undertaken.

The delivery mode is recorded well in hospital records.<sup>2</sup> We used OPCS-4 procedure codes, which are available for 98% of births in HES,<sup>50</sup> to derive the mode of delivery and ICD-10 codes for the remaining deliveries. Our estimates showed that the delivery mode is also accurately recorded in primary care using Read codes (98% verified against hospital records). The recording, however, was incomplete (the delivery mode was known for 50% and 69% of children in THIN and CPRD data sets, respectively, with the higher proportion in CPRD due to the supplied data set being restricted to the records in the CPRD pregnancy register). For THIN and CPRD records not linked to HES, we used the Read codes to identify the mode of delivery, which increased the number of children in the sample.

## Study outcomes

The primary outcomes in this study were the incidence of (1) asthma and (2) eczema. Asthma and eczema outcomes in the THIN–CPRD data set were defined using lists of relevant Read codes, which were created following the steps described above (see *Population and eligibility criteria*). Furthermore, Read code lists for both asthma and eczema have been previously validated in primary care.<sup>51,52</sup> Therefore, existing validated lists were used as the basis for the outcome definition in this study and further codes were added following consultation with the wider research team, which included a GP

and an allergy and immunology consultant. In line with the paper on the validation of eczema coding,<sup>51</sup> in addition to a Read code for eczema diagnosis, at least two prescriptions on separate dates for any eczema-related treatment were also required to reflect the chronic nature of the condition. In the HES data set, asthma and eczema were defined if a ICD-10 code for asthma or eczema was used as the main primary diagnosis for the hospital admission.

The main analysis for these outcomes was carried out separately in the primary care data set and the secondary care (HES) data set (the latter analysis including only those hospitals for which the year of antibiotic prescribing policy change was known).

We also explored the relationship between antibiotic exposure and asthma and eczema severity in the primary care data set. Moderate/severe asthma was defined as having a Read code for asthma diagnosis and a prescription code for a corticosteroid inhaler and either a leukotriene receptor antagonist or a systemic steroid. As the severity of asthma is not reliably coded, a prescription for a leukotriene receptor antagonist or a systemic steroid is indicative of asthma that is uncontrolled on inhaled corticosteroids (i.e. moderate or severe asthma). Moderate/severe eczema was defined as having a Read code for eczema diagnosis and at least two prescriptions on separate dates, with at least one prescription for treating moderate or severe eczema (i.e. moderate, potent or very potent steroid, topical calcineurin, systemic therapy or phototherapy), as described in the NICE guideline for eczema.<sup>53</sup>

Secondary outcomes are listed in *Table 1*. We excluded immune deficiencies from the outcome list, as Read and ICD-10 codes did not allow us to differentiate between congenital and acquired immunodeficiencies. We also did not include pelvic abscess as a separate outcome in the analysis of secondary care data, as there was no specific ICD-10 code for this condition.

## Covariates

To assess the validity of the model we used in controlling for temporal confounders, we explored changes in the case mix covariates to identify any differential changes over time in relation to the mode of birth. To identify relevant covariates, a literature review of reviews was conducted on the risk factors for the primary study outcomes (i.e. asthma and eczema) and postnatal maternal infections. MEDLINE and Google Scholar (Google Inc., Mountain View, CA, USA) were searched for articles written in English that reported the effect of any risk factor for the conditions mentioned. Identified covariates included maternal demographic characteristics,<sup>54</sup> behaviour-related factors,<sup>54-58</sup> pregnancy- and labour-related factors,<sup>54,57</sup> antibiotic prescribing during pregnancy,<sup>56,59,60</sup> maternal long-term allergy-related conditions,<sup>61-64</sup> deprivation,<sup>54,55,58,65,66</sup> child demographic and birth characteristics,<sup>54,55,58,59,62,64-67</sup> breastfeeding,<sup>55,67</sup> child health conditions<sup>55,61-65,67</sup> and antibiotic prescribing in childhood<sup>55,60,67</sup> (*Table 2*).

## Data sources and mother–baby linkage

### *Electronic primary and secondary health-care records*

#### **THIN and CPRD**

The Health Improvement Network and CPRD GOLD are two UK-wide primary care databases of anonymised patient records from general practices that use the same computer software (Vision, Cegedim Rx Ltd and In Practice Systems Ltd, London, UK), together covering over 10% of the UK population.<sup>68</sup> In addition, a significant proportion of patients (about 30% in THIN and 60% in CPRD) have linked secondary care (HES) data. Both THIN and CPRD GOLD databases are broadly generalisable to the UK population in terms of patient demographics and health condition prevalence.<sup>69,70</sup> The University of Birmingham (Birmingham, UK) holds a sublicense for the full THIN database. The CPRD GOLD data set was acquired from the CPRD centre of the Medicines and Healthcare products Regulatory Agency (MHRA) for use in this specific study.

TABLE 1 The list of secondary outcomes

Outcome	Corresponding secondary objective	Data set analysed	
		Primary care	Secondary care <sup>a</sup>
Health conditions and symptoms in children	To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS		
Other allergic and allergy-related conditions	To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS on other allergic and allergy-related health conditions		
Food allergy/intolerance		✓	
Allergic rhinitis and conjunctivitis		✓	
One or more allergy-related disease (e.g. asthma, eczema, food allergy/intolerance, allergic rhinitis and conjunctivitis)		✓	
Penicillin allergy <sup>b</sup>		✓	
Anaphylaxis <sup>b</sup>		✓	✓
High risk of anaphylactic reaction (prescribing of automatic injection devices containing adrenaline) <sup>b</sup>		✓	
Autoimmune diseases	To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS on autoimmune conditions		
Type 1 diabetes <sup>b</sup>		✓	✓
Coeliac disease <sup>b</sup>		✓	✓
Juvenile idiopathic arthritis <sup>b</sup>		✓	✓
Scleroderma/systemic sclerosis <sup>b</sup>		✓	✓
Inflammatory myopathies <sup>b</sup>		✓	✓
Systemic lupus erythematosus <sup>b</sup>		✓	✓
Autoimmune (idiopathic) thrombocytopenic purpura <sup>b</sup>		✓	✓
Juvenile pernicious (megaloblastic) anaemia <sup>b</sup>		✓	✓
Childhood vitiligo <sup>b</sup>		✓	
Infections and inflammation	To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS on infections and inflammation		
Neonatal sepsis (early and late onset)			✓
Other sepsis <sup>b</sup>			✓
Wheeze		✓	
Upper respiratory tract infections <sup>b</sup>		✓	
Lower respiratory tract infections <sup>b</sup>		✓	✓
Bronchiolitis <sup>b</sup>		✓	✓
Gastroenteritis <sup>b</sup>		✓	✓
Inflammatory bowel disease		✓	✓
Urinary tract infections <sup>b</sup>		✓	✓
Antibiotic prescribing <sup>b</sup>		✓	

continued



TABLE 1 The list of secondary outcomes (continued)

Outcome	Corresponding secondary objective	Data set analysed	
		Primary care	Secondary care <sup>a</sup>
Other immune system-related conditions	To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS on other immune system-related health conditions		
Necrotising enterocolitis			✓
Leukaemia <sup>b</sup>		✓	✓
Neurodevelopmental conditions	To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS on neurodevelopmental health conditions		
Cerebral palsy		✓	
Autism spectrum disorder <sup>b</sup>		✓	
ADHD <sup>b</sup>		✓	
Less specific measures of child health	To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS on less-specific child health measures		
Colic <sup>b</sup>		✓	
Failure to thrive <sup>b</sup>		✓	
Health-care utilisation in children	To investigate the impact of exposure to pre-incision antibiotics in children delivered by CS on utilisation of health services (defined as overall primary care consultation frequency and hospital admissions)		
Primary care consultations <sup>b</sup>		✓	
Hospital admissions <sup>b</sup>			✓
Maternal outcomes (up to 6 weeks post partum)	To investigate if the effects of reducing post-partum infections in mothers, as reported in randomised controlled trials conducted outside the UK, can be replicated in the UK using routine health-care records		
Composite infectious morbidity (wound infection, endometritis/endomyometritis, pelvic abscess, <sup>c</sup> maternal sepsis, maternal death <sup>d</sup> )		✓	✓
Endometritis/endomyometritis		✓	✓
Wound infection		✓	✓
Urinary tract infection/cystitis/pyelonephritis		✓	✓
Sepsis		✓	✓
Pelvic abscess		✓	
Maternal death <sup>b,e</sup>			✓
Antibiotic prescribing <sup>b</sup>		✓	
Length of hospital stay <sup>b</sup>			

ADHD, attention deficit hyperactivity disorder.

a In secondary care, the main primary diagnosis was used, except for maternal outcomes, neonatal sepsis and necrotising enterocolitis, for which any diagnosis mention in the hospital admission episode was included.

b These are exploratory outcomes where the existing evidence of an association between microbiota/early antibiotic exposure and the outcome of interest was inconsistent or poor (e.g. because of a lack of longitudinal studies).

c Pelvic abscess was part of the composite infectious morbidity recorded in primary care.

d Only if there was also a record of a diagnosis of any of the health conditions included in the composite infectious morbidity outcome.

e Information on the cause of death was not available and the deaths reported here include deaths if there was also a diagnosis of any of the health conditions included in the composite infectious morbidity outcome in the maternal record in the post-partum period.

TABLE 2 The list of potential covariates and data sets used to analyse each variable

Covariate	Data set analysed		
	Primary care	Secondary care	National maternity surveys
Maternal characteristic			
Age at childbirth	✓	✓	
Ethnicity	✓	✓	
Smoking status	✓		
BMI before pregnancy	✓		
Parity		✓	
Premature rupture of membranes		✓	
Post-partum haemorrhage		✓	
Manual placental removal/retained products of conception		✓	
Antibiotic prescribing during pregnancy	✓		
Asthma	✓		
Eczema	✓		
Allergic rhinitis and conjunctivitis	✓		
Household characteristic			
Deprivation score	✓	✓	
Child characteristic			
Sex	✓	✓	
Ethnicity	✓	✓	
Gestational age		✓	
Birthweight		✓	
Age <sup>a</sup>	✓	✓	
Breastfeeding (first few days and 3 months)			✓
Asthma <sup>b</sup>	✓	✓	
Eczema <sup>b</sup>	✓	✓	
Allergic rhinitis and conjunctivitis <sup>b</sup>	✓		
Food allergy/intolerance <sup>b</sup>	✓		
Upper respiratory tract infections <sup>b</sup>	✓		
Lower respiratory tract infections <sup>b</sup>	✓	✓	
Bronchiolitis <sup>b</sup>	✓	✓	
Antibiotic prescribing <sup>b</sup>	✓		

BMI, body mass index.

a Accounted for in person-years calculation.

b These variables were both outcomes and potential covariates for other outcomes in this study.

### ***Identification and removal of duplicate practices***

The Health Improvement Network and CPRD GOLD databases have some overlap at practice level, with 37% and 46% unique practices, respectively, reported previously.<sup>68</sup> Our sample size calculations showed that both primary care databases were required to provide sufficient power to answer the research questions. We adapted a previously published algorithm to identify practices common to both CPRD GOLD and THIN.<sup>71</sup> Although the databases do not use the same identifiers for patients or practices, the overlapping practices can be identified and removed reliably using practice-related information, patient registration, demographic and medical record information.<sup>68,71</sup>

We extracted practice- and patient-level data to identify common/duplicate practices in THIN and CPRD. The following practice-level data were extracted: (1) the number of males and females born between 1905 and 1910, between 1910 and 1915 and between 1915 and 1920; (2) the number of males and females newly diagnosed with type 2 diabetes in the year 2010; and (3) the total number of patients who received at least one drug prescription in the year 2010. In total, this amounted to nine practice-level variables that we extracted from the THIN database and the same variables were provided to us on request from CPRD GOLD.

For patient-level data, we examined aggregated information from a sample of patients. To extract our patient-level variables, we calculated an eligible time period where both THIN and corresponding CPRD GOLD practices were contributing data to their respective data set. The eligible period was defined as the time between the 'latest' and 'earliest' set of dates for each database as follows: latest of (1) THIN Vision date, (2) THIN acceptable mortality reporting date, (3) THIN computerisation date or (4) CPRD GOLD 'up to standard' date (a quality indicator); and the earliest of (1) THIN collection date or (2) CPRD collection date. Defining the eligible time period was important, as the patient-level data we extracted for deduplication can vary outside this period. For example, there might be patients who were registered with THIN earlier, but were transferred out before the practice started contributing data to CPRD GOLD. If such patient-level data were extracted from THIN, then we would not be able to confirm their characteristics in CPRD GOLD, as their data were never present in it. Alternatively, we might have found similar patient-level characteristics by chance in candidate practices that are not duplicates.

For each THIN and CPRD GOLD practice pair, we used CPRD GOLD data and randomly selected 10 patients who were registered in the practice within the eligible period. We extracted their registration date, year and month of birth, sex, family identification number, first three consultation types, consultation dates and duration of consultations for matching. We created two new scores, (1) 'patient point' and (2) 'consultation point', and set both to zero. We looked in the corresponding THIN practice to find patients with the same information. If a patient was found in THIN with the same registration data, sex and date of birth information, then the patient point was incremented by 1 and, for the same patient, we incremented consultation points by 1 for each consultation information that was matched as equal in both databases.

After considering patient- and practice-level scores, we found 450 practices contributing to both THIN and CPRD. Among the duplicate practices, we retained the practice (from THIN or CPRD GOLD) that contributed the highest number of babies to the study.

### ***Linkage of mothers and babies***

Information on mothers and their babies can be linked in CPRD GOLD and THIN using the family identification number, delivery codes, mother's registered or estimated date of delivery, child's birth month, gestational age at delivery and, where available, the sex of the baby, with reported identification of the vast majority of mother-child pairs.<sup>72,73</sup>

Clinical Practice Research Datalink GOLD data held by the CPRD centre of the MHRA include a mother-baby link and, because of CPRD data minimisation requirements, we were given access to

already linked mother–baby CPRD data. CPRD has linked mothers and children using several methods, including delivery-related information, information indicating pregnancy and pre- and postnatal information, which is explained in detail elsewhere.<sup>74</sup>

To link mothers and babies in the THIN–HES and THIN primary care database, for each mother and for each delivery record she had within the study period, we looked in the associated database record to see if there was a baby with the same family number as that of the mother and linked them to the mother if the following conditions were true:

- The baby’s year and month of birth were the same as the mother’s year and month of delivery.
- The baby was registered with the practice within a year of birth.

In addition, after linkage, if the sex of the newborn was provided in the mother’s HES delivery record, then we cross-checked it with that in the primary care data to ensure accuracy. In addition, where a mother had more than one baby matching (e.g. twins), we randomly chose one baby.

We excluded delivery records and baby records that did not meet our matching criteria.

### **Defining index and exit date for patients in THIN and CPRD**

For each of the records containing delivery information in HES, we checked if patient data existed in the associated THIN/CPRD practice records. If found, for each mother–baby pair, we set the index date as the date of delivery, defined as the OPCS-4 date or the hospital episode end date if the OPCS-4 date was missing. For mother and baby pairs for whom HES data did not exist, we assigned the date of birth of the baby as the index date for the baby and the date of delivery for the mother. These two dates can differ because only the month of birth is given in the baby’s records. At the same time, delivery date may reflect the date the information was entered in primary care records, as opposed to the true delivery date. We also defined the patient start date separately for the mother and baby as the latest of the date the quality of data was verified, study start date (1 January 2006) or registration date with the practice. For the mother, the day when they reached age 13 years was also included in determining the patient start date. We also defined the patient end date separately for the mother and baby, to determine the end of maximum follow-up for each patient, as the earliest of the death date, the date the patient left the general practice, 31 December 2018 or the last practice data collection date. If the patient was a mother, we added 6 weeks to the date of delivery in the list when calculating the patient end date, as maternal outcomes were limited to the post-partum period. If the patient was a baby, we included their date of birth plus 5 years in the list when calculating the patient end date. Once we defined these three key dates (i.e. the index date, patient start date and patient end date), we removed any patients whose start date was after their end date (e.g. error in recording of dates), whose index date was not between the start and end dates (e.g. if the HES data had information after the patient left the practice) or whose age at index date was not between 13 and 50 years (mother only).

### **HES data covering the whole of England**

A mother–baby linked database was created using anonymised HES data collected for all NHS hospital admissions in England<sup>75</sup> to allow the investigation of more severe outcomes of interest resulting in hospital admissions.

We requested HES data from NHS Digital on all delivery events occurring in English hospitals from financial years 2005/6 to 2017/18. We also asked for any admissions data relating to patients under the age of 5 years with the same encrypted HES identifier as a baby delivered in any of these delivery events and, for the mothers who underwent a delivery episode, any admissions either 1 month before delivery or 6 weeks after the start of the delivery episode. The application process was protracted.

We completed the application in August 2018, but received data for the financial years 2005/6 to 2016/17 in April 2019. A data update for 2017/18 and 2018/19 was received in March 2020, but because of the project time restrictions, we were able to add only the latest admission data for the mother–baby pairs that we had already linked in the database using records for 2005/6 to 2016/17.

There is no shared identifier in the UK to link maternal and baby records in HES. We adapted a strategy that had already been validated by another recent study<sup>76</sup> using deterministic and probabilistic linkage algorithms, allowing linkage of up to 98% of baby and mother secondary care records in England and still remaining nationally representative for the main birth characteristics (e.g. gestational age, birthweight, sex and maternal age). The processing workflow is outlined below.

We identified all of the delivery episodes and the spells to which they belonged. Episodes in which maternity care is delivered have a specific set of fields that contain critical data about the delivery pathway, as well as the usual data set of diagnostic and procedure fields that occur in any other kind of hospital admission episode. These are called the ‘maternity tail’ and include variables such as the weight of the baby, the maternal age, the pregnancy term in weeks and other clinical details. There is not an automatic linking field between babies and mothers in the anonymised data available in HES and so a simple linkage allowing details of a birth to be linked to future admissions involving the child is not possible. However, a baby born in hospital is technically admitted to the hospital and has an admission episode, even if they require no clinical treatment. This episode should contain all of the same data as the ‘maternity tail’ in the mother’s record. In practice, there are often a number of missing data items in the mother’s record and, more often, in the baby’s record. It is possible, however, to create an algorithm that evaluates the likelihood of a particular baby’s episode being linked to a particular mother’s birth event. For example, if all of the maternity fields match, if the baby’s admission date is the same day as the delivery and if the registered GP, the hospital and the postal district prefix of the postcode of residence are the same, then the chance that this delivery did not relate to this baby would be very low. If most of the data matched, but there were some missing items and no data items that contradicted each other, then the chances of mismatch would also be very small. If there was only one likely baby match, we could assume a deterministic linkage. The chances of an erroneous match would increase a little with each missing pair of data items, and it is possible that a situation could occur in which more than one baby could be matched to the birth episode could occur. In these cases, we had to apply probabilistic matching based on a matching threshold.

The first major data manipulation task was identifying all of the delivery episodes that we were going to match. This is not a straightforward task, as episodes that contain data relating to deliveries are sometimes not specifically flagged as a delivery episode. In addition, some episodes that are clearly flagged as delivery episodes do not contain all of the data needed to obtain a match. This is because there can be a number of episodes in a spell in hospital that include a delivery and, despite coding and clerking standards, some data that belong in one episode can be spread across more than one. We identified any episode that met the criteria used by Harron *et al.*,<sup>76</sup> namely that the episode should contain a code indicating the delivery of a live infant, a procedure code for a delivery procedure or have two or more ‘maternity tail’ fields that are completed with a valid (i.e. not null or system missing) value. When these episodes had been identified, we used the unique spell identifier to extract all episodes in each spell containing a delivery episode.

Cleaning was carried out to remove duplicate records, episode durations with implausible date ranges and births where there was an implausible interval between two or more birth events. This happens rarely and is usually because a mother is misidentified in the data set and is given the same NHS identifier (ID) as someone else. If both these women had given birth within, for example, 6 weeks of each other, then it appears that one woman has given birth twice, with an implausible duration between the two deliveries. In these cases, records for both women were censored.

### ***Mother–baby linkage***

The Harron *et al.*<sup>76</sup> methodology was based on a complex synthetic data set where iterations of data removal were undertaken in key mother and baby variables and probabilities of mismatches were calculated given that different variable or combinations of variable were missing on one side or the other of the match. Through this process, a series of probabilities for different matching scenarios were calculated, as well as a series of weights to determine the likelihood of a valid match, given that a specific variable was matched or not matched. The process was based on 1 year of data for 2012/13. Data recording in HES was improving year on year in the period of our study. It is likely that the data years before 2012/13 would have had more missingness than the Harron *et al.*<sup>76</sup> data and the years afterwards. As Harron *et al.*'s<sup>76</sup> weights were calculated roughly in the middle of our period of study, we felt that they could be applied reliably to our data. We decided that rather than replicating the original synthetic data set creation, which would have been outside the resource capabilities of this study as originally designed, we would repeat Harron *et al.*'s<sup>76</sup> matching methods, but use the matching weights published in their paper.<sup>76</sup>

During key stages in the work, we had clarification from Harron *et al.*<sup>76</sup> on some of the aspects of their method that were not covered in detail in the publication. The linkage was carried out in two stages. Where data could be linked using a simple rules-based approach following the original study, we followed the original authors in referring to this as deterministic linkage. Any delivery events that could not be linked deterministically were linked probabilistically.

### ***Deterministic (rules-based) linkage***

Mother and baby records were treated as matching if records matched on general practice, maternal age, birthweight, gestation, birth order and sex. The matching could allow for missing data, but not for any contradictory data on either side of the match. If three or more of the variables matched exactly, and no variables were mismatched, the match was assumed to be valid.

### ***Probabilistic linkage***

Any delivery records that were unmatched deterministically were compared with baby records on 21 separate variables. Each one had a positive match weight where there was a match and a negative weight where there was a mismatch. These were applied to a matching matrix and the weights summed to derive a total weight for each candidate pair. The weights were determined from the synthetic data analysis produced by Harron *et al.*<sup>76</sup> and were available in their published paper. Their team also used the same threshold (a match score of 20) to decide whether or not the match was probable.

### ***Linkage to survey data***

The final stage involved matching national survey data on hospital prophylactic antibiotic administration policies (see *National survey data* for more details on the survey) to births. This involved identifying the NHS organisation code for each site about which the respondent was answering. This was carried out by cross-checking all of the hospital names with the NHS Coding and Classification Service records. In addition, each site had to be checked to see whether or not its site code had changed during the period of study; this happens when the trust responsible for the site changes. This also involved manual searches on a database of successor and predecessor organisations held by the NHS Coding and Classification Service. Not all deliveries were matched because not all sites replied to the questionnaire. There were some cases where individual units did not collect their site codes with sufficient specificity. This can happen when one trust manages a large number of smaller sites. There is a highly specific site code capable of attributing activity to an individual site; however, some organisations do not use the code appropriately, choosing to apply a more generic code with a trust prefix but no suffix (i.e. the part of the codes that identifies the site specifically). We linked only those questionnaire data where a valid and site-specific code was captured in HES and was the same as a site code attributed to a hospital that had responded to the survey.



## *National survey data*

### **National survey of hospital prophylactic antibiotic administration policies**

Information about which prophylactic antibiotics are given and the timing of their administration is not available in HES. Therefore, we obtained the year when the policy to administer pre-incision antibiotics was introduced in each hospital from a survey of maternity care providers.

A national survey of the clinical directors for UK maternity units was completed to investigate (1) to what extent the recommendation in the NICE Clinical Guideline 132<sup>7</sup> regarding the timing of prophylactic antibiotic administration for CS has been adopted across the country, (2) when the updated national guidance was implemented and (3) the types of pre-incision antibiotics used in practice.

The survey was developed using a secure, web-based software platform REDCap (Research Electronic Data Capture) designed to support data capture for research studies (version 7, Vanderbilt University, Nashville, TN, USA)<sup>77</sup> and a link to the survey was sent to all clinical directors of maternity units in 2017, with follow-up of non-responders undertaken by e-mail, telephone and at national professional conferences. During the follow-up, an option to complete the survey in Microsoft Word (Microsoft Corporation, Redmond, WA, USA) was also offered. A copy of the survey questionnaire is included in *Report Supplementary Material 1*. If the respondents did not specify the exact year of the policy change, but had entered a free-text comment saying, for example, a year before which the policy was changed (e.g. 'before 2009') then this year was used in the analysis as the year of the policy change.

### **National maternity care surveys**

Information on breastfeeding in health-care data is incomplete and we, therefore, investigated the trends in this case mix variable by the mode of delivery using data from the national maternity surveys, with the survey methodology described in detail elsewhere.<sup>78,79</sup> Briefly, the Care Quality Commission undertook nationwide surveys of women who had a live birth and received care from NHS trusts in 2007, 2010, 2013, 2015 and 2017 in England, asking about their experiences during labour and birth, including the type of delivery and newborn feeding in the first few days after birth.<sup>79</sup> Care Quality Commission survey data were available from the UK Data Service.<sup>80</sup> National surveys were also carried out in 2006, 2010 and 2014 by the National Perinatal Epidemiology Unit (Oxford, UK) using a random sample from live birth registrations in England. The questionnaires were posted to women at 3 months after delivery and asked questions on antenatal and postnatal care and health, including questions on the mode of delivery and infant feeding at the time of the survey (e.g. breast milk only, both breast milk and formula milk, and formula milk only).<sup>78</sup>

## **Estimated sample size and statistical power**

### *THIN-CPRD database sample size estimates*

To estimate the number of CSs and VDs in primary care over our study period, we first calculated the completeness of recording in THIN database using THIN data linked to secondary care records in 2010. This was extrapolated over all years in our study (2006–18), taking into consideration the changes in the numbers of births nationally over time. We assumed that the overall size of the THIN and CPRD databases, the proportions with linked secondary care data and the reported overlap between THIN and CPRD databases remained constant over the study period. We also assumed that 86% of mothers and babies could be linked. The number of births we expected to have data on over the study period was 777,389 (206,615 children born by CS and 570,774 children born by VD).

Our estimates of asthma incidence in 0- to 5-year-old children in the UK using the THIN database matched the previously published figures.<sup>38</sup> In 2014, the incidence ranged from 0.8 and 6.5 per 1000 person-years in those aged 0–1 and 1–2 years, respectively, to 12.1 and 11.4 in those aged 3–4 and 4–5 years, respectively. Based on our estimates of the incidence of asthma in each age group in each year

from 2006 onwards, and assuming a 5% annual loss of follow-up due to patients changing their general practice, Table 3 shows the estimated number of children available for follow-up depending on their year of birth, and the number of new asthma cases in each of the study years by the mode of delivery.

### HES database sample size estimates

Using the HES secondary care database available for England and assuming 95% linkage between mothers and babies (the linkage estimate varied between 91% in the earlier years and 98% in 2012/13),<sup>76</sup> we estimated that we would obtain data from 8,043,600 children with a known mode of delivery across 2006–18 (2,070,500 children born by CS and 5,973,100 born by VD).

TABLE 3 Estimated person-years of follow-up and the number of new asthma cases by the year of life in children born by CS and VD during 2006–18, using the THIN–CPRD database (if the incidence of asthma was the same in all children irrespective of the mode of delivery)

Birth year <sup>a</sup>	Person-years of follow-up by year of life					Asthma cases by year of life				
	1	2	3	4	5	1	2	3	4	5
<b>Children born by CS</b>										
2006	14,448	13,725	13,038	12,386	11,766	70	214	230	254	183
2007	15,136	14,379	13,660	12,977	12,328	56	196	220	236	166
2008	15,308	14,542	13,814	13,123	12,466	38	169	201	207	140
2009	15,394	14,624	13,892	13,197	12,537	35	153	179	194	147
2010	15,781	14,991	14,241	13,528	12,851	31	140	160	184	157
2011	15,824	15,032	14,280	13,566	12,887	28	126	166	193	159
2012	16,254	15,441	14,668	13,934	13,237	26	116	175	206	166
2013	16,082	15,277	14,513	13,787	13,097	19	107	154	185	157
2014	15,996	15,196	14,436	13,714	13,028	12	99	134	166	149
2015	16,598	15,768	14,979	14,230		8	95	121	156	
2016	16,598	15,768	14,979			5	88	106		
2017	16,598	15,768				3	82			
2018	16,598					3				
<b>Children born vaginally</b>										
2006	43,172	41,013	38,962	37,013	35,162	209	640	688	759	548
2007	44,462	42,238	40,126	38,119	36,213	163	576	646	692	486
2008	44,892	42,647	40,514	38,488	36,563	112	497	590	608	412
2009	44,720	42,484	40,359	38,341	36,423	101	445	520	564	427
2010	45,744	43,456	41,283	39,218	37,257	91	405	463	534	454
2011	45,580	43,301	41,135	39,078	37,124	82	364	477	555	459
2012	45,408	43,137	40,980	38,931	36,984	72	324	490	575	463
2013	43,344	41,176	39,117	37,161	35,302	51	288	415	500	423
2014	42,484	40,359	38,341	36,423	34,601	32	262	355	442	396
2015	42,742	40,604	38,573	36,644		21	245	312	402	
2016	42,742	40,604	38,573			14	227	273		
2017	42,742	40,604				9	211			
2018	42,742					9				

a The numbers in the year 2015 were applied to the later years.



## METHODS

Annually, there are around 10,000 hospital admissions with asthma as the primary diagnosis in children aged 0–4 years.<sup>81</sup> Assuming a re-admission rate during the follow-up of 50% (our estimates using HES indicate that, in the later years of the cohort, the proportion of children re-admitted was as low as 29–39%), we calculated the numbers of children who were admitted to hospital for the first time with asthma as the primary diagnosis in each year of follow-up (Table 4).

**TABLE 4** Estimated person-years of follow-up and the number of first-time hospital admissions for asthma by the year of life in children born by CS and VD during 2006–18, using the THIN–CPRD database (if the incidence of asthma was the same in all children irrespective of the mode of delivery)

Birth year <sup>a</sup>	Person-years of follow-up by year of life					Asthma cases by year of life				
	1	2	3	4	5	1	2	3	4	5
<b>Children born by CS</b>										
2006	145,200	145,178	144,838	144,499	144,160	22	343	342	341	340
2007	151,800	151,777	151,422	151,067	150,713	23	358	357	357	356
2008	152,400	152,377	152,021	151,664	151,308	23	360	359	358	357
2009	153,700	153,677	153,317	152,958	152,599	23	363	362	361	360
2010	157,400	157,376	157,008	156,640	156,272	24	371	371	370	369
2011	158,800	158,776	158,405	158,033	157,662	24	375	374	373	372
2012	162,700	162,676	162,295	161,914	161,534	24	384	383	382	381
2013	160,700	160,681	160,321	159,961	159,602	19	360	359	358	358
2014	160,200	160,187	159,846	159,505	159,164	13	340	339	338	337
2015	166,900	166,887	166,531	166,176		13	354	353	352	
2016	166,900	166,887	166,531			13	354	353		
2017	166,900	166,887				13	354			
2018	166,900					13				
<b>Children born by VD</b>										
2006	452,400	452,364	451,400	450,437	449,475	68	1059	1056	1054	1052
2007	465,400	465,363	464,371	463,380	462,391	70	1089	1087	1084	1082
2008	467,500	467,463	466,467	465,471	464,478	70	1094	1092	1089	1087
2009	466,000	465,963	464,970	463,978	462,987	70	1090	1088	1086	1083
2010	477,300	477,262	476,245	475,229	474,214	72	1117	1114	1112	1110
2011	476,600	476,600	476,600	476,600	476,600	71	1115	1115	1115	1115
2012	474,900	474,900	474,900	474,900	474,900	71	1111	1111	1111	1111
2013	453,700	453,700	453,700	453,700	453,700	54	1012	1012	1012	1012
2014	444,500	444,500	444,056	443,167	441,834	36	947	946	944	941
2015	448,700	448,664	447,708	446,753		36	956	954	952	
2016	448,700	448,664	447,708			36	956	954		
2017	448,700	448,664				36	956			
2018	448,700					36				

a The numbers in the year 2015 were applied to the later years.

### Estimates of statistical power

To estimate statistical power, and to assess the impact of misclassification of antibiotic exposure on estimates of increase in risk with pre-incision prophylactic antibiotics for CS, we simulated the study (1) based on our estimates using the THIN database regarding the number of children for whom maternal data could be linked and the asthma diagnosis rates in each year group between 0 and 5 years, and (2) using HES data based on our estimates of children with linked maternal data and rates of children newly hospitalised for asthma based on HES statistics.

In each simulation, we created a data set for the whole study, with 13 birth cohorts from 2006 to 2018 and follow-up included across the first 5 years of life (curtailed at the end of 2018). Each birth was classified by the delivery mode and, for those children born by CS, whether or not prophylactic antibiotics were administered prior to skin incision (generated randomly using a binomial random number generator using an underlying probability identified in the national survey of hospital prophylactic antibiotic administration policies during that year of birth).<sup>49</sup>

We randomly simulated outcome events according to the year-age event rates using a binomial random number generator, with increased rates in all those born by CS and further increases in those who had pre-incision antibiotics (Table 5). A ratio of incidence ratios of 1.20 was used for increased risk of asthma with CS.<sup>47</sup> Further increases (ratio of incidence ratios from 1.10 to 1.20, increasing in steps of 0.02) were used for the increase with pre-incision antibiotics rather than antibiotics after cord clamping.

Simulations were repeated 1000 times and statistical power estimated by noting the proportion of simulations for which the lower limit of the 95% CI for the variable indicating if antibiotics were administered prior to skin incision was greater than a ratio of incidence ratios of 1. We also assessed attenuation bias created by misclassification.

TABLE 5 The number of births, years of follow-up and expected events in each simulation

Variable	THIN-CPRD database, <i>n</i>	HES database, <i>n</i>
CS births	206,615	2,070,500
Post-cord clamping antibiotics	111,508	1,115,670
Pre-incision antibiotics	95,107	954,830
VD births	570,774	5,973,100
Total births	777,389	8,043,600
CS person-years of follow-up	792,265	8,661,832
Post-cord clamping antibiotics	501,401	5,524,890
Pre-incision antibiotics	290,864	3,136,942
VD person-years of follow-up	2,215,405	25,339,526
Total person-years of follow-up	3,007,670	34,001,358
New events in children born by CS	7173	15,333
Post-cord clamping antibiotics	5324	10,454
Pre-incision antibiotics	1849	4880
New events in children born by VD	20,378	44,906
Total events	27,551	60,240
Average event rate per 1000 person-years	9.2	1.8

The model that was fitted to analyse the simulation data included a trend term for the probability of receiving antibiotics before skin incision, where the value for 2006–9 = 0, 2010 = 0.2, 2011 = 0.4, 2012 = 0.6, 2013 = 0.8 and 2014–18 = 1 (with a zero value for those who were born by VD). Although in the analysis we used values obtained from the national survey on hospital prophylactic antibiotic administration policies, as the simulations used the national survey to allocate women to a treatment, we would have overestimated power if we had used exactly the same function in the analysis model.

For outcomes in primary care, we estimated that we would have 80% power of detecting a ratio of incidence ratios of 1.16 and > 90% power of detecting ratio of incidence ratios of 1.18, being able to estimate them with a maximum of 15% underestimation from misclassification.

For outcomes recorded in secondary care, in the full HES data set, we estimated that we would have > 80% power to detect a ratio of incidence ratios of 1.10 and 90% power to detect a ratio of incidence ratios of 1.12, with similar underestimation rates due to misclassification.

This relates to detecting an increase of seven additional new cases of asthma per 1000 children aged 0–4 years or an increase of 4% (1400/35,000) of all new asthma cases in 0- to 4-year-olds annually in the UK. This also relates to detecting an increase of one additional new case of asthma requiring hospital admission per 1000 children aged 0–4 years or an increase of 3% (200/7000) of all newly hospitalised asthma cases in 0- to 4-year-olds annually.

We also estimated that this study would be adequately powered to detect differences in some of the other outcomes of interest, as their incidence is higher than asthma incidence in children, including:

- GP-diagnosed eczema (with incidence rates of 2.5 and 6.6 per 1000 person-years reported in children aged 0–1 and 1–2 years, respectively<sup>36,37</sup>)
- maternal post partum infectious morbidity, including caesarean wound infection (with the incidence ranging from 1.4 to 8.2 per 100 births<sup>82</sup>).

## Statistical methods and analyses

The statistical analysis methods for this project can be broken down into the methods used to analyse the primary care data set (THIN-CPRD) and the methods used to analyse the secondary care data set (HES). We describe these methods separately for each data set.

### *Primary care data (THIN-CPRD)*

#### **Summarising data in primary care**

The primary outcomes (of asthma and eczema) are summarised in the THIN-CPRD data set using the number of children diagnosed with asthma or eczema and the length of time at risk. Each child is classified as either diagnosed with the outcome or not, using the methods of diagnosing asthma and eczema described earlier (see *Study outcomes*). For each outcome, the length of time at risk is calculated as the time from birth to the earliest of the child's fifth birthday, the date the child is lost to follow-up (e.g. the child moves practice or the practice is not included in THIN-CPRD), the study end date (31 December 2018) or the date at which the child is diagnosed with the outcome. We present the rate of the outcome per 1000 person-years, which is calculated as the ratio of the number of events and the exposure time multiplied by 1000. We do not present results stratified by prophylactic antibiotic status, as this was not possible (see *Analysis methods used*).

All dichotomous secondary outcomes are summarised in the same way as the primary outcomes. Secondary outcomes that are of a count form, such as the number of primary care consultations in the first 12 months, are summarised using the total number of events and the length of time at risk.

The length of time at risk is calculated as the time from birth to the earliest of the date the child is lost to follow-up or the date at which the outcome-specific length of time has passed (e.g. 12 months). The rate of the outcome is presented per 1000 person-years.

Maternal outcomes are summarised using the total number of events and the percentage of total births to which this corresponds. All maternal outcomes in primary care were dichotomous. For the composite maternal infectious morbidity, we categorised mothers as having either 'none' or 'one or more' of the individual composite outcomes (i.e. wound infection, endometritis/endomyometritis, sepsis and pelvic abscess) recorded in primary care data. Results are presented stratified by delivery mode (VD or CS).

### Analysis methods used

To analyse the primary outcomes (asthma and eczema), we calculated for each child's year of life whether or not a diagnosis of the outcome was made and the exposure time for that particular year of life. For example, a child diagnosed with asthma aged 18 months would have zero events and 12 months' exposure during their first year of life, and one event and 6 months' exposure during their second year of life. This allowed us to explore cases by year of birth and year of life. To estimate the impact of antibiotic timing (pre-incision or post-cord clamping prophylactic antibiotics), we fitted a Poisson regression model to the data, with an offset for exposure time and robust standard errors to allow for misspecification. The model included terms for year of birth and age (year of life), and their interaction. Two further terms were also included in the model: (1) mode of birth (CS or VD) to allow for differential risk of the outcome in those receiving CS compared with VD and (2) antibiotic timing to allow for differential risk in those receiving pre-incision rather than post-cord clamping prophylactic antibiotics. For all CS births, as the exact timing of antibiotic provision was not known, we used the probability of antibiotic use before skin incision derived from the national survey. This coefficient provides an estimate of the effect of the policy change in antibiotic timing, adjusting for misclassification. As the policy change was applicable for CS births only, all VD births were classified as pre-policy change. We present the incidence rate ratio (IRR) and the 95% CI for the antibiotic timing variable, comparing the rate of events in those given prophylactic antibiotics pre incision with the rate of events in those given prophylactic antibiotics post cord clamping.

All dichotomous secondary outcomes are analysed in the same manner as the primary outcomes. For outcomes with a small number of events (< 200), we present the summary statistics only. For count outcomes, a Poisson model without robust standard errors was fitted to the data. All other terms in the model were the same as those used for the primary outcomes.

### Sensitivity analyses

To assess the robustness of the results, we conducted several sensitivity analyses. Sensitivity analyses were performed for the two co-primary outcomes (asthma and eczema). Some secondary outcomes were included in the sensitivity analyses to check the robustness of the primary analysis, particularly where results suggested a significant association with the timing of antibiotic provision and the association was unexpected.

In the primary care data set, we conducted the following sensitivity analyses:

- outcome definition
- definition of timing of the prophylactic antibiotic policy change
- data recording quality
- random effect.

The rationale for these sensitivity analyses and the statistical methods used for each of them are described in more detail below.

### **Outcome definition**

The main outcome definition for asthma in primary care was based on relevant Read codes and the main definition of eczema was based on relevant Read codes in combination with two eczema-related prescriptions on separate dates, as described earlier. We considered the impact of prophylactic antibiotic timing on severity of asthma and eczema based on prescribing of medications indicative of moderate or severe asthma and eczema. In addition, we also considered several alternative definitions of asthma and eczema, including:

- asthma diagnosed in children aged 3–5 years (as it is more difficult to distinguish asthma from other more common diagnoses, such as bronchiolitis, in very young children)
- asthma definition based on Read codes used in the QOF
- eczema diagnosis based on Read codes in children aged 1–5 years and at least two prescriptions within 90 days before or 365 days after the eczema Read code record
- eczema diagnosis based on Read codes only.

### **Definition of timing of the prophylactic antibiotic policy change**

For the primary analysis, we used a probability that the prophylactic antibiotics were given pre incision using data from the national survey. To test the sensitivity of this method, we restricted the data set to the births from 2006 to 2010 and from 2013 to 2018. This was carried out to compare births in the years before the change in the NICE guidelines (i.e. 2006–10) with the years in which > 50% of hospitals had introduced the policy (i.e. 2013–18). Children born by CS were dichotomised as having prophylactic antibiotics post cord clamping (children born 2006–10) or prophylactic antibiotics pre incision (children born 2013–18). A Poisson model was fitted to the data, with an offset for exposure time and robust standard errors. The model included terms for year of birth, year of life, their interaction, delivery mode (CS or VD) and antibiotic timing (pre incision or post cord clamping).

### **Data recording quality**

To evaluate the impact of data recording quality, we restricted the data set to THIN–CPRD records linked to secondary care records. It was expected that these records would be the most accurate source for mode of delivery. A Poisson model was fitted to the data in the same manner as the primary analysis.

### **Random effect**

Our primary analysis assumes that all observations are independent. As the outcomes are based on Read codes that have been entered onto an electronic medical health system at the general practice, it is possible that observations from children within the same general practice are correlated in some way (both because of access to the same general practice and also because they are likely to share socioeconomic similarities). To explore the possibility of non-independence of observations, we explored whether or not the results were robust to the inclusion of a random effect for general practice. This allows observations within a general practice to be correlated. To this end, a mixed-effects Poisson model was fitted to the data, with an offset for exposure time and robust standard errors and a random effect for general practice. Fixed effects were included for year of birth, year of life, their interaction, mode of birth (CS or VD) and antibiotic timing (i.e. probability of pre-incision prophylactic antibiotics).

### **Subgroup analyses**

Children born by elective CS are likely to be exposed to antibiotics in utero for longer than children born by emergency CS. To assess whether or not the impact of the antibiotic policy change is different in elective CS and emergency CS, we categorised each birth as being elective CS, emergency CS or VD. A Poisson model was fitted to the data, with an offset for exposure time and robust standard errors. Fixed effects were included for year of birth and year of life, and their interaction. There were also terms for mode of delivery (i.e. emergency CS, elective CS or VD) and antibiotic timing (i.e. probability of pre-incision prophylactic antibiotics), and an interaction between them. We report the

IRR for antibiotic timing in the emergency CS and elective CS groups, and the  $p$ -value for the interaction between them. This  $p$ -value indicates the strength of evidence of a differential effect of antibiotic timing based on CS type.

### Secondary care data (HES)

#### Summarising data in secondary care

The primary outcomes (asthma and eczema) are summarised in the HES database using the number of children admitted to hospital at least once and the length of time at risk. For each outcome, an admission is indicated by ICD-10 codes, as described earlier (see *Study outcomes*). Children are categorised as having 'no admission' or as having 'one or more admissions'. The length of time at risk is calculated as the time from birth to the earliest of the child's fifth birthday or the study end date of 31 March 2019. We present the rate of the outcome per 1000 person-years, which is calculated as the ratio of the number of events and the exposure time multiplied by 1000.

Most dichotomous secondary outcomes are summarised in the same way, where we present the number of children admitted at least once, the total follow-up time and the outcome rate per 1000 person-years. For secondary outcomes with short exposure time (such as neonatal sepsis), we present the outcome rate per 1000 births.

Dichotomous maternal outcomes are summarised in the HES data set using the number of events and the percentage of total events to which this corresponds. One continuous maternal outcome (i.e. hospital length of stay) was not normally distributed and so the median and interquartile range are presented. All maternal outcomes are summarised stratified by delivery mode (VD or CS).

#### Analysis methods used

To analyse the primary outcomes (asthma and eczema), for each child we calculated whether or not they had been admitted to hospital admission for the primary reason of asthma or eczema and their exposure time. Owing to data limitations, we did not have the date of admission and so could not look at cases by year of life. We did, however, examine cases by year of birth. To estimate the impact of antibiotic timing (pre-incision or post-cord clamping prophylactic antibiotics), a Poisson model was fitted to the data, with an offset for exposure time and robust standard errors to allow for misspecification. The model included terms for year of birth, mode of birth (CS or VD) and antibiotic timing. Data were not available on the antibiotic timing (pre incision or post cord clamping) for individual births, but data on the hospital policy for each year were known. It was assumed that prophylactic antibiotics for each CS were administered in accordance with the hospital's policy for that particular year. Antibiotic timing was categorised as before policy change, year of policy change and after policy change. As the policy change was applicable to CS births only, all VD births were classified as 'before policy change'. The comparison between children born after the policy change and those born before the policy provides an estimate of the effect of the policy change in antibiotic timing. This comparison did not include those children born in the year of policy change, as their exposure to prophylactic antibiotics is not known. We present the IRR and 95% CI for the antibiotic timing variable, comparing the rate of events in those given prophylactic antibiotics pre incision with the rate of events in those given prophylactic antibiotics post cord clamping.

All dichotomous secondary outcomes are analysed in the same manner as the primary outcomes. For outcomes with a small number of events (< 200), we present the summary statistics only. For continuous outcomes (i.e. maternal length of stay), we fitted a linear regression model, with fixed effects for year of birth, mode of birth (CS or VD) and antibiotic timing. We present the difference in mean length of stay between those children born by CS with pre-incision prophylactic antibiotics and those children born by CS with post-cord clamping prophylactic antibiotics.



### **Sensitivity analyses**

To assess the robustness of the results, we conducted several sensitivity analyses. Sensitivity analyses were performed for the two co-primary outcomes (asthma and eczema). Some secondary outcomes were included in the sensitivity analyses to check for the robustness of the primary analysis.

In the secondary care data set (HES), we conducted the following sensitivity analyses:

- definition of timing of the prophylactic antibiotic policy change
- random effect
- exploratory discordant sibling analysis.

### ***Definition of timing of the prophylactic antibiotic policy change***

The primary analysis of the secondary care data set is limited to hospitals that responded to the national survey, as we required information on whether or not the antibiotic policy was changed and the year in which the change was made. As not all hospitals responded to the survey, we wanted to explore the sensitivity of the results to the timing of antibiotic policy change. To this end, we estimated the probability of pre-incision prophylactic antibiotics based on calendar year. These probabilities were calculated using responses to the national survey from England hospitals, as HES includes data from hospitals in England only. A Poisson model was fitted to the data, with an offset for exposure time and robust standard errors. Fixed effects were included for year of birth, mode of birth (CS or VD) and antibiotic timing (probability of pre-incision prophylactic antibiotics).

### ***Random effect***

Our primary analysis assumes that observations are independent. However, it is possible that observations from children born from the same hospital are correlated in some way, perhaps because of sociodemographic and health-care access similarities. To explore the possibility of non-independence of observations, we explored whether or not the results were robust to the inclusion of a random effect for hospital. This allows observations from children born within the same hospital to be correlated. To this end, a mixed-effects Poisson model was fitted to the data, with an offset for exposure time and robust standard errors, and a random effect for hospital. Fixed effects were included for year of birth, mode of birth (CS or VD) and antibiotic timing (pre incision or post cord clamping).

### ***Discordant sibling analysis***

In an attempt to control further for family-related genetic and environmental factors, we employed a discordant sibling analysis. For this, we created a subset of data in which women gave birth at least twice using the same mode of birth (VD or CS) during the study, including before and after the change in antibiotic policy. A Poisson model was fitted to the data in the same manner as the primary analysis of the secondary care data.

### ***Subgroup analyses***

In the secondary care data set, we performed two subgroup analyses: (1) CS type analysis (i.e. elective or emergency) and (2) antibiotic regiment analysis (i.e. cefuroxime only, cefuroxime and metronidazole, and co-amoxiclav only).

### ***Caesarean section type***

To assess whether or not the impact of the antibiotic policy change differs between elective CS and emergency CS, we categorised each birth as being elective CS, emergency CS or VD. A Poisson model was fitted to the data, with an offset for exposure time and robust standard errors. Fixed effects were included for mode of delivery (emergency CS, elective CS or VD) and antibiotic timing (using probability of antibiotic policy change), and an interaction between them. Adjustments were included for year of birth. We report the IRR for antibiotic timing in the emergency and elective CS groups, and the *p*-value for the interaction between them.

### **Antibiotic regimen**

Different antibiotic regimens may have a differential effect on longer-term child health. Based on the national survey, the most common antibiotics used were co-amoxiclav alone, cefuroxime alone, and cefuroxime and metronidazole. We restricted the analysis to hospitals that used the same antibiotics before and after the policy change. A Poisson model was fitted to the data, with an offset for exposure time and robust standard errors. Fixed effects were included for year of birth, mode of delivery (CS or VD) and antibiotic timing (pre incision or post cord clamping). We fitted a model separately for each antibiotic type (co-amoxiclav alone, cefuroxime alone, cefuroxime and metronidazole). We report the IRR for antibiotic timing separately for each antibiotic type. This exploratory subgroup analysis was undertaken for primary outcomes (asthma and eczema) and necrotising enterocolitis because of the previously reported increased risk of this condition in babies born to mothers who were exposed to co-amoxiclav.<sup>83</sup>

Analysis was carried out using Stata<sup>®</sup> MP version 16 (StataCorp LP, College Station, TX, USA).

### **Research Ethics Committee approval**

The Ethics Review Committee of the University of Birmingham provided the ethics approval required for this study (reference number ERN\_17-1675).

The NHS South-East Multi-Centre Research Ethics Committee approved the use of the THIN database, subject to independent scientific review to help ensure appropriate analysis and interpretation of the data.<sup>84</sup> The Independent Scientific Ethical Advisory Committee – Scientific Review Committee Panel of the data provider IQVIA (Durham, NC, USA) approved the use of the THIN and HES-linked data in this study (reference number 18THIN047).

The CPRD data set has ethics approval from a National Research Ethics Service Committee for observational research using anonymised data.<sup>85</sup> For this study, the use of CPRD has been approved by the Independent Scientific Advisory Committee for MHRA Database Research (reference number 18\_181AR2).

The use of the HES database is exempt from NHS Research Ethics Committee approval because it involves the analysis of an existing data set of non-identifiable data. The standard NHS Digital data approval process was followed to obtain approval for the use of HES data.<sup>86</sup> The Health Research Authority confirmed that Health Research Authority approval was not required for this research, as it involved linking anonymised patient data from established databases for this study only.

### **Changes to the protocol**

There were no changes to the protocol.

### **Patient and public involvement**

#### **Aims**

There were two main aims of patient and public involvement (PPI) in this project. First, we involved women to ensure that we included outcomes that are important for parents and children. We explored with parents and parents-to-be which health conditions, particularly allergy- and immune system-related conditions and maternal infections after birth, are most important to them and, therefore, which health conditions the study should ideally investigate (assuming that information for these conditions is well recorded in routine medical practice). Second, our public involvement activities helped ensure that key



messages from the research about the timing of prophylactic antibiotic administration in CS were communicated to relevant audiences in ways that were clear and accessible. We report our PPI here using the format recommended by the Guidance for Reporting Involvement of Patients and the Public Short Form (GRIPP2-SF).<sup>87</sup>

### Methods

The chief investigator (DS) provided leadership for all public involvement in the project and was the first point of contact for public contributors and researchers on all matters relating to public involvement. Two women (RH and MS) were recruited to be involved in the study. Ruth Hewston is a volunteer with the National Childbirth Trust (London, UK) and has experience of involvement in a range of maternity projects. Magdalena Skrybant had a CS in 2013 and has an interest in maternity research. Both Magdalena Skrybant and Ruth Hewston were invited to attend all Project Management Group meetings. Materials were sent in advance of meetings and Ruth Hewston and Magdalena Skrybant could contact Dana Šumilo at any point to discuss the project. Both Magdalena Skrybant and Ruth Hewston were invited to contribute to all reports and they are acknowledged as co-authors to publications. Public contributors were also offered an honorarium for their involvement.

We also recruited an independent public contributor to our Project Steering Group (MC). MC was recruited through the Royal College of Obstetricians and Gynaecologists (RCOG) (London, UK) Women's Voices Involvement Panel. Maria Clark was invited to attend all meetings, received paperwork in advance and could contact Dana Šumilo to discuss the study.

To gain wider public perspectives, public involvement sessions took place as part of the 'Yoga for Bump' sessions, which were facilitated by National Institute for Health and Care Research (NIHR) Collaborations for Leadership in Applied Health Research and Care and funded through a Wellcome Trust (London, UK) Engagement Fund. These sessions were free for women to attend and included an informal chat with a midwife, a research engagement session and then a pregnancy yoga session. The sessions were held in June 2018 in two different community locations in the West Midlands (Hall Green and Perry Barr) and at two different times of the day, which helped maximise the diversity of the contributors. Eight mothers or mothers-to-be took part in the sessions. They came from a variety of backgrounds, and included women from ethnic minority communities, an often under-represented group in research. The researcher (DS) and a PPI advisor (MS) of the project explained the background of this research and the research questions. This was followed by the discussion, in relation to this study, of which health conditions are most important to women and how the findings of the study can be shared.

We also obtained perspectives from women from the RCOG Women's Voices Involvement Panel who responded to the wider clinician and public consultation survey in July 2018. A link to the online survey was also sent to the British Intrapartum Care Society (London, UK), the British Maternal & Fetal Medicine Society (London, UK) and the British Association of Perinatal Medicine (Bristol, UK). In the survey, respondents were asked to select up to three conditions from each group of health conditions that we were interested in for inclusion as study outcomes (the survey questionnaire is included in *Report Supplementary Material 2*). Twenty-nine respondents (22 clinicians and seven parents) completed the survey.

Both Magdalena Skrybant and Ruth Hewston contributed to the writing of this report, including *Patient and public involvement* and the *Plain English summary*.

### Results

Patient and public involvement, including the public involvement sessions and the wider survey, helped us to confirm that we should look at a wide range of outcomes, including neurodevelopmental conditions. From the proposed outcome list in the online survey, there were no outcomes that were not selected by the respondents, apart from septic thrombophlebitis, which we excluded from the final outcome list. Our public involvement sessions also confirmed that we should consider the severity of outcomes.

Patient and public involvement also helped us to identify other information mothers-to-be wanted explained in relation to the study, including how antibiotics work, what antibiotics are recommended, the difference between intrapartum antibiotics and antibiotics during pregnancy, and what impact antibiotics may have depending on when they are provided. PPI also confirmed the importance of balancing the risks and benefits to the mother and baby when communicating the study findings.

### **Discussion and conclusions**

Patient and public involvement helped us to confirm the finding from our initial PPI while developing this research proposal that a broad range of outcomes should be investigated. PPI engagement sessions informed the development of the wider consultation through the online survey and the final outcome list. PPI also confirmed the importance of capturing and interpreting the data, taking into account the severity of health conditions, which was addressed in this study by assessing the health conditions in both primary care and hospital data. Furthermore, PPI strengthened the importance of comparing the impact on children with the impact on mothers and helped us to better understand what relevant information women need to know when communicating the results of the study.

### **Reflections**

The study benefited from having two very experienced public contributors as full members of the Project Management Group since the inception of this research and also a very experienced independent public contributor as a member of the Project Steering Group.

Wider PPI activities were useful in confirming that the outcomes we were planning to investigate were relevant to parents and parents-to-be and in identifying additional outcomes of interest. Public involvement sessions were also useful in identifying what contextual information needs to be provided when communicating the findings to the wider public. The 30-minute duration of the public involvement sessions was sufficient for addressing the main objectives of this PPI. Given the complexity of the research topic and uncertainty around the potential impact the antibiotics may have, it was initially difficult for women to comment on the outcomes that were important to them. It was very helpful to have an experienced PPI advisor facilitating public involvement sessions, maximising the benefit gained from the sessions.



## Chapter 3 Results

### THIN–HES-linked and THIN primary care data sets descriptions

During the study period, 219,390 deliveries were identified in the THIN–HES-linked data set. We excluded 32,808 delivery records, as they did not have a baby with the same family number as the mother. We then matched a baby for each of the remaining 186,582 deliveries. We excluded a further 72,807 records, either because they were linked to more than one potential mother or because the baby was not registered within the first year from birth. This left us with a total of 113,775 valid deliveries linked to a baby identified in the THIN–HES-linked data set.

In the THIN primary care data set, we looked for incident deliveries (VD or CS) from 1 January 2006 to 31 December 2018 in women aged 13–50 years at the time of delivery who were already registered with the practice. We found a total of 441,540 delivery records in the database, of which 54,939 were excluded, as there was no baby born in the same month and year of delivery with the same family number as the mother. We further excluded 135,318 records of babies who were either linked to more than one potential mother or not registered within a year from birth. This left a total of 251,283 mother–baby pairs identified using Read codes in the THIN primary care database. Finally, we extracted information from records of the babies who had ‘born by vaginal delivery’ or ‘born by caesarean section’ Read codes from the THIN primary care database and found 46,593 records. All of these babies, however, were already present in our linked primary care data set derived from the delivery codes noted in the mother’s medical record and, therefore, did not add any new babies that could be linked to a mother.

Combined, there were a total of 365,058 mother–baby pairs from THIN–HES-linked and THIN primary care data sets. A total of 57,317 of these pairs were identified in both the THIN primary care and THIN–HES-linked databases (i.e. duplicates) and, therefore, we removed those records from the THIN primary care database. This left us with a final total of 307,741 unique mother–baby pairs from the THIN primary care and THIN–HES-linked databases (*Figure 2*).

### CPRD–HES-linked and CPRD primary care data sets descriptions

The CPRD mother–child-linked database contained 646,967 mother–baby pairs in total. When examining CPRD data, our main goal was to identify linked mothers and babies who had a recorded mode of delivery (VD/CS).

We used the same criteria to define patient start date and patient end date for the CPRD database as we did for THIN. There were 444,823 mother–baby pairs in the CPRD–HES-linked data set. To retain only the valid mother–baby pairs in the CPRD–HES-linked data, we excluded (1) 11,172 records because information on babies was not present in the primary care practice data and (2) 171,269 records because either the mother or baby did not meet the study inclusion criteria (78,229 babies were excluded because they were not registered within 1 year from date of birth, 61,553 mothers were excluded because their delivery date was not in between the patient start date and the patient end date or their age at delivery did not match study inclusion criteria, and 31,487 mother–baby pairs were excluded because both the mother and the baby did not meet the study inclusion criteria). This left us with 262,382 mother–baby pairs that had an OPCS-4 or ICD-10 delivery code identifying the mode of delivery and met our study inclusion criteria (as explained in *Chapter 2*).

## RESULTS




FIGURE 2 Study population selection, including mother-baby data linkage in THIN data sets.

In the CPRD primary care data set, there were 452,353 mother-baby pairs, from which we excluded 121,598 records as they did not meet the study inclusion criteria, leaving us with 330,755 mother-baby pairs with a recorded mode of delivery in the CPRD primary care database.

In total, we had 593,137 mother-baby pairs from both CPRD data sets, of which we excluded 183,230 duplicates (valid mother-baby pairs found independently in both the CPRD primary care and CPRD-HES data sets), removing them from the CPRD primary care data set. This left us with 409,907 valid mother-baby pairs across the two CPRD data sets (Figure 3).




FIGURE 3 Study population selection in CPRD data sets.

## Final THIN-CPRD data set description

Across all data sets, we identified 717,648 valid deliveries. We then excluded 201,703 (28.1%) duplicates (163,408 from THIN data sets and 38,295 from the CPRD data sets). This resulted in a final total of 515,945 mother-baby pairs for inclusion in our analysis [144,333 (28.0%) from THIN data sets combined and 371,612 (72.0%) from CPRD data sets combined] (Figure 4).

Out of the total of 515,945 births, 144,861 (28.1%) were births by CS and the remaining 371,084 (71.9%) were by VD. The number of actual linked mother-baby pairs is smaller than the estimate in our sample size justification. This was mainly because we used THIN data from the year 2010 to derive our estimates and, since 2010, many practices have left the Vision system and in turn the number of practices contributing to THIN and CPRD GOLD has substantially reduced over the years, resulting in decreasing numbers of deliveries in the THIN-CPRD data set in the more recent years (Figure 5). At the time of producing our sample size estimates, we overlooked this phenomenon and did not account for it and, hence, ended up with an overestimate of the number of deliveries in this combined data set.




FIGURE 4 Flow diagram of the final THIN-CPRD data set.




FIGURE 5 The number of births by delivery mode and year in the final THIN-CPRD data set.

Overall, 57.2% (295,079/515,945) of the births in the final THIN-CPRD data set were from THIN-HES- or CPRD-HES-linked data sets (Figure 6). The proportion of births from HES-linked data sets decreased over the years, with the majority of births from 2015 coming from primary care databases, and HES-linked data were not available after the beginning of 2018. As the recording of delivery mode is less complete in primary care, the decrease of births from HES-linked data sets explains the larger proportions of CS births in the later years of the study in the final THIN-CPRD data set. Over one-quarter [26.0% (76,819/295,079)] of births identified in HES-linked data sets were delivered by CS.

## HES data set description

The derivation of the HES analysis set covering the whole of England, which was produced from the matching of delivery episodes and baby records, is summarised in Figure 7.

After randomly selecting one baby in cases of multiple births from 7,222,967 successfully matched mother-baby pairs, the mother-baby-linked HES data set covering the whole of England included 7,147,884 mother-baby pairs, of which 25.4% (1,813,799/7,147,884) were CS births. The data set linked to the responses to the national survey of hospital prophylactic antibiotic administration policies contained records of 3,945,351 mother-baby pairs (with one baby in the data set in cases of multiple births), 25.4% ( $n = 1,001,598$ ) of which were CS births. Figure 8 shows the absolute numbers of CS and VD births over time in the full HES data set and the HES data set linked to the survey data. The sharp drop in the number in the final year is because it includes births only until the end of March 2017.

## Results of the national survey of hospital prophylactic antibiotic administration policies

An overall survey response rate of 75.7% (143/189) was achieved.

The vast majority of hospitals [95.8% (137/143)] reported that their unit's policy was to provide antibiotic prophylaxis before skin incision and five (or fewer) hospitals had this policy for either pre-labour or in-labour CS only.




FIGURE 6 The number of births by delivery mode and year from the THIN-CPRD data set, with linked HES data used for sensitivity analysis.




FIGURE 7 Flow diagram for derivation of the mother-baby-linked HES data set covering the whole of England and linkage to the national survey of the hospital prophylactic antibiotic administration policies.

Of the hospitals with a pre-incision antibiotic policy, 86.9% (119/137) indicated in which year they had implemented this policy change. The increase in the proportion of hospitals with a pre-incision antibiotics policy was gradual (*Figure 9*) and there was relatively little variation between different countries in the UK and regions within England (*Appendix 1*). No hospitals reported that they had implemented a pre-incision antibiotic policy before 2008. By 2013, over half of all hospitals had a policy to administer antibiotic prophylaxis before skin incision.

All of the hospitals that responded to the question about the type of prophylactic antibiotics currently administered used broad-spectrum antibiotics. The most common regimens were co-amoxiclav (40.6%, 54/133), cefuroxime (29.3%, 39/133) and cefuroxime together with metronidazole (26.3%, 35/133).

Of the 125 hospitals that had changed the practice to pre-incision antibiotics and responded to whether or not they used the same antibiotics before the policy change, 72.0% (90/125) had not changed their antibiotic regimen. The vast majority ( $\geq 95\%$ ) of those hospitals that had changed antibiotics after implementing pre-incision antibiotic policy had previously used co-amoxiclav.

Clindamycin was the most commonly used prophylactic antibiotic for women with a penicillin allergy (71.4%, 95/133), either administered on its own (53.4%, 71/133) or used along with gentamicin (12.8%, 17/133). Other regimens included gentamicin and teicoplanin and/or metronidazole in 12.8% (17/133) of hospitals. Metronidazole was used on its own or along with other antibiotics (such as cefuroxime or cefaclor) in 7.5% (10/133) of hospitals and teicoplanin alone was administered in 6.0% (8/133) of hospitals.



RESULTS




FIGURE 8 The number of births by delivery mode and year in (a) the HES data set covering the whole of England; and (b) the HES data set linked to the data from the national survey of hospital prophylactic antibiotic administration policies used in the main analysis.




FIGURE 9 Cumulative percentage of hospitals over time with policies to administer antibiotic prophylaxis before skin incision for women undergoing CS in the whole of the UK and England separately.

Of the 123 hospitals that had changed their practice to pre-incision antibiotics and responded to whether or not they had used the same antibiotics before the policy change for women with penicillin allergy, 91.1% (112/123) used the same antibiotic regimen.

Eight hospitals with pre-incision antibiotic policies had conducted audits from 2014 onwards regarding the proportion of women given prophylactic antibiotics before skin incision, and reported that 70–100% of women had received pre-incision antibiotics.

## Results of covariate analysis

Covariate analysis graphs are included in *Appendix 2*. There were no marked differential changes over time between the CS and VD groups in terms of maternal, household and child characteristics.

## Primary outcome results

### Main analysis

#### Outcomes recorded in primary care

*Table 6* shows the numbers of children with a first-time diagnosis of asthma and eczema, the total years of follow-up and the overall rate per 1000 person-years (note that these rates are not directly comparable to the rates in the total 0- to 4-year-old population, as rates differ by age and the maximum age to which the children born in 2015, 2016, 2017 and 2018 were followed up to was 4 years, 3 years, 2 years and 1 year, respectively). As the rates of outcomes are compared according to the probability that each mother had received pre-incision antibiotics based on the year of delivery and the national uptake of the pre-incision antibiotic policy for CS in that year, it is not possible to present this information in a table by exposure group. Therefore, we have plotted the rates of outcomes by delivery mode, year of birth and age in *Appendix 3*.

There was a 9% decrease in diagnosis of asthma in children exposed to pre-incision antibiotics compared with those with no such exposure (IRR 0.91, 95% CI 0.78 to 1.05). There was a 2% decrease in diagnosis of eczema in children with pre-incisional antibiotics compared with those with no such exposure (IRR 0.98, 95% CI 0.94 to 1.03). Together, these show that there was not enough evidence of an association between timing of prophylactic antibiotics administration and asthma and eczema diagnoses. The minimum increase in risk we estimated that we would be able to detect during our power calculations was not within the width of the CIs.

TABLE 6 Impact of pre-incision vs. post-cord clamping antibiotics on primary outcomes in the primary care (THIN-CPRD) database

Outcome	Total number (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup> (based on national policy uptake, %)		
			IRR	95% CI	p-value
Asthma	16,540 (1,670,173)	9.90	0.91	0.78 to 1.05	0.18
Eczema	102,888 (1,430,708)	71.91	0.98	0.94 to 1.03	0.46

a After adjustment for age of child, year of delivery and mode of birth. The model incorporates a probability that each mother received pre-incisional antibiotics based on national policy uptake rates in the year of delivery.

As part of the analysis model, a term was included to allow for delivery mode (CS or VD). For each study outcome, we have calculated an IRR comparing CS with VD to ascertain the difference in risk based on delivery mode (see *Appendix 4*).

### Outcomes recorded in secondary care

*Table 7* shows the numbers of children with a first-time hospital admission for asthma and eczema, the total years of follow-up (calculated assuming a follow-up of 5 years for children born before 2015 and follow-up of 4 years, 3 years, 2 years and 1 year for the children born in 2015, 2016, 2017 and 2018, respectively) and the overall rate per 1000 person-years. Pre-incision antibiotics were not associated with statistically significant increases in the risk of a childhood asthma or eczema resulting in hospital admission.

There was a 5% increase in first-time hospital admissions for asthma in children exposed to pre-incision antibiotics compared with those with no such exposure (IRR 1.05, 95% CI 0.99 to 1.11). There was a 4% decrease in first-time hospital admissions for eczema in children exposed to pre-incision antibiotics compared with those with no such exposure (IRR 0.96, 95% CI 0.71 to 1.29). Together, these findings show that there was not enough evidence of an association between timing of prophylactic antibiotics administration and asthma and eczema resulting in hospital admission, although, owing to a small number of hospital admissions, the CIs for eczema were very wide.

### Sensitivity analyses

The results of sensitivity analyses for asthma diagnosis in primary care (*Table 8*) were fairly similar to the results of the main analysis, with generally slightly lower IRRs than in the main analysis, including for moderate and severe asthma, based on prescribing information. We performed several additional sensitivity analyses for asthma outcome definition and these IRRs were also similar to the IRRs reported in the main analysis.

The sensitivity analysis of HES data for more severe asthma resulting in hospital admission produced very similar results to the main analysis, with no indication of significantly increased or reduced risk with introduction of pre-incision antibiotics (*Table 9*).

The results of sensitivity analyses for eczema were similar to the main results, suggesting no significant impact of pre-incision antibiotics on the risk of eczema, including for moderate and severe eczema, defined based on prescribing information (*Table 10*) and admission to hospital (*Table 11*).

A Poisson model has the potential for overdispersion, although we included robust standard errors to allow for the misspecification of the variance. A comparison of the results from the Poisson model and the results from a negative binomial model (with the same covariates) showed very similar results.

**TABLE 7** Impact of pre-incision vs. post-cord clamping antibiotics on primary outcomes in the secondary care (HES) database

Outcome	Total number (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup> (based on the year of policy change in each hospital)		
			IRR	95% CI	p-value
Asthma	30,274 (18,137,690)	1.67	1.05	0.99 to 1.11	0.12
Eczema	1154 (18,137,690)	0.06	0.96	0.71 to 1.29	0.77

<sup>a</sup> After adjustment for year of delivery and mode of birth. The model includes data from only those hospitals for which the year of antibiotic prescribing policy change is known.

TABLE 8 Impact of pre-incision vs. post-cord clamping antibiotics on asthma in the primary care (THIN-CPRD) database (sensitivity analyses)

Outcome	Total number (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup>	
			IRR	95% CI
<b>Sensitivity to population changes</b>				
Asthma (2006–10 vs. 2013–18) <sup>b,c</sup>	13,488 (1,339,371)	10.07	0.91	0.82 to 1.00
Asthma (HES-linked primary care data set) <sup>b,d</sup>	9494 (933,557)	10.17	0.89	0.72 to 1.10
<b>Sensitivity to model changes</b>				
Asthma (random effect for general practice) <sup>b</sup>	16,540 (1,670,173)	9.90	0.89	0.77 to 1.03
<b>Sensitivity to outcome definition</b>				
Asthma (age ≥ 3 years) <sup>b</sup>	12,125 (1,687,601)	7.18	0.86	0.70 to 1.05
Asthma (QOF Read codes) <sup>e</sup>	12,512 (1,677,394)	7.46	0.94	0.79 to 1.11
Moderate/severe asthma <sup>b,f</sup>	13,895 (1,676,660)	8.29	0.84	0.72 to 0.99
Moderate/severe asthma <sup>e,f</sup>	10,987 (1,681,617)	6.53	0.89	0.74 to 1.07

a After adjustment for age of child, year of delivery and mode of birth.  
b Asthma defined based on Read codes used in the primary analysis.  
c Comparing years with > 50% uptake of pre-incision antibiotics (2013–18) with years with very low uptake of pre-incision antibiotics (2006–10).  
d Sensitivity analysis evaluating the impact of data recording quality.  
e Defined using a conservative list of Read codes for asthma diagnosis adapted from the QOF.  
f Defined as having a Read code for asthma, a prescription for a corticosteroid inhaler and a prescription for a leukotriene receptor antagonists/systemic steroid).

TABLE 9 Impact of pre-incision vs. post-cord clamping antibiotics on asthma in the secondary care (HES) database (sensitivity analyses)

Outcome	Total number (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup>	
			IRR	95% CI
Asthma [based on national policy uptake (%) in England] <sup>b</sup>	56,748 (33,094,684)	1.71	1.04	0.97 to 1.11
Asthma (random effect for hospital)	30,274 (18,137,690)	1.67	1.03	0.97 to 1.10
Asthma (discordant sibling analysis)	3756 (2,183,199)	1.72	0.97	0.83 to 1.13

a After adjustment for year of delivery and mode of birth.  
b Analysis of the full HES data set using the estimated probability of introduction of pre-incisional antibiotics according to calendar year.

## Secondary outcome results

### Outcomes in children

#### Outcomes recorded in primary care

We found no evidence of a significant risk difference for any of the other allergic, allergy-related, autoimmune diseases, infections and less specific measures of child health (i.e. colic and failure to thrive) recorded in primary care in relation to the timing of prophylactic antibiotic administration (Table 12).

## RESULTS

**TABLE 10** Impact of pre-incision vs. post-cord clamping antibiotics on eczema in the primary care (THIN-CPRD) database (sensitivity analyses)

Outcome	Total number (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup>	
			IRR	95% CI
<b>Sensitivity to population changes</b>				
Eczema (2006–10 vs. 2013–18) <sup>b,c</sup>	81,704 (1,149,270)	71.10	0.99	0.96 to 1.02
Eczema (HES-linked primary care data set) <sup>b,d</sup>	61,328 (793,746)	77.26	0.96	0.90 to 1.02
<b>Sensitivity to model changes</b>				
Eczema (random effect for general practice) <sup>b</sup>	102,888 (1,430,708)	71.91	0.99	0.95 to 1.04
<b>Sensitivity to outcome definition</b>				
Eczema (age ≥ 1 year) <sup>b,e</sup>	46,663 (1,597,254)	29.21	1.02	0.94 to 1.10
Eczema <sup>f</sup>	121,938 (1,367,826)	89.15	0.98	0.94 to 1.02
Moderate/severe eczema <sup>b,g</sup>	44,380 (1,565,679)	28.35	0.96	0.90 to 1.04

a After adjustment for age of child, year of delivery and mode of birth.  
b Eczema defined based on Read codes and two prescriptions on separate dates, as used in primary analysis.  
c Comparing years with > 50% uptake of pre-incision antibiotics (2013–18) with years with very low uptake of pre-incision antibiotics (2006–10).  
d Sensitivity analysis evaluating the impact of data recording quality.  
e Definition further restricted to children aged ≥ 1 year with at least two prescriptions within the 90 days before or 365 days after the first eczema Read code record.  
f Defined using eczema Read codes only.  
g Defined as having a Read code for eczema and two prescriptions on separate dates, with at least one prescription for moderate/severe eczema (i.e. a moderate topical steroid/potent topical steroid/very potent steroid/topical calcineurin/systemic therapy/phototherapy), as per the NICE guideline for eczema 2007.<sup>53</sup>

**TABLE 11** Impact of pre-incision vs. post-cord clamping antibiotics on eczema in the secondary care (HES) database (sensitivity analyses)

Outcome	Total number (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup>	
			IRR	95% CI
Eczema [based on national policy uptake (%) in England] <sup>b</sup>	2004 (33,094,684)	0.06	0.78	0.58 to 1.06
Eczema (random effect for hospital)	1154 (18,137,690)	0.06	0.95	0.69 to 1.31
Eczema (discordant sibling analysis) <sup>c</sup>	124 (2,183,199)	0.06		

a After adjustment for year of delivery and mode of birth.  
b Analysis of the full HES data set using the estimated probability of introduction of pre-incisional antibiotics according to calendar year.  
c Too few cases (< 200) to fit the model.

The absolute numbers of children with autoimmune and neurodevelopmental diseases were small in this data set, resulting in a high level of uncertainty around the estimates. Given that multiple tests were undertaken and many of the included outcomes were exploratory because of a poor evidence base for an association between microbiota, early antibiotic exposure and these outcomes, a higher degree of caution is required when considering these results where the strength of the association is not high.

TABLE 12 Impact of pre-incision vs. post-clamping antibiotics on secondary outcomes in children in the primary care (THIN-CPRD) database

Outcome	Total number (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup> (based on national policy uptake, %)		
			IRR	95% CI	p-value
Other allergic and allergy-related conditions					
Food allergy/intolerance	8609 (1,680,729)	5.12	1.02	0.89 to 1.17	0.76
Allergic rhinitis and conjunctivitis	10,511 (1,680,973)	6.25	0.98	0.83 to 1.16	0.81
More than one allergy-related disease	20,146 (1,634,317)	12.33	0.99	0.88 to 1.12	0.85
Penicillin allergy <sup>b</sup>	1020 (1,698,282)	0.60	0.68	0.42 to 1.08	0.10
Anaphylaxis <sup>b</sup>	253 (1,700,221)	0.15	1.07	0.43 to 2.63	0.89
High risk of anaphylactic reaction <sup>b</sup>	2365 (1,696,513)	1.39	0.81	0.60 to 1.09	0.17
Autoimmune diseases					
Type 1 diabetes <sup>b</sup>	251 (1,700,377)	0.15	0.57	0.20 to 1.67	0.30
Coeliac disease <sup>b</sup>	285 (1,700,259)	0.17	0.54	0.21 to 1.39	0.20
Juvenile idiopathic arthritis <sup>b,c</sup>	115 (1,700,555)	0.07			
Scleroderma/systemic sclerosis <sup>b,c</sup>	≤ 5 (1,700,760)	0.00			
Inflammatory myopathies <sup>b,c</sup>	16 (1,700,750)	0.01			
Systemic lupus erythematosus <sup>b,c</sup>	≤ 5 (1,700,754)	0.00			
Autoimmune (idiopathic) thrombocytopenic purpura <sup>b,c</sup>	164 (1,700,430)	0.10			
Juvenile pernicious (megaloblastic) anaemia <sup>b,c</sup>	9 (1,700,741)	0.01			
Childhood vitiligo <sup>b</sup>	206 (1,700,390)	0.12	1.13	0.36 to 3.52	0.84
Infections and inflammation					
Wheeze	49,079 (1,576,600)	31.13	1.00	0.93 to 1.06	0.87
Upper respiratory tract infections <sup>b</sup>	314,783 (823,002)	382.48	0.99	0.97 to 1.02	0.47
Lower respiratory tract infections (excluding bronchiolitis) <sup>b</sup>	81,784 (1,495,270)	54.70	1.04	0.99 to 1.10	0.14
Bronchiolitis <sup>b</sup>	33,133 (1,604,809)	20.65	1.05	0.98 to 1.12	0.20
Gastroenteritis <sup>b</sup>	56,403 (1,550,710)	36.37	1.03	0.97 to 1.10	0.37
Inflammatory bowel disease <sup>c</sup>	10 (1,700,743)	0.01			
Urinary tract infection <sup>b</sup>	24,416 (1,655,549)	14.75	1.00	0.90 to 1.11	0.99
Antibiotic prescribing <sup>b</sup>	336,893 (783,562)	429.95	1.03	1.00 to 1.06	0.02
Other immune system-related conditions					
Leukaemia <sup>b,c</sup>	116 (1,700,571)	0.07			
Neurodevelopmental conditions					
Cerebral palsy	375 (1,699,874)	0.22	1.65	0.79 to 3.45	0.18
Autism spectrum disorder <sup>b</sup>	2021 (1,698,425)	1.19	1.14	0.77 to 1.67	0.52
ADHD <sup>b</sup>	436 (1,700,183)	0.26	2.53	1.05 to 6.12	0.04

continued

## RESULTS

**TABLE 12** Impact of pre-incision vs. post-clamping antibiotics on secondary outcomes in children in the primary care (THIN-CPRD) database (*continued*)

Outcome	Total number (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup> (based on national policy uptake, %)		
			IRR	95% CI	p-value
Less-specific measures of child health					
Colic <sup>b</sup>	20,949 (1,633,464)	12.82	1.06	0.96 to 1.16	0.26
Failure to thrive <sup>b</sup>	4018 (1,688,880)	2.38	1.08	0.87 to 1.34	0.47
Health-care utilisation in children					
Consultations recorded in primary care (in the first 12 months) <sup>b</sup>	6,688,462 (513,518)	13,024.80	1.02	1.01 to 1.02	< 0.001

ADHD, attention deficit hyperactivity disorder.

a After adjustment for age of child, year of delivery and mode of birth. The model incorporates a probability that each mother received pre-incisional antibiotics based on national policy uptake rates in the year of delivery.

b Exploratory outcomes.

c Too few cases (< 200) in the THIN-CPRD data set to fit the model.

Adapted with permission from Šumilo *et al.*<sup>88</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>.

Some of the autoimmune conditions and immune system-related diseases were extremely rare in children aged < 5 years [i.e. juvenile idiopathic arthritis, systemic sclerosis and scleroderma, inflammatory myopathies, systemic lupus erythematosus, autoimmune (idiopathic) thrombocytopenic purpura, juvenile pernicious (megaloblastic) anaemia, inflammatory bowel disease and leukaemia], preventing any meaningful calculation of risk.

We observed a very small (3%) increase in the likelihood of being prescribed antibiotics in early childhood (IRR 1.03, 95% CI 1.00 to 1.06), which was statistically significant because of the overall very high rates of antibiotic prescribing in young children. Similarly, there was a very small (2%) relative increase in the total number of consultations for any reason recorded in primary care (IRR 1.02, 95% CI 1.01 to 1.02).

### Outcomes recorded in secondary care

We did not find evidence of a significant increase in the relative risk associated with pre-incision antibiotics for any of the following more severe secondary outcomes of interest resulting in a hospital admission [i.e. anaphylaxis, type 1 diabetes, juvenile idiopathic arthritis, autoimmune (idiopathic) thrombocytopenic purpura, lower respiratory tract infections and bronchiolitis, urinary tract infection, necrotising enterocolitis and leukaemia] (*Table 13*). The numbers of children with a diagnosis of coeliac disease, systemic sclerosis and scleroderma, inflammatory myopathies, systemic lupus erythematosus, juvenile pernicious (megaloblastic) anaemia and inflammatory bowel disease were very small in the study population and we could not estimate IRRs for these outcomes in secondary care. There was a very small (2%) increase in the risk of being admitted to hospital for gastroenteritis (IRR 1.02, 95% CI 1.00 to 1.05) and a very small (1%) relative increase in the risk of having a hospital admission for any reason (IRR 1.01, 95% CI 1.01 to 1.02). These outcomes were exploratory and, although the differences in risk were statistically significant, they may not be clinically significant.

Having a pre-incision antibiotics policy was associated with a 25% relative reduction in early-onset neonatal sepsis (IRR 0.75, 95% CI 0.65 to 0.87) and a 12% reduction in late-onset sepsis (IRR 0.88, 95% CI 0.80 to 0.97), although the overall recorded incidence of neonatal sepsis has increased over the study period both in children born by CS and in those born by VD (see *Appendix 3*).

TABLE 13 Impact of pre-incision vs. post-clamping antibiotics on secondary outcomes in children in the secondary care (HES) database

Outcome	Total number (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup> (based on the year of policy change in each hospital)		
			IRR	95% CI	p-value
Other allergic and allergy-related conditions					
Anaphylaxis <sup>b</sup>	1665 (18,137,690)	0.09	1.01	0.82 to 1.25	0.91
Autoimmune diseases					
Type 1 diabetes <sup>b</sup>	2445 (18,137,690)	0.13	0.99	0.82 to 1.20	0.94
Coeliac disease <sup>b,c</sup>	178 (18,137,690)	0.01			
Juvenile idiopathic arthritis <sup>b</sup>	297 (18,137,690)	0.02	0.97	0.54 to 1.74	0.92
Scleroderma/systemic sclerosis <sup>b,c</sup>	≤ 5 (18,137,690)	0.00			
Inflammatory myopathies <sup>b,c</sup>	26 (18,137,690)	0.00			
Systemic lupus erythematosus <sup>b,c</sup>	≤ 5 (18,137,690)	0.00			
Autoimmune (idiopathic) thrombocytopenic purpura <sup>b</sup>	1506 (18,137,690)	0.08	1.11	0.88 to 1.39	0.37
Juvenile pernicious (megaloblastic) anaemia <sup>b,c</sup>	≤ 5 (18,137,690)	0.00			
Infections and inflammation					
Early-onset neonatal sepsis (within 3 days of birth) <sup>d</sup>	3336 (3,945,351)	0.85	0.75	0.65 to 0.87	< 0.001
Late-onset neonatal sepsis (between 4 and 28 days after birth) <sup>d</sup>	7226 (3,945,351)	1.83	0.88	0.80 to 0.97	0.008
Other sepsis (from 29 days after birth) <sup>b</sup>	15,182 (17,835,240)	0.85	0.98	0.91 to 1.04	0.48
Lower respiratory tract infections (excluding bronchiolitis) <sup>b</sup>	128,399 (18,137,690)	7.08	0.99	0.96 to 1.01	0.19
Bronchiolitis <sup>b</sup>	153,411 (18,137,690)	8.46	1.01	0.98 to 1.03	0.64
Gastroenteritis <sup>b</sup>	145,293 (18,137,690)	8.01	1.02	1.00 to 1.05	< 0.001
Inflammatory bowel disease <sup>c</sup>	87 (18,137,690)	0.00			
Urinary tract infection <sup>b</sup>	41,676 (18,137,690)	2.30	1.00	0.95 to 1.04	0.86
Other immune system-related conditions					
Necrotising enterocolitis <sup>d</sup>	1178 (3,945,351)	0.30	1.16	0.95 to 1.42	0.16
Leukaemia <sup>b</sup>	1094 (18,137,690)	0.06	0.97	0.74 to 1.29	0.86
Health-care utilisation in children					
Any hospital admission <sup>b</sup>	1,459,776 (18,137,690)	80.48	1.01	1.01 to 1.02	< 0.001

a After adjustment for year of delivery and mode of birth. The model includes data from only those hospitals for which the year of antibiotic prescribing policy change is known.

b Exploratory outcomes.

c Too few cases (< 200 in HES data set) to fit the model.

d Owing to these conditions occurring in the neonatal period, rates were calculated per 1000 births.

Adapted with permission from Šumilo *et al.*<sup>88</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>.



### Maternal outcomes

Table 14 shows the overall numbers and percentages of women who developed maternal infections during the study period by delivery mode, the uncontrolled risk estimates comparing pre-incision antibiotics with antibiotics administered after cord clamping and the estimates adjusting for rates in the VD comparator group, as there were changes in the recorded incidence of different maternal post-partum infection indicators in routine data over the time (see Appendix 3).

We found a significant negative association between giving antibiotics before skin incision and the composite outcome of maternal infectious morbidity, with a relative reduction in infectious morbidity of 33% in the uncontrolled analysis in primary care (IRR 0.67, 95% CI 0.56 to 0.79) and 30% in the analysis controlling for infection rates in the VD group (IRR 0.70, 95% CI 0.63 to 0.77). The overall rates of maternal sepsis recorded in routine health-care records increased substantially over the study period (see Appendix 3). The observed reduction in the risk of the maternal infectious morbidity outcome was principally due to the marked decrease in wound infections in the CS group recorded in primary care over the study period, and differences in endometritis and maternal sepsis in the adjusted analyses were not statistically significant. In the controlled analysis, there was also no evidence of a significantly reduced risk of urinary tract infections. Pre-incision antibiotic policy was associated with a 6% (IRR 0.94, 95% CI 0.85 to 1.03) and an 11% reduction (IRR 0.89, 95% CI 0.85 to 0.92) in women being prescribed antibiotics in the post-natal period in primary care in the uncontrolled analysis and analysis adjusted for delivery mode, respectively.

Table 15 shows results for maternal infectious morbidity recorded in hospital data. Diagnoses were recorded after delivery, during the birth episode or as a new hospital admission in the post-partum period and, therefore, the incidence (apart for maternal sepsis) is lower than that in the primary care records.

TABLE 14 Impact of pre-incision vs. post-clamping antibiotics on maternal outcomes in the primary care (THIN-CPRD) database

Outcome	Delivery mode, n (%) <sup>a</sup>		Pre-incision vs. post-clamping antibiotics (based on national policy uptake, %)					
	CS	VD	IRR <sup>b</sup>	95% CI	p-value	IRR <sup>c</sup>	95% CI	p-value
Composite infectious morbidity <sup>d</sup>	12,466 (8.61)	5303 (1.43)	0.67	0.56 to 0.79	<0.001	0.70	0.63 to 0.77	<0.001
Endometritis/endomyometritis	617 (0.43)	1269 (0.34)	0.63	0.26 to 1.53	0.31	0.98	0.72 to 1.33	0.88
Wound infection	11,717 (8.09)	3800 (1.02)	0.64	0.53 to 0.77	<0.001	0.62	0.55 to 0.69	<0.001
Urinary tract infection/cystitis/pyelonephritis	2551 (1.76)	4935 (1.33)	0.64	0.43 to 0.97	0.04	1.01	0.87 to 1.17	0.93
Sepsis	212 (0.15)	254 (0.07)	11.55	3.66 to 34.41	<0.001	1.40	0.85 to 2.31	0.19
Pelvic abscess <sup>e</sup>	≤ 5 (0.00)	7 (0.00)						
Antibiotic prescribing	39,000 (26.92)	59,138 (15.94)	0.94	0.85 to 1.03	0.17	0.89	0.85 to 0.92	<0.001

a These numbers and percentages describe the overall frequency of outcomes in CS and VD groups and do not include a comparison of pre-incision vs. post-cord clamping antibiotics.

b After adjustment for year of delivery.

c After adjustment for year of delivery and delivery mode.

d Composite infectious morbidity includes wound infection, endometritis/endomyometritis, sepsis and pelvic abscess.

e Too few cases to fit the model.

Adapted with permission from Sumilo *et al.*<sup>88</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>.

TABLE 15 Impact of pre-incision vs. post-clamping antibiotics on maternal outcomes in secondary care (HES) database

Outcome	Delivery mode		Pre-incision vs. post-clamping antibiotics (based on the year of policy change in each hospital)					
	CS	VD	IRR <sup>a</sup>	95% CI	p-value	IRR <sup>b</sup>	95% CI	p-value
Composite infectious morbidity, n (%) <sup>cd</sup>	18,934 (1.89)	9112 (0.31)	0.98	0.94 to 1.02	0.31	0.84	0.81 to 0.87	<0.001
Endometritis/ endomyometritis, n (%) <sup>ce</sup>	41 (0.00)	40 (0.00)						
Wound infection, n (%) <sup>c</sup>	16,185 (1.62)	6701 (0.23)	0.94	0.90 to 0.98	0.006	0.84	0.81 to 0.87	<0.001
Urinary tract infection/cystitis/ pyelonephritis, n (%) <sup>c</sup>	3148 (0.31)	5526 (0.19)	1.14	1.03 to 1.26	0.01	1.04	0.96 to 1.14	0.32
Sepsis, n (%) <sup>c</sup>	2878 (0.29)	2389 (0.08)	1.22	1.09 to 1.36	<0.001	1.15	1.05 to 1.26	0.003
Maternal deaths, n (%) <sup>ce,f</sup>	≤ 5 (0.00)	≤ 5 (0.00)						
Length of stay in days, median (IQR)	3 (2-4)	1 (1-2)	-0.004 <sup>g</sup>	-0.02 to 0.01	0.66	-0.23 <sup>g</sup>	-0.24 to -0.21	<0.001

IQR, interquartile range.

a After adjustment for year of delivery.

b After adjustment for year of delivery and delivery mode.

c These numbers and percentages describe the overall frequency of outcomes in CS and VD groups and do not include a comparison of pre-incision vs. post-cord clamping antibiotics.

d Composite infectious morbidity consists of wound infection, endometritis/endomyometritis and sepsis.

e There were too few cases to fit the model.

f The HES data set did not contain information on the cause of death. The deaths reported here include deaths if there was also a diagnosis of any of the health conditions included in the composite infectious morbidity outcome in the maternal record in the post-partum period.

g Mean difference.

Adapted with permission from Šumilo *et al.*<sup>88</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>.

The relative risk for the composite maternal infectious morbidity outcome was significantly reduced in the analysis adjusted for delivery mode only, showing a 16% reduction associated with pre-incision antibiotic policy (IRR 0.84, 95% CI 0.81 to 0.87). For individual outcomes, the risk of wound infection recorded in secondary care was reduced by 16% in the adjusted analysis (IRR 0.84, 95% CI 0.81 to 0.87); however, the risk of maternal sepsis was still increased, even after adjusting for increasing rates of maternal sepsis in women who delivered vaginally in the same locations where CSs were performed. After adjusting for delivery mode, there was no significant association between urinary tract infections and giving antibiotics before skin incision. The length of hospital stay was slightly reduced in the analysis adjusted for delivery mode.

### Additional sensitivity analyses

The effect sizes in the sensitivity analyses for all childhood outcomes with unexpected statistically significant findings in primary care were reduced, compared with the main analysis (Table 16). Sensitivity analyses suggest a high degree of imprecision in the estimate of the risk of attention deficit hyperactivity disorder (ADHD) in relation to exposure to pre-incision antibiotics. Given the poor existing evidence base on whether or not antibiotics or microbiota changes are clearly associated with ADHD, these results may be spurious.

Overall, the results of the sensitivity analyses in HES data were similar to the results of the main analysis. They confirm the reduced risk for early-onset neonatal sepsis; however, there was more uncertainty around the estimates for late-onset sepsis. The associations between pre-incision antibiotics and hospital admission for gastroenteritis, as well as admission to hospital for any reason, remained statistically significant, although the size of the increased risk remains very small (Table 17).

## RESULTS

**TABLE 16** Sensitivity analyses for secondary outcomes recorded in primary care, with unexpected findings in the main analysis

Outcome	Total n (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup>	
			IRR	95% CI
Antibiotic prescribing				
2006–10 vs. 2013–18 <sup>b</sup>	268,872 (629,840)	426.89	1.01	1.00 to 1.03
HES-linked primary care data only	192,224 (443,140)	433.78	1.02	0.98 to 1.06
Random effect for general practice	336,893 (783,562)	429.95	1.03	1.00 to 1.05
ADHD <sup>c</sup>				
2006–10 vs. 2013–18 <sup>b</sup>	344 (1,364,177)	0.25	1.24	0.66 to 2.34
HES-linked primary care data only	237 (950,702)	0.25	2.42	0.61 to 9.58
Consultations recorded in primary care (12 months) <sup>c</sup>				
2006–10 vs. 2013–18 <sup>b</sup>	5,319,832 (414,034)	12,848.79	1.01	1.01 to 1.02
HES-linked primary care data only	3,850,551 (295,070)	13,049.62	1.02	1.01 to 1.03

a After adjustment for age of child, year of delivery and mode of birth.  
b Comparing years with > 50% uptake of pre-incision antibiotics (2013–18) with years with very low uptake of pre-incision antibiotics (2006–10).  
c Random-effect model for general practice for this outcome did not converge and so no results were obtained.

**TABLE 17** Sensitivity analyses for secondary outcomes recorded in secondary care, with unexpected findings in the main analysis

Outcome	Total n (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup>	
			IRR	95% CI
Early-onset neonatal sepsis <sup>c</sup>				
Based on national policy uptake (%) in England <sup>b</sup>	12,629 (7,147,884)	1.77	0.76	0.68 to 0.85
Random effect for hospital	7226 (3,945,351)	1.83	0.86	0.77 to 0.97
Late-onset neonatal sepsis <sup>c</sup>				
Based on national policy uptake (%) in England <sup>b</sup>	6075 (7,147,884)	0.85	0.68	0.58 to 0.81
Random effect for hospital	3336 (3,945,351)	0.85	0.82	0.57 to 1.17
Gastroenteritis <sup>d</sup>				
Based on national policy uptake (%) in England <sup>b</sup>	249,521 (33,094,684)	7.54	1.08	1.05 to 1.11
Any hospital admission <sup>d</sup>				
Based on national policy uptake (%) in England <sup>b</sup>	2,572,391 (33,094,684)	77.73	1.02	1.01 to 1.02

a After adjustment for year of delivery and mode of birth.  
b Analysis of the full HES data set using the estimated probability of introduction of pre-incision antibiotics according to calendar year.  
c Owing to these conditions occurring in the neonatal period, rates were calculated per 1000 births.  
d Random-effect model for hospital for this outcome did not converge and so no results were obtained.

## Results of subgroup analyses

### *Type of caesarean section*

The results of subgroup analyses comparing the effect of pre-incision antibiotics with post-cord clamping antibiotics in emergency and elective CS on asthma and eczema, adjusted for rates of VD, were similar to the main results (*Tables 18 and 19*). Although uncertainty was larger around the estimates, the results do not suggest an increased risk associated with a change from post-cord clamping to pre-incision antibiotics in either elective or emergency CS.

### *Antibiotic regimen*

*Table 20* shows results of analyses restricted to hospitals that were administering the same antibiotic regimen before and after policy change regarding the timing of prophylactic antibiotics. No particular antibiotic regimen was associated with a higher risk of being admitted to hospital because of asthma. Hospital admissions due to eczema were very rare and more evidence would be required to confirm if there may be a clinically significant decrease in the risk of eczema associated with pre-incision administration of co-amoxiclav. Overall, there was no evidence that a particular antibiotic regimen was associated with a different risk of necrotising enterocolitis when comparing pre-incision and post-clamping antibiotics.

TABLE 18 Impact of pre-incision vs. post-cord clamping antibiotics on child outcomes by emergency and elective CS in the primary care (THIN-CPRD) database

Outcome	Pre-incision vs. post-cord clamping antibiotics <sup>a</sup> (based on national policy uptake, %)										
	Emergency CS					Elective CS					p-value interaction
	Total n (follow-up time in person-years)	Overall rate per 1000 person-years	IRR	95% CI	p-value	Total n (follow-up time in person-years)	Overall rate per 1000 person-years	IRR	95% CI	p-value	
Asthma	2256 (210,139)	10.74	1.05	0.86 to 1.27	0.65	1786 (179,873)	9.93	0.86	0.69 to 1.07	0.16	0.15
Eczema	14,564 (176,401)	82.56	1.03	0.97 to 1.09	0.38	10,428 (155,825)	66.92	0.98	0.92 to 1.05	0.58	0.28

a After adjustment for age of child, year of delivery and mode of birth (VD). The model incorporates a probability that each mother received pre-incisional antibiotics based on national policy uptake rates in the year of delivery.

TABLE 19 Impact of pre-incision vs. post-cord clamping antibiotics on child outcomes by emergency and elective CS in the secondary care (HES) database

Outcome	Pre-incision vs. post-cord clamping antibiotics <sup>a</sup> (based on the year of policy change in each hospital)										
	Emergency CS					Elective CS					p-value interaction
	Total n (follow-up time in person-years)	Overall rate per 1000 person-years	IRR	95% CI	p-value	Total n (follow-up time in person-years)	Overall rate per 1000 person-years	IRR	95% CI	p-value	
Asthma	4984 (2,675,442)	1.86	1.05	0.98 to 1.13	0.17	3104 (1,897,257)	1.64	1.04	0.96 to 1.14	0.34	0.90
Eczema	175 (2,675,442)	0.07	0.87	0.60 to 1.26	0.47	106 (1,897,257)	0.06	1.15	0.73 to 1.80	0.55	0.34

a After adjustment for year of delivery, follow-up time and mode of birth (VD). The model is based on the year of prophylactic antibiotic policy change in each hospital.

TABLE 20 Impact of pre-incision vs. post-cord clamping antibiotics on child outcomes in units administering different antibiotic regimens in the secondary care (HES) database

Outcome	Total n (follow-up time in person-years)	Overall rate per 1000 person-years	Pre-incision vs. post-clamping antibiotics <sup>a</sup> (based on the year of policy change in each hospital)		
			IRR	95% CI	p-value
Asthma					
Cefuroxime alone	5697 (3,555,311)	1.60	0.88	0.77 to 1.01	0.08
Cefuroxime and metronidazole	5236 (2,951,897)	1.77	1.04	0.91 to 1.19	0.59
Co-amoxiclav alone	10,477 (6,013,240)	1.74	1.08	0.98 to 1.19	0.13
Eczema					
Cefuroxime alone	253 (3,555,311)	0.07	1.36	0.75 to 2.46	0.30
Cefuroxime and metronidazole <sup>b</sup>	171 (2,951,897)	0.06			
Co-amoxiclav alone	447 (6,013,240)	0.07	0.55	0.32 to 0.97	0.04
Necrotising enterocolitis <sup>c</sup>					
Cefuroxime alone	213 (771,945)	0.28	1.38	0.83 to 2.28	0.22
Cefuroxime and metronidazole	232 (639,624)	0.36	1.22	0.76 to 1.95	0.41
Co-amoxiclav alone	347 (1,310,208)	0.26	1.32	0.92 to 1.89	0.13

a After adjustment for year of delivery, follow-up time and mode of birth.

b Too few cases (< 200) to fit the model.

c Owing to this occurring in the neonatal period, rates were calculated per 1000 births.



## Chapter 4 Discussion and implications

This large population-wide study of routine primary and secondary health-care records did not find evidence of an increased risk of asthma and eczema (including severe asthma and eczema, and other allergic and allergy-related conditions) in children aged < 5 years in relation to the change in the guidelines recommending administration of antibiotics before skin incision in CSs.

There is also no convincing evidence that pre-incision antibiotics are associated with significant risk of development of autoimmune and other conditions investigated in this study, including infections, necrotising enterocolitis, leukaemia, neurodevelopmental conditions, colic and failure to thrive. Most of these outcomes in our study were purely exploratory, as there was insufficient evidence regarding the role of microbiota in the development of these conditions. Many of these health conditions are rare in young children, resulting in large uncertainty around the estimates. Our study was not sufficiently powered to detect clinically important differences in the rarer outcomes.

We found a statistically significant reduction in neonatal sepsis similar to the relative reduction in the point estimate found in a systematic review of randomised controlled trials, although the review's results were not statistically significant.<sup>89</sup> The results confirm previous findings<sup>89</sup> that antibiotics before skin incision do not increase the risk of neonatal sepsis, but the observed relative reduction in the risk associated with pre-incision antibiotics in babies born by CS, which was estimated by controlling for the risk of sepsis in babies born by VD, should be interpreted with caution in this study. The overall incidence of neonatal sepsis diagnoses recorded in routine health-care data has increased over the years. Clinically diagnosed neonatal sepsis often has no organism isolated from blood culture.<sup>90</sup> The diagnosis of neonatal sepsis in our study is likely to be culture-confirmed sepsis, in which case the receipt of antibiotics immediately prior to birth may result in an increase in the likelihood of being culture negative, even if the baby develops signs of neonatal sepsis (i.e. it may be an artefact of the antibiotics rather than an actual decrease in the relative risk of disease).

The very small (ranging from 1% to 3%) relative increases in the number of consultations recorded in primary care, the increased likelihood of children exposed to pre-incision antibiotics being prescribed antibiotics in early childhood, the increased likelihood of hospital admission for gastroenteritis and ever being admitted to hospital for any reason that were observed in this study are all common events and, therefore, produce statistically significant differences. Residual confounding and bias may explain these differences; however, even if they are real, they are very small and unlikely to be clinically important.

In this research, we obtained risk estimates for > 50 outcomes across primary and secondary care data sets; however, because of multiple comparisons, some of the statistically significant differences we observed may have occurred by chance. Some of the health conditions, such as ADHD, may show symptoms in early childhood, but are most commonly diagnosed later in life, with the incidence being the highest in school-aged children.<sup>91</sup> Therefore, the numbers of children born by CS with a new diagnosis of ADHD in primary care were very small in each year during our study, resulting in large variations in the incidence between the years. More evidence would be required to confirm or refute this finding before any conclusion of an association can be made. Previous research has shown conflicting results regarding exposure to antibiotics in early life and ADHD. For example, recent population-based Canadian and Danish studies<sup>92,93</sup> did not observe a significant association between antibiotic exposure in the first years of life and ADHD, particularly in sibling-controlled analysis that adjusted for familial confounding factors. However, a large Finnish study<sup>94</sup> suggested an association between exposure to antibiotics in early life and ADHD that may not be fully explained by familial confounding.



Our study did not identify a significant association between necrotising enterocolitis and pre-incision antibiotics for CS, including co-amoxiclav. There was some degree of uncertainty around the estimates, and they do not exclude the possibility of an increased risk. There was a slight increase in the overall incidence of necrotising enterocolitis over the study period, as recorded in the routine secondary care records. In this study, we assessed the overall association only and did not examine the risk in any specific subgroups of pregnancies and babies previously reported to be at higher risk of necrotising enterocolitis.<sup>83,95</sup>

The relative reduction in the composite outcome of maternal infectious morbidity in the post-partum period associated with pre-incision antibiotics in CS that we observed in this study is comparable to the reduced risks previously reported in randomised controlled trials.<sup>9,89</sup> We found an overall increase in maternal sepsis recorded in health-care records, which may be due to an increase in diagnosis, prevention and treatment of sepsis over the study period. The relative increase in the CS group may, therefore, be an artefact, as any operation increases the suspicion of sepsis, leading to an increased rate of diagnosis. Evidence from randomised controlled trials shows that prophylactic antibiotics significantly reduce serious infectious complications compared with no antibiotic prophylaxis for CS.<sup>96</sup>

In this study, we investigated the impact of the timing of prophylactic antibiotics in CS deliveries. Babies born by CS have a different composition of gut microbiota after birth and are more likely to be colonised by opportunistic pathogenic bacteria than babies born by VD.<sup>13</sup> Therefore, the impact of antibiotic prophylaxis around the time of birth in babies born by VD may be different.

The strengths of this study include using data from large population-based mother–baby linked data sets and examining the impact of pre-incision antibiotic policy on a wide range of allergy, immune system and other related outcomes. It also assessed the impact on the severity of outcomes by examining the risk of health conditions recorded in primary care and health conditions resulting in a hospital admission. The study employed a strong design, using VD as a comparison group to control for any temporal changes (e.g. changes in diagnoses and recording in medical records) over time, which could not be achieved by simple adjustment for confounding factors. We also undertook a number of sensitivity analyses to assess the robustness of our findings, including the impact of missing data, and the results were similar to those of the main analyses.

The study also has several limitations that need to be taken into account when interpreting the findings. This was an observational study that used routinely collected health-care data, and validated case definitions for different health conditions in electronic medical records, where such exist, have mostly been derived from populations that include older age groups.<sup>51,52,97</sup> Making diagnoses for some conditions in early childhood can be difficult and rely on symptoms (e.g. asthma objective tests can be performed in children aged  $\geq 5$  years only).<sup>44,98</sup> Some health conditions we investigated in this study were very rare in young children and our study was not sufficiently powered to detect clinically significant differences in risks for these outcomes. The timing of prophylactic antibiotic administration was not recorded in routine health-care records and, therefore, we were not able to ascertain exposure to pre-incision antibiotics at an individual level. It is also possible that there is residual confounding that was not fully accounted for by using VD as a comparator group. Finally, the results may not be generalisable to settings where different prophylactic antibiotic regimens are used.

### Implications for practice and research recommendations

The overall findings from this study provide further evidence for the currently prevailing practice in the UK of giving prophylactic antibiotics before skin incision to help reduce the risk of maternal infections in the post-partum period.

Some of the secondary health outcomes we investigated in this study were exploratory because of a lack of or inconclusive evidence regarding an association between newborn microbiota, early exposure to antibiotics and children's development. Many of the health conditions were also very rare in young children, resulting in large uncertainty around the estimates. We suggest undertaking a further study using routinely collected health-care data in other countries where there was no change in the timing of prophylactic antibiotic administration to assess if there have also been changes in the risk over time of developing these health conditions, particularly ADHD and gastroenteritis, irrespective of the exposure to prophylactic antibiotics around the time of birth. The current study includes health-care records until 2018, but it could also be repeated in the future to capture outcomes of interest in children aged > 5 years.

Other research is ongoing in the UK using the Born in Bradford birth cohort, allowing the ascertainment of antibiotic exposure at an individual level. The original Born in Bradford cohort included 13,776 children, and the majority of these children were born before the recommendation to give antibiotics pre incision.<sup>99</sup> This may limit the ability of this study to assess the risk for most of the outcomes of interest investigated in this research.



# Acknowledgements

We would like to thank our independent Steering Group members (Elizabeth Draper, Alison Wright, Maria Clark and Daniel Prieto-Alhambra) for providing expert advice and oversight of the study.

We would also like to thank Anuradha Subramanian for helping with the literature review, Max Feltham, the Birmingham Surgical Trials Consortium (Birmingham, UK) and Mary Perrins for their help with the survey on prophylactic antibiotic policies; Fiona Alderdice and Jane Henderson for providing aggregate data on breastfeeding from the National Perinatal Epidemiology Unit's Maternity Surveys; Rachel Rowe for her advice regarding information on free-standing midwifery units; and Katie Harron for her advice on mother-baby linkage in the HES data set.

We also thank all of the women who were involved in our PPI engagement sessions, and the members of the RCOG's Women's Voices Involvement Panel and clinicians who completed the survey.

Dana Šumilo is affiliated to the National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at University of Liverpool in partnership with the UK Health Security Agency (UKHSA), in collaboration with University of Warwick. Dana Šumilo is based at the University of Warwick. The views expressed are those of the author(s) and not necessarily those of NIHR, the Department of Health and Social Care or UKHSA.

This study is based, in part, on data from the CPRD, obtained under licence from the UK NHRA, and THIN, obtained under licence from IQVIA. IQVIA Medical Research Data incorporates data from THIN, a Cegedim database. Reference made to THIN is intended to be descriptive of the data asset licensed by IQVIA. This work used de-identified data provided by patients as a part of their routine care.

## Contributions of authors

**Dana Šumilo** (<https://orcid.org/0000-0001-6732-2459>) (Consultant and Honorary Senior Research Fellow, Public Health and Epidemiology) contributed to the study design, analysis and interpretation of the results and led the writing of the report.

**Krishnarajah Nirantharakumar** (<https://orcid.org/0000-0002-6816-1279>) (Professor, UK Research and Innovation Clinical Fellow and Honorary Consultant, Public Health and Health Informatics) led the preparation of the THIN-CPRD data set and contributed to the analysis, interpretation of the results and writing of the final report.

**Brian H Willis** (<https://orcid.org/0000-0002-0821-8624>) (Medical Research Council Clinician Scientist and General Practitioner) contributed to the study design, development of study outcome definitions, interpretation of the results and writing of the final report.

**Gavin Rudge** (<https://orcid.org/0000-0002-9857-6547>) (Research Fellow, Health Informatics) was responsible for data linkage and preparation of the HES data set, and contributed to the development of study outcome definitions, analysis, interpretation of the results and writing of the final report.

**James Martin** (<https://orcid.org/0000-0002-6949-4200>) (Lecturer, Statistics) was responsible for statistical analysis and contributed to the interpretation of the results and writing of the final report.

**Krishna Gokhale** (<https://orcid.org/0000-0002-2167-9572>) (Research Fellow, Computer Science) was responsible for data linkage and preparation of the THIN-CPRD data set and contributed to the analysis, interpretation of the results and writing of the final report.

## ACKNOWLEDGEMENTS

**Rasiah Thayakaran** (<https://orcid.org/0000-0002-4422-4095>) (Research Fellow, Statistics) was responsible for preparation of the THIN–CPRD data set and contributed to the analysis, interpretation of the results and writing of the final report.

**Nicola J Adderley** (<https://orcid.org/0000-0003-0543-3254>) (Lecturer, Health Informatics and Epidemiology) contributed to data acquisition, interpretation of the results and writing of the final report.

**Joht Singh Chandan** (<https://orcid.org/0000-0002-9561-5141>) (Academic Clinical Lecturer, Public Health) contributed to data acquisition, preparation of the THIN–CPRD data set, development of study outcome definitions and writing of the final report.

**Kelvin Okoth** (<https://orcid.org/0000-0002-2745-4083>) (Research Fellow, Epidemiology) contributed to the development of study outcome definitions and preparation of the THIN–CPRD data set.

**Isobel M Harris** (<https://orcid.org/0000-0001-8125-3832>) (Research Fellow, Systematic Reviews) contributed to the literature review for this study, and the analysis and writing of the final report.

**Ruth Hewston** (<https://orcid.org/0000-0002-2035-184X>) (Patient and Public Contributor) advised on all PPI aspects of the project, including defining study outcomes, wider PPI engagement, interpretation of the results, development of lay messages and writing of the final report.

**Magdalena Skrybant** (<https://orcid.org/0000-0001-7119-2482>) (Patient and Public Contributor) advised on all PPI aspects of the project, including defining study outcomes, wider PPI engagement, interpretation of the results, development of lay messages and writing of the final report.

**Jonathan J Deeks** (<https://orcid.org/0000-0002-8850-1971>) (Professor, Biostatistics) developed statistical methodology and oversaw the analysis, and contributed to the study design, interpretation of the results and writing of the report.

**Peter Brocklehurst** (<https://orcid.org/0000-0002-9950-6751>) (Professor, Women's Health and Perinatal Epidemiology) contributed to the study design, development of study outcome definitions, interpretation of the results and writing of the report.

## Publications

Šumilo D, Nirantharakumar K, Willis BH, Rudge G, Martin J, Gokhale K, *et al.* Long term impact of giving antibiotics before skin incision versus after cord clamping on children born by caesarean section: protocol for a longitudinal study based on UK electronic health records. *BMJ Open* 2019;**9**:e033013.

Šumilo D, Willis BH, Rudge GM, Martin J, Gokhale K, Thayakaran R, *et al.* Long term impact of prophylactic antibiotic use before incision versus after cord clamping on children born by caesarean section: longitudinal study of UK electronic health records. *BMJ* 2022;**377**:e069704.

## Data-sharing statement

All data queries and requests should be submitted to the corresponding author for consideration in the first instance. Please note that data for this study were derived from THIN and CPRD GOLD primary care and linked data obtained under licence from IQVIA World Publications Ltd and UK MHRA. A secondary care database was derived from HES data obtained under licence from the Health and Social Care Information Centre (NHS Digital). Data for similar cohorts can be requested from IQVIA World Publications Ltd, the UK MHRA and NHS Digital, subject to protocol approval and licence agreements.

## Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.



## References

1. Public Health Scotland. *Births in Scottish Hospitals*. URL: [www.isdscotland.org/Health-Topics/Maternity-and-Births/Births/](http://www.isdscotland.org/Health-Topics/Maternity-and-Births/Births/) (accessed 27 January 2020).
2. NHS Digital. *NHS Maternity Statistics*. URL: <https://digital.nhs.uk/data-and-information/publications/statistical/nhs-maternity-statistics> (accessed 27 January 2020).
3. Public Health Agency of Northern Ireland. *Children's Health in Northern Ireland*. URL: [www.publichealth.hscni.net/directorates/operations/statistics](http://www.publichealth.hscni.net/directorates/operations/statistics) (accessed 27 January 2020).
4. Thomas C. *Maternity and Birth Statistics: 2020*. 2021. URL: <https://gov.wales/maternity-and-birth-statistics-2020.html> (accessed 27 January 2020).
5. Leth RA, Møller JK, Thomsen RW, Uldbjerg N, Nørgaard M. Risk of selected postpartum infections after cesarean section compared with vaginal birth: a five-year cohort study of 32,468 women. *Acta Obstet Gynecol Scand* 2009;**88**:976–83. <https://doi.org/10.1080/00016340903147405>
6. National Institute for Health and Care Excellence (NICE). *Caesarean Birth*. NICE Guideline NG192. London: NICE; 2021.
7. National Institute for Health and Care Excellence (NICE). *Caesarean Section*. NICE Clinical Guideline CG132. London: NICE; 2011.
8. Bailey SR, Field N, Townsend CL, Rodger AJ, Brocklehurst P. Antibiotic prophylaxis for women undergoing caesarean section and infant health. *BJOG* 2016;**123**:875–6. <https://doi.org/10.1111/1471-0528.13701>
9. Mackeen AD, Packard RE, Ota E, Berghella V, Baxter JK. Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery. *Cochrane Database Syst Rev* 2014;**12**:CD009516. <https://doi.org/10.1002/14651858.CD009516.pub2>
10. Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Biggio JR. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. *Am J Obstet Gynecol* 2015;**212**:812.e1–6. <https://doi.org/10.1016/j.ajog.2015.01.015>
11. Azad MB, Konya T, Persaud RR, Guttman DS, Chari RS, Field CJ, *et al*. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. *BJOG* 2016;**123**:983–93. <https://doi.org/10.1111/1471-0528.13601>
12. Korpela K, de Vos WM. Early life colonization of the human gut: microbes matter everywhere. *Curr Opin Microbiol* 2018;**44**:70–8. <https://doi.org/10.1016/j.mib.2018.06.003>
13. Shao Y, Forster SC, Tsaliki E, Vervier K, Strang A, Simpson N, *et al*. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. *Nature* 2019;**574**:117–21. <https://doi.org/10.1038/s41586-019-1560-1>
14. Zimmermann P, Messina N, Mohn WW, Finlay BB, Curtis N. Association between the intestinal microbiota and allergic sensitization, eczema, and asthma: a systematic review. *J Allergy Clin Immunol* 2019;**143**:467–85. <https://doi.org/10.1016/j.jaci.2018.09.025>
15. Lawley TD, Walker AW. Intestinal colonization resistance. *Immunology* 2013;**138**:1–11. <https://doi.org/10.1111/j.1365-2567.2012.03616.x>



16. Murgas Torrazza R, Neu J. The developing intestinal microbiome and its relationship to health and disease in the neonate. *J Perinatol* 2011;**31**(Suppl. 1):29–34. <https://doi.org/10.1038/jp.2010.172>
17. Honda K, Littman DR. The microbiome in infectious disease and inflammation. *Annu Rev Immunol* 2012;**30**:759–95. <https://doi.org/10.1146/annurev-immunol-020711-074937>
18. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, *et al.* Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. *Gut* 2007;**56**:661–7. <https://doi.org/10.1136/gut.2006.100164>
19. Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. *Nat Med* 2016;**22**:713–22. <https://doi.org/10.1038/nm.4142>
20. Bisgaard H, Bønnelykke K, Stokholm J. Immune-mediated diseases and microbial exposure in early life. *Clin Exp Allergy* 2014;**44**:475–81. <https://doi.org/10.1111/cea.12291>
21. Neu J, Rushing J. Cesarean versus vaginal delivery: long-term infant outcomes and the hygiene hypothesis. *Clin Perinatol* 2011;**38**:321–31. <https://doi.org/10.1016/j.clp.2011.03.008>
22. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. *World J Gastroenterol* 2015;**21**:8787–803. <https://doi.org/10.3748/wjg.v21.i29.8787>
23. Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Müller G, *et al.* Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. *J Allergy Clin Immunol* 2011;**128**:646–52.e1–5. <https://doi.org/10.1016/j.jaci.2011.04.060>
24. Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, *et al.* The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature* 2018;**562**:589–94. <https://doi.org/10.1038/s41586-018-0620-2>
25. Verdu EF, Galipeau HJ, Jabri B. Novel players in coeliac disease pathogenesis: role of the gut microbiota. *Nat Rev Gastroenterol Hepatol* 2015;**12**:497–506. <https://doi.org/10.1038/nrgastro.2015.90>
26. Rosser EC, Mauri C. A clinical update on the significance of the gut microbiota in systemic autoimmunity. *J Autoimmun* 2016;**74**:85–93. <https://doi.org/10.1016/j.jaut.2016.06.009>
27. Volkmann ER, Hoffmann-Vold AM, Chang YL, Jacobs JP, Tillisch K, Mayer EA, *et al.* Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. *BMJ Open Gastroenterol* 2017;**4**:e000134. <https://doi.org/10.1136/bmjgast-2017-000134>
28. Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. *Cell Host Microbe* 2015;**17**:553–64. <https://doi.org/10.1016/j.chom.2015.04.006>
29. Arrieta MC, Stiemsma LT, Amenyogbe N, Brown EM, Finlay B. The intestinal microbiome in early life: health and disease. *Front Immunol* 2014;**5**:427. <https://doi.org/10.3389/fimmu.2014.00427>
30. Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. *Nat Rev Cancer* 2018;**18**:471–84. <https://doi.org/10.1038/s41568-018-0015-6>
31. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, Taylor DJ. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. *Lancet* 2008;**372**:1319–27. [https://doi.org/10.1016/S0140-6736\(08\)61203-9](https://doi.org/10.1016/S0140-6736(08)61203-9)

32. Kelly JR, Minuto C, Cryan JF, Clarke G, Dinan TG. Cross talk: the microbiota and neurodevelopmental disorders. *Front Neurosci* 2017;**11**:490. <https://doi.org/10.3389/fnins.2017.00490>
33. Prehn-Kristensen A, Zimmermann A, Tittmann L, Lieb W, Schreiber S, Baving L, Fischer A. Reduced microbiome alpha diversity in young patients with ADHD. *PLOS ONE* 2018;**13**:e0200728. <https://doi.org/10.1371/journal.pone.0200728>
34. Dubois NE, Gregory KE. Characterizing the intestinal microbiome in infantile colic: findings based on an integrative review of the literature. *Biol Res Nurs* 2016;**18**:307–15. <https://doi.org/10.1177/1099800415620840>
35. White RA, Bjørnholt JV, Baird DD, Midtvedt T, Harris JR, Pagano M, *et al.* Novel developmental analyses identify longitudinal patterns of early gut microbiota that affect infant growth. *PLOS Comput Biol* 2013;**9**:e1003042. <https://doi.org/10.1371/journal.pcbi.1003042>
36. Pols DH, Wartna JB, Moed H, van Alphen EI, Bohnen AM, Bindels PJ. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. *Scand J Prim Health Care* 2016;**34**:143–50. <https://doi.org/10.3109/02813432.2016.1160629>
37. Puneekar YS, Sheikh A. Establishing the incidence and prevalence of clinician-diagnosed allergic conditions in children and adolescents using routinely collected data from general practices. *Clin Exp Allergy* 2009;**39**:1209–16. <https://doi.org/10.1111/j.1365-2222.2009.03248.x>
38. British Lung Foundation. *Asthma Statistics*. URL: <https://statistics.blf.org.uk/asthma> (accessed 27 January 2020).
39. NHS England. *Childhood Asthma*. URL: [www.england.nhs.uk/ourwork/ltc-op-eolc/ltc-eolc/si-areas/childhood-asthma/](http://www.england.nhs.uk/ourwork/ltc-op-eolc/ltc-eolc/si-areas/childhood-asthma/) (accessed 27 January 2020).
40. Office for National Statistics (ONS). *Death Registration Summary Statistics, England and Wales, 2015*. London: ONS; 2015.
41. Simpson CR, Newton J, Hippisley-Cox J, Sheikh A. Trends in the epidemiology and prescribing of medication for eczema in England. *J R Soc Med* 2009;**102**:108–17. <https://doi.org/10.1258/jrsm.2009.080211>
42. Scottish Intercollegiate Guidelines Network (SIGN). *Management of Atopic Eczema in Primary Care. A National Clinical Guideline 125*. Edinburgh: SIGN; 2011.
43. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. *Int J Epidemiol* 2017;**46**:348–55. <https://doi.org/10.1093/ije/dyw098>
44. British Thoracic Society. *British Guideline on the Management of Asthma*. 2019. URL: [www.sign.ac.uk/media/1773/sign158-updated.pdf](http://www.sign.ac.uk/media/1773/sign158-updated.pdf) (accessed 22 November 2020).
45. NHS Digital. *Quality and Outcomes Framework (QOF), Enhanced Services and Core Contract Extraction Specifications (Business Rules)*. URL: <http://content.digital.nhs.uk/qof> (accessed 27 January 2020).
46. Black M, Bhattacharya S, Philip S, Norman JE, McLernon DJ. Planned cesarean delivery at term and adverse outcomes in childhood health. *JAMA* 2015;**314**:2271–9. <https://doi.org/10.1001/jama.2015.16176>
47. Thavagnanam S, Fleming J, Bromley A, Shields MD, Cardwell CR. A meta-analysis of the association between caesarean section and childhood asthma. *Clin Exp Allergy* 2008;**38**:629–33. <https://doi.org/10.1111/j.1365-2222.2007.02780.x>

48. Sandall J, Tribe RM, Avery L, Mola G, Visser GH, Homer CS, *et al.* Short-term and long-term effects of caesarean section on the health of women and children. *Lancet* 2018;**392**:1349–57. [https://doi.org/10.1016/S0140-6736\(18\)31930-5](https://doi.org/10.1016/S0140-6736(18)31930-5)
49. Šumilo D, Nirantharakumar K, Willis BH, Rudge G, Martin J, Gokhale K, *et al.* Long-term impact of giving antibiotics before skin incision versus after cord clamping on children born by caesarean section: protocol for a longitudinal study based on UK electronic health records. *BMJ Open* 2019;**9**:e033013. <https://doi.org/10.1136/bmjopen-2019-033013>
50. Martin P, Cortina-Borja M, Newburn M, Harper G, Gibson R, Dodwell M, *et al.* Timing of singleton births by onset of labour and mode of birth in NHS maternity units in England, 2005–2014: a study of linked birth registration, birth notification, and hospital episode data. *PLOS ONE* 2018;**13**:e0198183. <https://doi.org/10.1371/journal.pone.0198183>
51. Abuabara K, Magyari AM, Hoffstad O, Jabbar-Lopez ZK, Smeeth L, Williams HC, *et al.* Development and validation of an algorithm to accurately identify atopic eczema patients in primary care electronic health records from the UK. *J Invest Dermatol* 2017;**137**:1655–62. <https://doi.org/10.1016/j.jid.2017.03.029>
52. Nissen F, Quint JK, Wilkinson S, Mullerova H, Smeeth L, Douglas IJ. Validation of asthma recording in electronic health records: a systematic review. *Clin Epidemiol* 2017;**9**:643–56. <https://doi.org/10.2147/CLEPS143718>
53. National Institute for Health and Care Excellence. *Atopic Eczema in Under 12s: Diagnosis and Management*. NICE Clinical Guideline CG57. 2007. URL: [www.nice.org.uk/guidance/cg57](http://www.nice.org.uk/guidance/cg57) (accessed 11 February 2020).
54. Galvão A, Braga AC, Gonçalves DR, Guimarães JM, Braga J. Sepsis during pregnancy or the postpartum period. *J Obstet Gynaecol* 2016;**36**:735–43. <https://doi.org/10.3109/01443615.2016.1148679>
55. Beasley R, Semprini A, Mitchell EA. Risk factors for asthma: is prevention possible? *Lancet* 2015;**386**:1075–85. [https://doi.org/10.1016/S0140-6736\(15\)00156-7](https://doi.org/10.1016/S0140-6736(15)00156-7)
56. Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. *J Am Acad Dermatol* 2016;**75**:1119–25.e1. <https://doi.org/10.1016/j.jaad.2016.07.017>
57. Lakhan P, Doherty J, Jones M, Clements A. A systematic review of maternal intrinsic risk factors associated with surgical site infection following caesarean sections. *Healthc Infect* 2010;**15**:35–41. <https://doi.org/10.1071/hi10001>
58. Oland AA, Booster GD, Bender BG. Psychological and lifestyle risk factors for asthma exacerbations and morbidity in children. *World Allergy Organ J* 2017;**10**:35. <https://doi.org/10.1186/s40413-017-0169-9>
59. Castro-Rodriguez JA, Forno E, Rodriguez-Martinez CE, Celedon JC. Risk and protective factors for childhood asthma: what is the evidence? *J Allergy Clin Immunol Pract* 2016;**4**:1111–22. <https://doi.org/10.1016/j.jaip.2016.05.003>
60. Tsakok T, McKeever TM, Yeo L, Flohr C. Does early life exposure to antibiotics increase the risk of eczema? A systematic review. *Br J Dermatol* 2013;**169**:983–91. <https://doi.org/10.1111/bjd.12476>
61. Fortson E, Feldman S, Strowd L. *Management of Atopic Dermatitis: Methods and Challenges*. New York, NY: Springer Publishing; 2017. <https://doi.org/10.1007/978-3-319-64804-0>
62. Bao Y, Chen Z, Liu E, Xiang L, Zhao D, Hong J. Risk factors in preschool children for predicting asthma during the preschool age and the early school age: a systematic review and meta-analysis. *Curr Allergy Asthma Rep* 2017;**17**:85. <https://doi.org/10.1007/s11882-017-0753-7>

63. Federico MJ, Hoch HE, Anderson WC, Spahn JD, Szeffler SJ. Asthma management for children: risk identification and prevention. *Adv Pediatr* 2016;**63**:103–26. <https://doi.org/10.1016/j.yapd.2016.04.010>
64. Milligan KL, Matsui E, Sharma H. Asthma in urban children: epidemiology, environmental risk factors, and the public health domain. *Curr Allergy Asthma Rep* 2016;**16**:33. <https://doi.org/10.1007/s11882-016-0609-6>
65. Hatfield SJ, Rogers NK, Lloyd-Lavery A, Grindlay D, Barnett R, Thomas KS. What's new in atopic eczema? An analysis of systematic reviews published in 2014. Part 1. Epidemiology, risk factors and outcomes. *Clin Exp Dermatol* 2016;**41**:843–6. <https://doi.org/10.1111/ced.12977>
66. Pyun BY. Natural history and risk factors of atopic dermatitis in children. *Allergy Asthma Immunol Res* 2015;**7**:101–5. <https://doi.org/10.4168/aair.2015.7.2.101>
67. Nutten S. Atopic dermatitis: global epidemiology and risk factors. *Ann Nutr Metab* 2015;**66**:8–16. <https://doi.org/10.1159/000370220>
68. Petersen I, McCrea RL, Sammon CJ, Osborn DP, Evans SJ, Cowen PJ, *et al.* Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. *Health Technol Assess* 2016;**20**(23). <https://doi.org/10.3310/hta20230>
69. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. *Inform Prim Care* 2011;**19**:251–5. <https://doi.org/10.14236/jhi.v19i4.820>
70. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. *Ther Adv Drug Saf* 2012;**3**:89–99. <https://doi.org/10.1177/2042098611435911>
71. Cai B, Xu W, Bortnichak E, Watson DJ. An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database. *Pharmacoepidemiol Drug Saf* 2012;**21**:770–4. <https://doi.org/10.1002/pds.3277>
72. Cea-Soriano L, García Rodríguez LA, Fernández Cantero O, Hernández-Díaz S. Challenges of using primary care electronic medical records in the UK to study medications in pregnancy. *Pharmacoepidemiol Drug Saf* 2013;**22**:977–85. <https://doi.org/10.1002/pds.3472>
73. Charlton R, Snowball J, Sammon C, de Vries C. The Clinical Practice Research Datalink for drug safety in pregnancy research: an overview. *Therapie* 2014;**69**:83–9. <https://doi.org/10.2515/therapie/2014007>
74. Williams R. *CPRD Mother Baby Link Documentation*. London: Medicines and Healthcare products Regulatory Agency; 2017.
75. NHS Digital. *Hospital Episode Statistics (HES)*. URL: <https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics> (accessed 27 September 2021).
76. Harron K, Gilbert R, Cromwell D, van der Meulen J. Linking data for mothers and babies in de-identified electronic health data. *PLOS ONE* 2016;**11**:e0164667. <https://doi.org/10.1371/journal.pone.0164667>
77. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;**42**:377–81. <https://doi.org/10.1016/j.jbi.2008.08.010>
78. National Perinatal Epidemiology Unit. *National Maternity Surveys*. URL: [www.npeu.ox.ac.uk/maternity-surveys](http://www.npeu.ox.ac.uk/maternity-surveys) (accessed 27 January 2020).

## REFERENCES

79. Care Quality Commission. *NHS Patient Surveys*. URL: <https://nhssurveys.org/surveys/survey/04-maternity/> (accessed 27 January 2020).
80. Care Quality Commission, Picker Institute Europe. *Maternity Services Survey, 2010*. 2011. URL: <https://doi.org/10.5255/UKDA-SN-6745-1> (accessed 15 November 2020).
81. NHS Digital. *Hospital Episode Statistics for England. Admitted Patient Care statistics; 2014–15*. Leeds: NHS Digital; 2015.
82. Public Health Wales. *Caesarean-Section Surgical Site Infection Surveillance. Annual Report: 2014*. Cardiff: Public Health Wales; 2015.
83. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. *Lancet* 2001;**357**:979–88. [https://doi.org/10.1016/S0140-6736\(00\)04233-1](https://doi.org/10.1016/S0140-6736(00)04233-1)
84. NHS Health Research Authority. *The Health Improvement Network (THIN) Database*. URL: [www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/the-health-improvement-network-thin-database/](http://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/the-health-improvement-network-thin-database/) (accessed 27 January 2020).
85. Clinical Practice Research Datalink. *Safeguarding Patient Data*. URL: [www.cprd.com/safeguarding-patient-data](http://www.cprd.com/safeguarding-patient-data) (accessed 27 January 2020).
86. NHS Digital. *Obtaining Data from NHS Digital from Health Research – A Guide for Researchers*. 2017. URL: <https://mrc.ukri.org/documents/pdf/obtaining-nhs-digital-data-guidance-v300317/> (accessed 27 September 2021).
87. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, *et al*. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. *BMJ* 2017;**358**:j3453. <https://doi.org/10.1136/bmj.j3453>
88. Šumilo D, Willis BH, Rudge GM, Martin J, Gokhale K, Thayakaran R, *et al*. Long term impact of prophylactic antibiotic use before incision versus after cord clamping on children born by caesarean section: longitudinal study of UK electronic health records. *BMJ* 2022;**377**:e069704. <https://doi.org/10.1136/bmj-2021-069704>
89. Bollig C, Nothacker M, Lehane C, Motschall E, Lang B, Meerpohl JJ, Schmucker CM. Prophylactic antibiotics before cord clamping in cesarean delivery: a systematic review. *Acta Obstet Gynecol Scand* 2018;**97**:521–35. <https://doi.org/10.1111/aogs.13276>
90. Klingenberg C, Kornelisse RF, Buonocore G, Maier RF, Stocker M. Culture-negative early-onset neonatal sepsis – at the crossroad between efficient sepsis care and antimicrobial stewardship. *Front Pediatr* 2018;**6**:285. <https://doi.org/10.3389/fped.2018.00285>
91. Holden SE, Jenkins-Jones S, Poole CD, Morgan CL, Coghill D, Currie CJ. The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). *Child Adolesc Psychiatry Ment Health* 2013;**7**:34. <https://doi.org/10.1186/1753-2000-7-34>
92. Hamad AF, Alessi-Severini S, Mahmud SM, Brownell M, Kuo IF. Antibiotic exposure in the first year of life and the risk of attention-deficit/hyperactivity disorder: a population-based cohort study. *Am J Epidemiol* 2019;**188**:1923–31. <https://doi.org/10.1093/aje/kwz178>
93. Axelsson PB, Clausen TD, Petersen AH, Hageman I, Pinborg A, Kessing LV, *et al*. Investigating the effects of cesarean delivery and antibiotic use in early childhood on risk of later attention deficit hyperactivity disorder. *J Child Psychol Psychiatry* 2019;**60**:151–9. <https://doi.org/10.1111/jcpp.12961>



94. Lavebratt C, Yang LL, Giacobini M, Forsell Y, Schalling M, Partonen T, Gissler M. Early exposure to antibiotic drugs and risk for psychiatric disorders: a population-based study. *Transl Psychiatry* 2019;**9**:317. <https://doi.org/10.1038/s41398-019-0653-9>
95. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. *Lancet* 2001;**357**:989–94. [https://doi.org/10.1016/S0140-6736\(00\)04234-3](https://doi.org/10.1016/S0140-6736(00)04234-3)
96. Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. *Cochrane Database Syst Rev* 2014;**10**:CD007482. <https://doi.org/10.1002/14651858.CD007482.pub3>
97. McBrien KA, Souri S, Symonds NE, Rouhi A, Lethebe BC, Williamson TS, *et al*. Identification of validated case definitions for medical conditions used in primary care electronic medical record databases: a systematic review. *J Am Med Inform Assoc* 2018;**25**:1567–78. <https://doi.org/10.1093/jamia/ocy094>
98. National Institute for Health and Care Excellence (NICE). *Asthma: Diagnosis, Monitoring and Chronic Asthma Management*. NICE Guideline NG80. 2017. URL: [www.nice.org.uk/guidance/ng80](http://www.nice.org.uk/guidance/ng80) (accessed 22 November 2020).
99. Pembrey L, Petherick E, Bird P, Wright J, Pearce N, Oddie S. *In-Utero Antibiotic Exposure in Babies Born by Caesarean Section and Subsequent Risk of Allergic Disease and Asthma in the Born in Bradford Birth Cohort*. 2018. URL: [www.journalslibrary.nihr.ac.uk/programmes/hta/1615006/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/1615006/#/) (accessed 22 November 2020).



# Appendix 1 Uptake of pre-incision antibiotics policy for caesarean section across England and the UK




FIGURE 10 Cumulative percentage of hospitals with policies to administer antibiotic prophylaxis before skin incision for women undergoing CS over time and in different countries in the UK.




FIGURE 11 Cumulative percentage of hospitals with policies to administer antibiotic prophylaxis before skin incision for women undergoing CS over time and in different regions in England.





# Appendix 2 Covariate graphs

## Maternal and household characteristics




FIGURE 12 Proportion of delivery mode in the THIN-CPRD data set over time and across different maternal age groups at childbirth: (a) <math>< 20</math> years; (b) 20-29 years; (c) 30-39 years; and (d) <math>\ge 40</math> years. (continued)




FIGURE 12 Proportion of delivery mode in the THIN-CPRD data set over time and across different maternal age groups at childbirth: (a) < 20 years; (b) 20–29 years; (c) 30–39 years; and (d) ≥ 40 years.




FIGURE 13 Proportion of delivery mode in the HES data set over time and by maternal age groups at childbirth: (a) < 20 years; (b) 20–29 years; (c) 30–39 years; and (d) ≥ 40 years. (continued)




FIGURE 13 Proportion of delivery mode in the HES data set over time and by maternal age groups at childbirth: (a) < 20 years; (b) 20-29 years; (c) 30-39 years; and (d) ≥ 40 years.




FIGURE 14 Proportion of delivery mode in the THIN-CPRD data set over time and by maternal ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white. (continued)




FIGURE 14 Proportion of delivery mode in the THIN-CPRD data set over time and by maternal ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white. (continued)




FIGURE 14 Proportion of delivery mode in the THIN-CPRD data set over time and by maternal ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white.




FIGURE 15 Proportion of delivery mode in the HES data set over time and by maternal ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white. (continued)




FIGURE 15 Proportion of delivery mode in the HES data set over time and by maternal ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white.




FIGURE 16 Proportion of delivery mode in the THIN-CPRD data set over time and by maternal smoking status before delivery: (a) discontinued; (b) missing; (c) no; and (d) yes. (continued)




FIGURE 16 Proportion of delivery mode in the THIN-CPRD data set over time and by maternal smoking status before delivery: (a) discontinued; (b) missing; (c) no; and (d) yes.






FIGURE 17 Proportion of delivery mode in the THIN-CPRD data set over time and by different maternal body mass index groups (latest measurement was 9 months before delivery): (a) 0–18.5 kg/m<sup>2</sup>; (b) 18.5–25 kg/m<sup>2</sup>; (c) 25–30 kg/m<sup>2</sup>; (d) 30–34 kg/m<sup>2</sup>; (e) ≥ 35 kg/m<sup>2</sup>; and (f) missing. (continued)




FIGURE 17 Proportion of delivery mode in the THIN-CPRD data set over time and by different maternal body mass index groups (latest measurement was 9 months before delivery): (a) 0–18.5 kg/m<sup>2</sup>; (b) 18.5–25 kg/m<sup>2</sup>; (c) 25–30 kg/m<sup>2</sup>; (d) 30–34 kg/m<sup>2</sup>; (e) ≥ 35 kg/m<sup>2</sup>; and (f) missing.




FIGURE 18 Proportion of delivery mode in the HES data set over time and by parity: (a) 0; (b) 1; (c) ≥ 2; and (d) missing. (continued)





FIGURE 18 Proportion of delivery mode in the HES data set over time and by parity: (a) 0; (b) 1; (c)  $\geq 2$ ; and (d) missing. (continued)




FIGURE 18 Proportion of delivery mode in the HES data set over time and by parity: (a) 0; (b) 1; (c)  $\geq 2$ ; and (d) missing.




FIGURE 19 Proportion of delivery mode in the HES data set with premature rupture of membranes over time.




FIGURE 20 Proportion of delivery mode in the HES data set with post-partum haemorrhage over time.




FIGURE 21 Proportion of delivery mode in the HES data set with manual placental removal/retained products of conception over time.




FIGURE 22 Proportion of women by delivery mode in the THIN-CPRD data set who were prescribed antibiotics during pregnancy over time.




FIGURE 23 Proportion of women by delivery mode in the THIN-CPRD data set over time and with a record of (a) asthma; (b) eczema; and (c) allergic rhinitis and conjunctivitis. (continued)




FIGURE 23 Proportion of women by delivery mode in the THIN-CPRD data set over time and with a record of (a) asthma; (b) eczema; and (c) allergic rhinitis and conjunctivitis.




FIGURE 24 Proportion of delivery mode in the THIN-CPRD data set over time and living in different areas of deprivation (as measured by Townsend score, with 1 being most affluent and 5 being most deprived): (a) Townsend score of 1; (b) Townsend score of 2; (c) Townsend score of 3; (d) Townsend score of 4; (e) Townsend score of 5; and (f) missing. (continued)






FIGURE 24 Proportion of delivery mode in the THIN-CPRD data set over time and living in different areas of deprivation (as measured by Townsend score, with 1 being most affluent and 5 being most deprived): (a) Townsend score of 1; (b) Townsend score of 2; (c) Townsend score of 3; (d) Townsend score of 4; (e) Townsend score of 5; and (f) missing.




FIGURE 25 Proportion of delivery mode in the HES data set over time and living in different areas of deprivation (as measured by Index of Multiple Deprivation 2015 score, with the lowest score being most affluent and the highest score being most deprived): (a) 0-0.2; (b) 0.2-0.4; (c) 0.4-0.6; (d) 0.6-0.8; (e) 0.8-1; and (f) missing. (continued)




FIGURE 25 Proportion of delivery mode in the HES data set over time and living in different areas of deprivation (as measured by Index of Multiple Deprivation 2015 score, with the lowest score being most affluent and the highest score being most deprived): (a) 0-0.2; (b) 0.2-0.4; (c) 0.4-0.6; (d) 0.6-0.8; (e) 0.8-1; and (f) missing. (continued)




FIGURE 25 Proportion of delivery mode in the HES data set over time and living in different areas of deprivation (as measured by Index of Multiple Deprivation 2015 score, with the lowest score being most affluent and the highest score being most deprived): (a) 0-0.2; (b) 0.2-0.4; (c) 0.4-0.6; (d) 0.6-0.8; (e) 0.8-1; and (f) missing.

### Child characteristics




FIGURE 26 Proportion of boys in CS and VD births over time in (a) the THIN-CPRD data set and (b) the HES data set. (continued)




FIGURE 26 Proportion of boys in CS and VD births over time in (a) the THIN-CPRD data set and (b) the HES data set.




FIGURE 27 Proportion of delivery mode in the THIN-CPRD data set over time and by child's ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white. (continued)




FIGURE 27 Proportion of delivery mode in the THIN-CPRD data set over time and by child's ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white. (continued)




FIGURE 27 Proportion of delivery mode in the THIN-CPRD data set over time and by child’s ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white.




FIGURE 28 Proportion of delivery mode in the HES data set over time and by child’s ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white. (continued)




FIGURE 28 Proportion of delivery mode in the HES data set over time and by child's ethnicity: (a) black; (b) missing; (c) mixed; (d) other; (e) South Asian; and (f) white.




FIGURE 29 Proportion of delivery mode in the HES data set over time and by gestational age: (a) <math>< 32</math> weeks; (b) 32-36 weeks; (c) <math>\ge 37</math> weeks; and (d) missing. (continued)






FIGURE 29 Proportion of delivery mode in the HES data set over time and by gestational age: (a) < 32 weeks; (b) 32–36 weeks; (c) ≥ 37 weeks; and (d) missing.




FIGURE 30 Proportion of delivery mode in the HES data set over time and by the child’s birthweight: (a) < 2500 g; (b) 2500–3999 g; (c) ≥ 4000 g; and (d) missing. (continued)




FIGURE 30 Proportion of delivery mode in the HES data set over time and by the child’s birthweight: (a) < 2500 g; (b) 2500–3999 g; (c) ≥ 4000 g; and (d) missing.




FIGURE 31 Proportion of women feeding their babies with breast milk only in the few days after birth by delivery mode (data source: Care Quality Commission’s Maternity Surveys in 2007, 2010, 2013 and 2017).<sup>79</sup>




FIGURE 32 Proportion of women feeding their babies with breast milk only at 3 months of age by delivery mode (data source: National Perinatal Epidemiology Unit maternity surveys in 2006, 2010 and 2014<sup>78</sup>).

## Appendix 3 Rates of outcomes of interest in the study population over time and by delivery mode

In this appendix, we present graphs displaying the rates of different outcomes in the study population over time. In each graph, we present the rates separately for delivery mode (CS or VD). In the primary care data set, individual graphs are presented for each year of life. No CIs have been included on these graphs; however, to aid the interpretation of the precision of these rates, we provide some example CIs for the rate of the outcome (per 1000 person-years) for a series of event rates based on the numbers of events and follow-up time found in primary care data (Table 21) and secondary care data (Table 22).

TABLE 21 Example CIs for the outcome rates found in primary care (THIN-CPRD) data

Number of events	Follow-up time (person-years)	Rate per 1000 person-years	CI for rate per 1000 person-years
2	11,868	0.17	0.02 to 0.61
71	11,850	5.99	4.68 to 7.56
1189	11,329	104.95	99.07 to 111.09
5583	9254	603.34	587.61 to 619.37

TABLE 22 Example CIs for the outcome rates found in secondary care (HES) data

Number of events	Follow-up time (person-years)	Rate per 1000 person-years	CI for rate per 1000 person-years
235	764,195	0.31	0.27 to 0.35
1865	764,195	2.44	2.33 to 2.55
4864	149,522	32.53	31.62 to 33.46
53,595	764,195	70.1	69.54 to 70.72

Outcomes in the THIN-CPRD data set




FIGURE 33 Incidence rate of asthma per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 33 Incidence rate of asthma per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 34 Incidence rate of eczema per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 34 Incidence rate of eczema per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.






FIGURE 35 Incidence rate of allergic rhinitis and conjunctivitis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 35 Incidence rate of allergic rhinitis and conjunctivitis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 36 Incidence rate of food allergy and intolerance per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 36 Incidence rate of food allergy and intolerance per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 37 Incidence rate of having two or more allergy-related conditions (e.g. asthma, eczema, food allergy/intolerance, allergic rhinitis and conjunctivitis) per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 37 Incidence rate of having two or more allergy-related conditions (e.g. asthma, eczema, food allergy/intolerance, allergic rhinitis and conjunctivitis) per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 38 Incidence rate of penicillin allergy per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 38 Incidence rate of penicillin allergy per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.






FIGURE 39 Incidence rate of anaphylaxis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 39 Incidence rate of anaphylaxis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.





FIGURE 40 Incidence rate of high risk of anaphylactic reaction (prescribing of automatic injection devices containing adrenaline) per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)



**FIGURE 40** Incidence rate of high risk of anaphylactic reaction (prescribing of automatic injection devices containing adrenaline) per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 41 Incidence rate of type 1 diabetes per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 41 Incidence rate of type 1 diabetes per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 42 Incidence rate of coeliac disease per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 42 Incidence rate of coeliac disease per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.






FIGURE 43 Incidence rate of childhood vitiligo per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 43 Incidence rate of childhood vitiligo per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 44 Incidence rate of wheeze per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 44 Incidence rate of wheeze per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 45 Incidence rate of upper respiratory tract infections per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 45 Incidence rate of upper respiratory tract infections per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 46 Incidence rate of lower respiratory tract infections per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 46 Incidence rate of lower respiratory tract infections per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.






FIGURE 47 Incidence rate of bronchiolitis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 47 Incidence rate of bronchiolitis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 48 Incidence rate of gastroenteritis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 48 Incidence rate of gastroenteritis per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 49 Incidence rate of urinary tract infection per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 49 Incidence rate of urinary tract infection per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 50 Incidence rate of first-time antibiotic prescription per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 50 Incidence rate of first-time antibiotic prescription per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.






FIGURE 51 Incidence rate of cerebral palsy per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 51 Incidence rate of cerebral palsy per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 52 Incidence rate of autism spectrum disorder per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 52 Incidence rate of autism spectrum disorder per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 53 Incidence rate of ADHD per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 53 Incidence rate of ADHD per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 54 Incidence rate of colic per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 54 Incidence rate of colic per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.






FIGURE 55 Incidence rate of failure to thrive per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years. (continued)




FIGURE 55 Incidence rate of failure to thrive per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set. Age (a) 0 years; (b) 1 year; (c) 2 years; (d) 3 years; and (e) 4 years.




FIGURE 56 Incidence rate of primary care consultations in the first 12 months of life per 1000 person-years in children born by CS and VD by age and year of birth in the THIN-CPRD data set.




FIGURE 57 Incidence of maternal composite infectious morbidity (e.g. wound infection, endometritis/endomyometritis, pelvic abscess and maternal sepsis) per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set.




FIGURE 58 Incidence of wound infection per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set.




FIGURE 59 Incidence of endometritis/endomyometritis per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set.




FIGURE 60 Incidence rate of maternal sepsis per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set.




FIGURE 61 Incidence rate of maternal urinary tract infection per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set.




FIGURE 62 Incidence of antibiotic prescribing in the post partum period per 1000 births by CS and VD by year of delivery in the THIN-CPRD data set.

### Outcomes in the HES data set

As HES captures all hospital admissions in England, all children were assumed to be followed up until age 5 years if they were born before 2015. For the birth years of 2015, 2016 and 2017, children were followed up to age 4, 3 and 2 years, respectively, and, therefore, for these years the incidence rate reflects the incidence of the outcome of interest in these age groups.




FIGURE 63 Incidence rate of asthma per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 64 Incidence rate of eczema per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 65 Incidence rate of anaphylaxis per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 66 Incidence rate of type 1 diabetes per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 67 Incidence rate of juvenile idiopathic arthritis per 1000 person-years in children born by CS and VD by year of birth in the HES data set.






FIGURE 68 Incidence rate of autoimmune (idiopathic) thrombocytopenic purpura per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 69 Incidence of late-onset neonatal sepsis per 1000 births in children born by CS and VD by year of birth in the HES data set.




FIGURE 70 Incidence of early-onset neonatal sepsis per 1000 births in children born by CS and VD by year of birth in the HES data set.




FIGURE 71 Incidence rate of other sepsis in children (developed after the neonatal period of 28 days after birth) per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 72 Incidence rate of lower respiratory tract infections per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 73 Incidence rate of bronchiolitis per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 74 Incidence rate of gastroenteritis per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 75 Incidence rate of urinary tract infections per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 76 Incidence of necrotising enterocolitis per 1000 births in children born by CS and VD by year of birth in the HES data set.




FIGURE 77 Incidence rate of leukaemia per 1000 person-years in children born by CS and VD by year of birth in the HES data set.




FIGURE 78 Incidence rate of first-time hospital admission per 1000 person-years in children born by CS and VD by year of birth in HES data set.




FIGURE 79 Incidence of maternal composite infectious morbidity (e.g. wound infection, endometritis/endomyometritis and maternal sepsis) per 1000 births by CS and VD by year of delivery in HES data set.




FIGURE 80 Incidence of wound infection per 1000 births by CS and VD by year of delivery in HES data set.




FIGURE 81 Incidence of maternal sepsis per 1000 births by CS and VD by year of delivery in HES data set.




FIGURE 82 Incidence of maternal urinary tract infection per 1000 births by CS and VD by year of delivery in HES data set.





## Appendix 4 Risk of different study outcomes by delivery mode

### Primary outcomes

#### Outcomes in children recorded in primary care

TABLE 23 Risk of developing primary outcomes in children born by CS compared with children born by VD in the primary care (THIN-CPRD) database

Outcome	CS vs. VD <sup>a</sup>		
	IRR	95% CI	p-value
Asthma	1.10	1.06 to 1.15	< 0.001
Eczema	1.04	1.02 to 1.05	< 0.001

a After adjustment for age of child, year of delivery and timing of antibiotics used in the main analysis (where applicable).

#### Outcomes in children recorded in secondary care

TABLE 24 Risk of developing primary outcomes in children born by CS compared with children born by VD in the secondary care (HES) database

Outcome	CS vs. VD <sup>a</sup>		
	IRR	95% CI	p-value
Asthma	1.09	1.05 to 1.12	< 0.001
Eczema	0.95	0.81 to 1.12	0.56

a After adjustment for year of delivery, mode of birth and timing of antibiotics used in the main analysis (where applicable). The model includes data from only those hospitals for which the year of antibiotic prescribing policy change is known.

## Secondary outcomes

### Outcomes in children recorded in primary care

TABLE 25 Risk of developing secondary outcomes in children born by CS compared with children born by VD in the primary care (THIN-CPRD) database

Outcome	CS vs. VD <sup>a</sup>		
	IRR	95% CI	p-value
Other allergic and allergy-related conditions			
Food allergy/intolerance	1.11	1.03 to 1.18	0.004
Allergic rhinitis and conjunctivitis	1.07	1.02 to 1.13	0.01
One or more allergy-related disease	1.10	1.06 to 1.15	< 0.001
Penicillin allergy <sup>b</sup>	1.12	0.93 to 1.34	0.22
Anaphylaxis <sup>b</sup>	0.87	0.59 to 1.29	0.49
High risk of anaphylactic reaction <sup>b</sup>	1.21	1.07 to 1.36	0.002
Autoimmune diseases			
Type 1 diabetes <sup>b</sup>	1.12	0.78 to 1.60	0.55
Coeliac disease <sup>b</sup>	1.24	0.88 to 1.75	0.22
Childhood vitiligo <sup>b</sup>	0.97	0.65 to 1.46	0.89
Infections and inflammation			
Wheeze	1.10	1.07 to 1.13	< 0.001
Upper respiratory tract infections <sup>b</sup>	1.04	1.03 to 1.05	< 0.001
Lower respiratory tract infections (excluding bronchiolitis) <sup>b</sup>	1.07	1.05 to 1.10	< 0.001
Bronchiolitis <sup>b</sup>	1.12	1.08 to 1.16	< 0.001
Gastroenteritis <sup>b</sup>	1.04	1.02 to 1.07	< 0.001
Urinary tract infection <sup>b</sup>	1.04	1.00 to 1.08	0.03
Antibiotic prescribing <sup>b</sup>	1.05	1.04 to 1.06	< 0.001
Other immune system-related conditions			
Leukaemia <sup>b</sup>	1.13	0.67 to 1.92	0.65
Neurodevelopmental conditions			
Cerebral palsy	2.27	1.74 to 2.95	< 0.001
Autism spectrum disorder <sup>b</sup>	1.26	1.10 to 1.44	0.001
ADHD <sup>b</sup>	0.79	0.60 to 1.05	0.10
Less-specific measures of child health			
Colic <sup>b</sup>	1.10	1.05 to 1.15	< 0.001
Failure to thrive <sup>b</sup>	1.06	0.96 to 1.16	0.24
Health-care utilisation in children			
Consultations recorded in primary care (12 months) <sup>b</sup>	1.08	1.077 to 1.082	< 0.001

a After adjustment for age of child, year of delivery and timing of antibiotics used in the main analysis (where applicable).

b Exploratory outcomes.

**Outcomes in children recorded in secondary care****TABLE 26** Risk of developing secondary outcomes in children born by CS compared with children born by VD in the secondary care (HES) database

Outcome	CS vs. VD <sup>a</sup>		
	IRR	95% CI	p-value
Other allergic and allergy-related conditions			
Anaphylaxis <sup>b</sup>	1.15	1.004 to 1.32	0.04
Autoimmune diseases			
Type 1 diabetes <sup>b</sup>	1.13	1.02 to 1.26	0.02
Coeliac disease <sup>b</sup>	0.95	0.62 to 1.46	0.82
Juvenile idiopathic arthritis <sup>b</sup>	1.02	0.75 to 1.38	0.91
Autoimmune (idiopathic) thrombocytopenic purpura <sup>b</sup>	1.08	0.94 to 1.24	0.28
Infections and inflammation			
Early-onset neonatal sepsis	1.21	1.13 to 1.29	< 0.001
Late-onset neonatal sepsis	1.31	1.19 to 1.44	< 0.001
Other sepsis <sup>b</sup>	1.23	1.17 to 1.29	< 0.001
Lower respiratory tract infections (excluding bronchiolitis) <sup>b</sup>	1.22	1.20 to 1.24	< 0.001
Bronchiolitis <sup>b</sup>	1.19	1.17 to 1.21	< 0.001
Gastroenteritis <sup>b</sup>	0.70	0.37 to 1.33	0.28
Urinary tract infection <sup>b</sup>	1.07	1.04 to 1.10	< 0.001
Other immune system-related conditions			
Necrotising enterocolitis	2.95	2.57 to 3.38	< 0.001
Leukaemia <sup>b</sup>	1.09	0.93 to 1.28	0.31
Health-care utilisation in children			
Any hospital admission <sup>b</sup>	1.07	1.06 to 1.07	< 0.001

a After adjustment for year of delivery, mode of birth and timing of antibiotics used in the main analysis (where applicable). The model includes data from only those hospitals for which the year of antibiotic prescribing policy change is known.

b Exploratory outcomes.

**Maternal outcomes**

TABLE 27 Risk of developing maternal outcomes in the primary care (THIN-CPRD) database by delivery mode

Outcome	Group, n (%)		CS vs. VD <sup>a</sup>		
	CS	VD	IRR	95% CI	p-value
Composite infectious morbidity	12,466 (8.61)	5303 (1.43)	6.82	6.52 to 7.14	< 0.001
Endometritis/endomyometritis	617 (0.43)	1269 (0.34)	1.27	1.11 to 1.45	< 0.001
Wound infection	11,717 (8.09)	3800 (1.02)	9.72	9.22 to 10.24	< 0.001
Urinary tract infection/cystitis/pyelonephritis	2551 (1.76)	4935 (1.33)	1.34	1.25 to 1.43	< 0.001
Sepsis	212 (0.15)	254 (0.07)	1.67	1.20 to 2.32	0.002
Pelvic abscess <sup>b</sup>	≤ 5 (0.00)	7 (0.00)			
Antibiotic prescribing	39,000 (26.92)	59,138 (15.94)	1.88	1.85 to 1.92	< 0.001

a After adjustment for year of delivery and timing of antibiotics used in the main analysis (where applicable).

b Too few cases to fit the model.

TABLE 28 Risk of developing maternal outcomes in the secondary care (HES) database by delivery mode

Outcome	CS	VD	CS vs. VD <sup>a</sup>		
			IRR	95% CI	p-value
Composite infectious morbidity, n (%) <sup>b</sup>	18,934 (1.9)	9112 (0.3)	6.49	6.31 to 6.68	< 0.001
Endometritis/endomyometritis, n (%) <sup>c</sup>	41 (0.004)	40 (0.001)			
Wound infection, n (%)	16,185 (1.62)	6701 (0.23)	7.56	7.32 to 7.81	< 0.001
Urinary tract infection/cystitis/pyelonephritis, n (%)	3148 (0.31)	5526 (0.19)	1.62	1.53 to 1.71	< 0.001
Sepsis, n (%)	2878 (0.3)	2389 (0.1)	3.08	2.84 to 3.34	< 0.001
Maternal deaths, n (%) <sup>c</sup>	≤ 5 (0.00)	≤ 5 (0.00)			
Length of stay in days, median (IQR)	3 (2 to 4)	1 (1 to 2)	1.75 <sup>d</sup>	1.74 to 1.75	< 0.001

IQR, interquartile range.

a After adjustment for year of delivery, follow-up time and timing of antibiotics used in the main analysis (where applicable). The model includes data from only those hospitals for which the year of antibiotic prescribing policy change is known.

b Composite infectious morbidity consists of wound infection, endometritis/endomyometritis and sepsis.

c Too few cases to fit the model.

d Mean difference.

TABLE 29 Risk of developing child outcomes in the secondary care (HES) database in CS vs. VD in hospitals with different antibiotic regimens for CS

Outcome	CS vs. VD <sup>a</sup>		
	IRR	95% CI	p-value
Asthma			
Cefuroxime alone	1.09	1.02 to 1.16	0.02
Cefuroxime plus metronidazole	1.05	0.98 to 1.13	0.19
Co-amoxiclav alone	1.11	1.06 to 1.17	< 0.001
Eczema			
Cefuroxime alone	0.72	0.49 to 1.05	0.09
Cefuroxime plus metronidazole	0.94	0.59 to 1.49	0.78
Co-amoxiclav alone	1.15	0.91 to 1.46	0.25
Necrotising enterocolitis			
Cefuroxime alone	1.99	1.25 to 3.15	0.003
Cefuroxime plus metronidazole	2.50	1.61 to 3.90	< 0.001
Co-amoxiclav alone	3.57	2.45 to 5.21	< 0.001

a After adjustment for year of delivery and timing of antibiotics used in the main analysis (where applicable). The model includes data from only those hospitals for which the year of antibiotic prescribing policy change is known.

## Subgroup analyses

TABLE 30 Risk of developing child outcomes by emergency and elective CS vs. VD in the primary care (THIN-CPRD) database

Primary outcome	CS vs. VD <sup>a</sup>									
	Emergency CS					Elective CS				
	<i>n</i> (follow-up time in person-years)	Rate per 1000 person-years	IRR	95% CI	<i>p</i> -value	<i>n</i> (follow-up time in person-years)	Rate per 1000 person-years	IRR	95% CI	<i>p</i> -value
Asthma	2256 (210,139)	10.74	1.11	1.05 to 1.17	< 0.001	1786 (179,873)	9.93	1.06	1.00 to 1.13	0.06
Eczema	14,564 (176,401)	82.56	1.13	1.11 to 1.16	< 0.001	10,428 (155,825)	66.92	0.95	0.93 to 0.99	< 0.001

a After adjustment for age of child, year of delivery and timing of antibiotics used in the main analysis (where applicable).

TABLE 31 Risk of developing child outcomes by emergency and elective CS vs. VD in the secondary care (HES) database

Primary outcome	CS vs. VD <sup>a</sup>									
	Emergency CS					Elective CS				
	<i>n</i> (follow-up time in person-years)	Rate per 1000 person-years	IRR	95% CI	<i>p</i> -value	<i>n</i> (follow-up time in person-years)	Rate per 1000 person-years	IRR	95% CI	<i>p</i> -value
Asthma	4984 (2,675,442)	1.86	1.13	1.09 to 1.17	< 0.001	3104 (1,897,257)	1.64	1.02	0.97 to 1.06	0.45
Eczema	175 (2,675,442)	0.07	1.06	0.88 to 1.28	0.55	106 (1,897,257)	0.06	0.79	0.61 to 1.02	0.07

a After adjustment for year of delivery and timing of antibiotics used in the main analysis (where applicable). The model includes data from only hospitals for which the year of antibiotic prescribing policy change is know.





EME  
HSDR  
**HTA**  
PGfAR  
PHR

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health and Care Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care*

***Published by the NIHR Journals Library***